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The N-end rule pathway relates the in vivo half-life of a protein to the identity of its N-terminal 
residue. In this pathway, a substrate bearing an N-degron is recognized and ubiquitylated by a 
family of E3 ubiquitin ligases named UBR proteins. The N-end rule pathway is implicated in 
various physiological and pathological processes including cardiac development and 
angiogenesis. It has been previously shown that mice lacking ATE1, which mediates N-terminal 
arginylation, die during embryogenesis associated with various defects in cardiovascular 
development. The goal of my graduate research was to understand the function of the N-end rule 
pathway in cardiovascular development, signaling, and homeostasis. In my first project, I 
employed a genome-wide functional proteomic approach to identify physiological substrates of 
ATE1 that potentially underlie the above cardiovascular phenotypes. I found that RGS4, RGS5, 
and RGS16 are in vivo substrates of the N-end rule pathway, the first to be identified in 
mammals. These RGS proteins, emerging regulators for cardiovascular G protein signaling, were 
degraded through sequential N-terminal modifications including N-terminal exposure of their 
Cys-2, its oxidation, and arginylation. In the second project, to understand the physiological 
meaning of ATE1-mediated RGS proteolysis in cardiac development and signaling, I 
characterized ATE1-/- mice and embryonic cardiomyocytes with an emphasis on GPCR signaling. 
I found that a cell-autonomous function of ATE1 regulates the proliferation of cardiomyocytes 
and the homeostasis of Gq-dependent cardiac signaling. In the third project, I explored a model 
of heterovalent interaction by developing RF-C11, a small molecule inhibitor of the N-end rule 
pathway. The two heterovalent ligands in RF-C11 were designed to cooperatively target two 
cognate sites of N-recognins. RF-C11 showed higher inhibitory efficiency than its homovalent 
controls, providing a molecular basis of designing multivalent inhibitors for specific intracellular 
pathways. Moreover, addition of RF-C11 reduced cardiac proliferation and hypertrophy in 
cardiomyocytes, unveiling a previously unknown function of the pathway in cardiac proliferation 
and signaling. In summary, my graduate research contributes to a comprehensive understanding 
of the function of the N-end rule pathway in the cardiovascular system. 
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Min Jae Lee, PhD 
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PREFACE 
 
 
 
 
 
“The deeper the waters are, the more still they run.” 
 
Korean proverb 
  1
1.0  THE MAMMALIAN N-END RULE PATHWAY 
The rates of proteolysis are a function of the cell’s physiological state and are controlled 
differentially for specific proteins. Regulatory proteins are often short-lived in vivo, providing a 
way to generate their spatial and temporal gradients and to rapidly adjust their concentrations 
through changes in the rates of their degradation. Ubiquitin (Ub) is a highly conserved 76-
residue protein and Ubiquitin-dependent proteolysis plays essential roles in controlling the levels 
of regulatory proteins in vivo for cell viability, cell cycle, DNA repair, protein synthesis, 
transcriptional regulation, and stress responses (Hershko et al. 2000; Finley et al. 2004; 
Ciechanover 2005; Ciechanover 2005; Varshavsky 2006). Ubiquitin is covalently attached to the 
substrates through a cascade of enzyme actions, and this process repeats to generate a 
polyubiquitin chain (Glickman and Ciechanover 2002). The internal lysine (Lys) residue of a 
substrate is the site of formation of a substrate-linked multiubiquitin chain.  
Ub-activating enzyme (E1) first uses ATP to form a thiol ester between an E1 cysteine 
residue and the C-terminus of Ubiquitin. Ubiquitin is then transferred to the active site cysteine 
of a Ub-conjugating enzyme (E2). The Ub in this thiol ester is then attacked by the ε-amino 
group of a substrate Lys. The final step is usually facilitated by a Ub–protein ligase (E3) that 
binds the E2–ubiquitin thiol ester and the substrate at distinct sites. This three step mechanism 
initiates most ubiquitylation reactions, regardless of whether the substrate-bound ubiquitin will 
signal proteasomal proteolysis, endocytosis, or some other fate (Pickart 2001). The polyubiquitin 
chain is recognized by the 26S proteasome complex, an ATP-dependent multisubunit protease, 
and degraded into small peptides with length of 3 to 24 amino acids (Rechsteiner et al. 1993; 
Coux et al. 1996; Rubin et al. 1997; Baumeister et al. 1998; Saric et al. 2004). Polyubiquitin 
chains linked by K48-G76 isopeptide bonds are usually destined for proteasomal degradation, 
while K63-G76 chains are strongly implicated in nonproteolytic signaling (Hochstrasser 2006).  
The selective targeting of individual substrates for ubiquitylation is facilitated by multiple 
CHAPTER  I 
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E2 and E3 enzymes. Most E3 enzymes belong to two protein families. RING E3s utilize a 
globular zinc-binding domain to recruit the E2–Ub intermediate (Deshaies 1999; Joazeiro and 
Weissman 2000) and HECT domain E3s accomplish this by using a different globular domain 
(Huibregtse et al. 1995; Huang et al. 1999). The HECT domain has a strictly conserved cysteine 
residue that forms an essential thiol ester intermediates during catalysis. RING finger includes a 
set of cysteine and histidine residues that have a distinctive spacing owing to their roles as the 
ligands of two zing ions that stabilize a characteristic globular conformation. The two families 
are also mechanistically distinct, in that each uses a different source of activated Ub in the 
isopeptide bond formation step. In RING E3-dependent reactions, the substrate Lys directly 
attacks the RING-bound E2–Ub intermediate, while, in HECT E3-dependent reactions, Ub must 
be transferred to a conserved cysteine of the E3 before it can be attacked by the substrate Lys. 
The first degradation signals (degrons) were discovered by Varshavsky and coworkers 
(Bachmair et al. 1986). Certain amino acids located on the N-termini of proteins functioned as an 
essential and sufficient determinant of a protein’s half-life, yielding the N-end rule pathway. N-
degrons are recognized by specific E3 Ub ligases called N-recognins, and precursor form of N-
degrons, pre-N-degron, can be converted into N-degron through specific N-terminal 
modifications, providing a means to conditionally destabilize otherwise stable polypeptides 
(Bachmair et al. 1986; Varshavsky 1996; Kwon et al. 2003; Tasaki et al. 2005; Hu et al. 2006; 
Hu et al. 2006; Varshavsky 2006). The N-end rule pathway is present in all organisms examined 
so far, including the Gram-negative model bacterium E. coli, the yeast S. cerevisiae, the plant 
Arabidopsis thaliana and mammalian cells (Mogk et al. 2007). However, N-degrons in these 
organisms show distinct differences. Recent identification of mammalian N-end rule components 
and construction of knockout mice lacking specific components reveal that this proteolytic 
pathway is implicated in many important processes such as cardiac development, angiogenesis, 
meiosis and pathogenesis of human genetic diseases(Varshavsky 2000; Mogk et al. 2007). 
1.1 N-TERMINAL MODIFICATION IN THE N-END RULE PATHWAY 
The N-terminal amino acid of a newly synthesized protein is methionine (Met). Therefore, the 
exposure of different amino acids on the N-terminus by endopeptidases or methionine 
  3
 
Table 1.  Definition of terms in the N-end rule pathway.  Only mainly used terms in this paper are shown. For more 
detail, see Varshavsky, 1996 and Tasaki, 2007. 
 
aminopeptidases (MetAPs) is a prerequisite for the creation of the N-degron (Table 1) as a post- 
translational modification. MetAPs remove Met from the N-terminus of a polypeptide if the 
residue at position 2 is valine (Val), glycine (Gly), proline (Pro), alanine (Ala), serine (Ser), 
threonine (Thr), or cysteine (Cys) (Kendall and Bradshaw 1992). Among them, only Cys can 
function as a tertiary destabilizing residue in the N-end rule pathway. The mammalian genome 
encodes approximately 500 proteins bearing an N-terminal Met-Cys sequence (Yonghua Jiang, 
Kwon Lab). It remains to be determined whether their secondary Cys acts as a degradation 
signal. Similar to the N-end rule pathway, the specificity of MetAPs is also conserved from 
prokaryotes to eukaryotes. A protein’s C-terminal fragment after cleavage events by intracellular 
endopeptidases, such as caspases, Separase and calpains, can also have an N-degron exposed on 
its new N-terminus.  
In the mammalian N-end pathway (Fig. 1), N-terminal aspartate (Asn) and glutamine 
(Gln) can be enzymatically modified by N-terminal amidohydrolases, NTAN1 and NTAQ1, into 
N-terminal aspartic acid (Asp) and glutamimc acid (Glu), respectively (Stewart et al. 1995; 
Grigoryev et al. 1996; Kwon et al. 2000), while a single enzyme, NTA1, deamidates the same 
residues in S. cerevisiae (Kwon et al. 2000).  There is no significant sequence similarity between  
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Figure 1.  The mammalian N-end rule pathway.  N-terminal residues are indicated by single-letter abbreviations for 
amino acids.  Secondary and tertiary destabilizing residues are highlighted with yellow and blue boxes, respectively. 
Type 1 and type 2 primary destabilizing residues are with purple and green, respectively. The orange ovals denote 
the rest of a protein substrate. C* denotes oxidized N-terminal Cys, either Cys-sulfinic acid or Cys-sulfonic acid, 
produced in reactions mediated by nitric oxide and oxygen as indicated, with subsequent arginylation of oxidized 
Cys by the ATE1-encoded isoforms of Arg-tRNA-protein transferase (R-transferase). The type 1 and type 2 primary 
destabilizing N-terminal residues are recognized by UBR box E3s of the N-end rule pathway along with E2s, HR6A 
and HR6B.  
 
S. cerevisiae NTA1 and mammalian NTAN1. N-terminal Asp, Glu, and Cys are destabilizing 
through their arginylation by the ATE1 Arg-transferase, creating an N-terminal Arg, one of 
primary destabilizing residues (Kwon et al. 1999; Hu et al. 2005).  Arginylation of N-terminal 
Cys requires its prior oxidation in a manner depending on nitric oxide and oxygen (Kwon et al. 
2002; Hu et al. 2005; Lee et al. 2005). In S. cerevisiae, an N-terminal Cys is stabilizing in 
contrast to in the mammalian system. N-terminal Arg together with other primary destabilizing 
residues are recognized for ubiquitylation by N-recognins (Kwon et al. 1998; Kwon et al. 2001; 
Kwon et al. 2003). NTAN1-deficient mice were found to be impaired in spontaneous activity, 
spatial memory and a socially conditioned exploratory behavior (Table 2). However, S. 
cerevisiae strains mutant were found to have only mild phenotypes (Kwon et al. 2000). N-
terminal arginylation mediated by ATE1, one of the posttranslational modifications in 
eukaryotes, was identified ~40 years ago (Kaji et al. 1963) and has been recognized to have 
important roles in controlling the half-lives of various putative substrates which can be generated 
by specific proteases including endopeptidases. ATE1-encoded R-transferases are evolutionarily 
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conserved protein observed in all eukaryotes from fungi to animal (Hu et al. 2006). In 
prokaryotes, Leu/Phe-transferase, a functionally analogous enzyme to ATE1, transfers Leu or 
Phe to N-terminal Arg, or Lys, distinguished from Asp, Glu, or oxidized Cys in eukaryotes, 
which are recognized by the ClpAP protease (Graciet et al. 2006). 
S. cerevisiae mutants lacking the ATE1-encoded Arg-transferase are viable and 
phenotypically normal (Balzi et al. 1990). However, ATE1-deficient mice died at a late stage of 
cardiac development, in which differentiating cardiomyocytes undergo ‘compaction’ and 
gradually become part of the compact wall and interventricular septum. This is associated with 
cardiovascular defects resembling human congenital heart disease (CHD) including ventricular 
hypoplasia, ventricular septal defect, and impaired angiogenesis (Kwon et al. 2002). In addition 
to the cardiac defects, the mutant embryos were also perturbed in late angiogenesis. These results 
suggest that ATE1-dependent proteolysis of unknown substrate(s) is a crucial regulatory 
mechanism for myocardial growth and blood vessel integrity/maturation. However, the 
underlying molecular mechanism to explain how knocking out the ATE1 gene in mice causes 
characteristic features of CHD remains elusive. However, the details of heart formation in mouse 
embryos have been known for decades and more and more genes that control its developmental 
program has been identified, including GATA4, Nkx2.5, TBX5, and MEF2 (Fishman and Chien 
1997; Srivastava and Olson 2000). Novel isoforms of ATE1 (ATE1-3, or ATE11A7A, ATE1-4, or 
ATE11A7B, ATE11A7AB, and ATE11B7AB) in mammalian system, in addition to the two previously 
known ATE1-1, or ATE11B7A, and ATE1-2, or ATE11B7B, from alternative exon splicing have 
been known (Rai and Kashina 2005; Hu et al. 2006). Nonetheless, the individual enzymatic 
activity of each R-transferase on unmodified N-terminal Cys, Asp, or Glu (Rai and Kashina 
2005; Hu et al. 2006) and its physiological function remain to be evaluated. 
The known functions of the N-end rule pathway in yeast include the regulation of peptide 
import through degradation of CUP9, which controls the expression of a peptide transporter 
(Byrd et al. 1998), and osmoregulation by controlling Sln1p-dependent phosphorylation (Ota and 
Varshavsky 1993). Moreover, it was also reported to regulate the degradation of Gpa1p, a Gα 
protein of S. cerevisiae (Madura and Varshavsky 1994), and alphaviral RNA polymerase in 
virus-infected metazoan cells (de Groot et al. 1991). Inhibition of the N-end rule pathway 
interfered with mammalian cell differentiation (Hondermarck et al. 1992) and limb degeneration 
in amphibians (Taban et al. 1996). More recently, a few in vivo ATE1 substrates, in common 
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with N-end rule substrates, have been identified. Yeast S. cerevisiae SCC1, a subunit of the 
cohesin complex, is cleaved by the ESP1 separase at the metaphase-anaphase transition, yielding 
a C-terminal Arg-SCC1 fragment which is degraded by yeast UBR1 (Rao et al. 2001). In S. 
cerevisiae, perturbation of SCC1 degradation resulted in chromosome instability. Drosophila 
melanogaster DIAP1, an apoptosis inhibitor has been identified as an ATE1 substrate, which is 
implicated in the regulation of Rpr and Hid-mediated apoptosis (Ditzel et al. 2003). Caspase-
mediated cleavage of Drosophila DIAP1 produces a C-terminal Asn-DIAP1 fragment that is 
deamidated by dNTAN1 into Asp-DIAP1, and subsequently arginylated for proteolysis by 
dATE1 into Arg-Asp-DIAP1 (Baker and Varshavsky 1995; Kwon et al. 2000). In mammals, 
arginylation of β-actin in mouse embryonic fibroblasts was reported, but, surprisingly, the 
stability of β-actin was unchanged regardless of arginylation (Karakozova et al. 2006). Instead, 
ATE1 regulates actin filament polymerization and lamella formation by preventing aggregation 
of the filament through electrostatic repulsion. A unique form of arginylation which is linked to 
the γ-carboxyl of internal Glu, instead of N-terminal amine, of neurotensin was also reported to 
control neurotensin’s binding affinity with its receptors (Eriste et al. 2005). 
1.2 N-TERMINAL RECOGNITION IN THE N-END RULE PATHWAY 
Even in prokaryotes where no ubiquitin exists, the N-end rule pathway is functional, indicating 
the ancient origin of the N-end rule pathway. However, the destabilizing residues in the N-end 
rule show organism specificity. While basic amino acids, such as Arg, Lys, and His, serve as 
type 1 and bulky hydrophobic amino acids, such as Leu, Phe, Trp, Tyr, and Ile, serve as type 2 
primary destabilizing resides in eukaryotes, similar but smaller number of amino acids, including 
Leu, Phe, Trp, and Tyr, function as primary destabilizing residues in E. coli. In plants, the N-
degron includes basic and aromatic residues. In eukaryotes, N-terminal Asn and Gln can act as 
tertiary destabilizing residues of the N-end rule pathway through deamidation by N-terminal 
amidohydrolases (Nt-amidases) into the secondary destabilizing N-terminal residues Asp and 
Glu, respectively (Fig. 1). N-terminal Asp and Glu function as secondary destabilizing residues 
through arginylation by ATE1-encoded R-transferase, creating the primary destabilizing residue  
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Table 2.  Phenotypes of N-end rule-related knockout mice. For more detail, see references, Kwon, 2000 for 
NTAN1; Kwon, 2002 for ATE1; Kwon, 2001 for UBR1; Kwon, 2003 for UBR2; and Tasaki, 2007 for UBR3.   
 
Arg at the N-terminus (Balzi et al. 1990; Kwon et al. 1999).  
In mammals, Arg, one of the primary destabilizing residues can be conjugated to 
secondary destabilizing residues by ATE1-encoded Arg-transferases (Kwon et al. 1999). The N-
terminal Arg and other N-terminal destabilizing residues, which can be categorized into type 1 
and type 2, are recognized and ubiquitylated by a family of E3 Ub ligases, UBR proteins (Kwon 
et al. 1998; Tasaki et al. 2005). UBR1/E3α has long been known as the only N-recognin in 
mammals. It has been characterized biochemically in rabbit reticulocyte extracts (Hershko et al. 
2000) and its cloned mouse gene, UBR1, encodes a 200-kDa protein that was similar to sc-UBR1 
not only in sequence but also in the substrate-binding properties as well (Kwon et al. 1998). Soon 
after that, additional N-recognins have been suggested and identified. The common feature of the 
UBR proteins is a 70-amino acid, zinc finger-like domain (termed the UBR box) for N-degron 
recognition, and another specific body structure (the RING domain in UBR1, UBR2, and UBR3; 
the HECT domain in UBR5; the F-box in UBR6; the PHD domain in UBR7) for Ub transfer 
and/or additional substrate recognition site (Tasaki et al. 2005). A genetic screen with S. 
cerevisiae UBR1 identified type 1-specific residues in the UBR box and type 2-specific residues 
scattered outside the UBR box. In the case of Arabidopsis UBR4, a conserved Cys in the UBR 
box was implicated in auxin transport and growth (Gil et al. 2001). UBR5/EDD is a 300 kDa 
nucleic E3 ligase with a HECT domain. UBR6 is a 90 kDa-F-box protein and UBR7 is a 50-kDa 
protein with the plant homeodomain (PHD), a conserved zinc finger that resembles the RING 
finger domain. 
The N-end rule pathway exists even in prokaryotes which lack Ub and Ub-proteasome 
  8
proteolytic system (Tobias et al. 1991; Shrader et al. 1993), suggesting that the N-end rule 
pathway existed prior to the evolution of the Ub-proteasome system. In Escherichia coli, N-end 
rule substrates are degraded by collective function of ClpA and ClpP (together forming ClpAP), 
and ClpS (recognizing destabilizing N-terminal residue) (Erbse et al. 2006). The substrate 
recognition domain of ClpS and a part of the type 2 binding site of S. cerevisiae UBR1 showed 
significant homology, suggesting an evolutionary conserved mechanism for the recognition of N-
degrons. Therefore, it is increasingly clear that the UBR box is essential for the recognition of 
both type 1 and type 2 N-degrons, probably providing a common structural element. 
Mutation in human UBR1 causes Johanson-Blizzard Syndrome (JBS) (Zenker et al. 
2005) and mice lacking UBR1 developed exocrine pancreatic insufficiency, despite normal 
synthesis of zymogens such as trypsinogen and proelastase, subtle growth retardation, altered fat 
metabolism, and behavioral abnormality, all related with the diagnostics of human JBS (Kwon et 
al. 2001; Zenker et al. 2005). In the mutant mice, endogenous skeletal muscle proteins also 
showed impaired degradation and ubiquitylation (Solomon et al. 1998; Lecker et al. 1999). The 
mild phenotypes of UBR1-/- mice were attributed to the functional compensation by UBR2. It 
was reported that UBR2-/- male mice are infertile as a result of testis degeneration due to defects 
in homologous chromosome pairing during meiotic prophase 1, whereas a majority of UBR2-/- 
female embryos were lethal without specific terminal phenotypes (Kwon et al. 2003). 
Spermatocytes lacking UBR2 are arrested before the pachytene status and undergo extensive 
apoptosis. Interestingly, in S. cerevisiae, the cleaved cohesin component SCC1 has N-terminal 
Arg and degraded by UBR1. This cleavage event by Separase is required to initiate sister 
chromatid separation at the metaphase-to-anaphase transition during mitosis and consequently 
for chromosome stability.  
UBR1 and UBR2 appear to cooperate with each other for ubiquitylation of N-end rule 
substrates. Mice lacking both UBR1 and UBR2  also died at early midgestation associated with 
severe abnormality in cardiogenesis and neurogenesis, where precocious differentiation and 
impaired proliferation of neural precursor cells were observed (An et al. 2006). In the double 
mutants, the balance between proliferation and differentiation of neural stem cells in the 
forebrain shifted toward decreased proliferation and increased differentiation. In contrast to 
UBR1 and UBR2, UBR3 does not bind to known destabilizing N-terminal residues (Tasaki et al. 
2007). UBR3 is prominently expressed in sensory cells and, especially, UBR3-deficient mice in 
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a C57BL/6 genetic background are impaired in the olfactory sensor system. Consequently, new-
born UBR3
-/- pups cannot feed themselves with mother’s milk and die within two days. In 
another study, UBR5/EDD-deficient mice showed embryonic lethality due to impaired 
development in yolk sac vessel and abnormal cell proliferation in extraembryonic tissues 
(Saunders et al. 2004). 
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2.0  IDENTIFICATION OF RGS4, RGS5, AND RGS16 AS IN VIVO SUBSTRATES 
OF THE N-END RULE PATHWAY 
2.1 OVERVIEW 
Mice lacking ATE1, which mediates N-terminal arginylation, die during embryogenesis 
associated with various defects in cardiovascular development. However, its underlying 
molecular mechanism remains elusive. To understand the function of ATE1 in the cardiac 
development, this study employed a functional proteomic approach. I demonstrate that ATE1 
Arg-transferase mediates the in vivo degradation of RGS4, RGS5, and RGS16. They function as 
negative regulators of specific G proteins which are implicated in cardiac growth and 
angiogenesis. Mutant RGS proteins in which the conserved Cys-2 residue could not become N-
terminus were long-lived in vivo. The proteolysis of these RGS proteins was perturbed in cells 
lacking Ub ligases UBR1 and/or UBR2. Hypoxia decreased the ubiquitylation of these RGS 
proteins both in vitro and in vito. These results together suggest that the sequential modifications 
of RGS4, RGS5, and RGS16 (N-terminal exposure of their Cys-2, its oxidation, and subsequent 
arginylation) act as a licensing mechanism in response to extracellular and intracellular signals 
prior to the targeting for proteolysis by UBR1 and UBR2. I also found that ATE1 
-/-
 embryos 
were impaired in the activation of ERK mitogen-activated protein kinases and in the expression 
of G protein-induced downstream effectors such as Jun, cyclin D1, and β-myosin heavy chain.  
The mRNA level of βMHC, a downstream gene of the GPCR pathway regulating cardiac 
development, was also decreased in ATE1
-/-
 embryos and embryonic hearts. These results 
established RGS4, RGS5, and RGS16 as in vivo substrates, the first to be identified, of the 
mammalian N-end rule pathway, and also suggested that the O2-ATE1-UBR1/UBR2 proteolytic 
circuit plays a role in RGS-regulated G protein signaling in the cardiovascular system. 
CHAPTER II 
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2.2 BACKGROUND 
In mammals, Asp and Glu, the two N-terminal residues known to be arginylated by ATE1-
encoded R-transferase, were shown to be destabilizing residues in the N-end rule pathway 
(Bachmair et al. 1986). Therefore, it was proposed that the function of R-transferase is to target 
proteins for degradation by conjugating Arg, one of the primary destabilizing residues, to 
secondary destabilizing N-terminal residues, which are Asp and Glu in fungi, and Asp, Glu, and 
Cys in metazoans (Gonda et al. 1989). It was also proposed that the analogous prokaryotic 
enzyme Leu, Phe-tRNA-protein transferase (L, F-transferase) mediates the activity of N-terminal 
Arg and Lys, which, in prokaryotes, would be secondary destabilizing residues (Hu et al. 2006). 
The physiological function of N-terminal arginylation has been known to be implicated in 
cardiovascular development (Kwon et al. 2002). ATE1
-/-
 embryos died associated with various 
cardiovascular defects including those resembling human congenital heart disorders. The mutant 
ventricular myocardium displayed severe hypoplasia, resembling thin myocardium syndrome, 
associated with ventricular septal defect. In addition to cardiac defects, the mutant embryos were 
also perturbed in late angiogenesis. These results suggest that ATE1-dependent proteolysis of 
unknown substrate(s) is a crucial regulatory mechanism for myocardial growth and blood vessel 
integrity/maturation. Given that myocardial diseases account for the leading causes of death in 
western society, a fundamental question is the identity of molecules underlying ATE1-dependent 
myocardial growth.  
 Heterodimeric G proteins are signal transducers that connect the ligand-activated G 
protein-coupled receptors (GPCRs) to effectors for the intracellular signaling pathways (Neves et 
al. 2002). Ligand-activated GPCRs stimulate the Gα subunit to exchange GDP to GTP, and 
thereby dissociate the inactive Gαβγ heterotrimer into the active Gα and Gβγ subunits, both of 
which activate independently second messenger-producing enzymes and ion channels. Signaling 
by Gα and Gβγ continues until Gα hydrolyzes GTP and the heterotrimer reassociates. The 
duration of signaling by G proteins is tightly controlled to produce appropriate cellular 
responses. The slow intrinsic rate of GTP hydrolysis by Gα can be drastically increased by G 
protein signaling (RGS) proteins (Berman et al. 1996), which contain a 120 amino acid RGS 
domain responsible for GTPase activation. RGS4, RGS5, and RGS16 act as GTPase activating 
proteins (GAPs) for Gαq and Gαi and have a crucial role in shutting off G protein-mediated 
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responses in all eukaryotes (Berman et al. 1996). GTP-bound Gαq activates phospholipase C 
(PLC) and mediates IP3-mediated calcium release and diacylglycerol-mediated protein kinase C 
(PKC) activation. Gβγ mediates activation of the small GTP-binding protein Ras and initiate a 
tyrosine kinase, leading to activation of mitogen-activated protein kinases (MAPKs) (Molkentin 
and Dorn 2001). Although the role of RGS5 and RGS16 in the heart is yet to be explored, given 
that RGS4, RGS5, and RGS16 are all prominently expressed in the ventricle (Wieland and 
Mittmann 2003), the potential role of RGS5 and RGS16 in the Gq- and Gi-activated 
cardiovascular signaling has been anticipated. 
In this study, a functional proteomic approach was employed in collaboration with Meso 
Scale Discovery (Gaithersburg, MD) to identify physiological substrates of the N-end rule 
pathway. I identified a set of RGS proteins, RGS4, RGS5, and RGS16, as in vivo substrates of 
the pathway, the first to be identified. These RGS proteins were degraded through sequential N-
terminal modifications including N-terminal exposure of their Cys-2, its oxidation, and 
arginylation. Consistent with the function of RGS proteins as negative regulator of GPCR 
signaling, downstream signal transducers of G protein signaling pathway, MAPKs, were 
impaired in ATE1
-/-
 and UBR1-/-UBR2-/- embryos and/or cells. These data indicate that the ATE1-
dependent N-end rule pathway plays a crucial role for RGS-regulated G protein signaling in the 
cardiovascular system and possibly in other biological processes as well. 
2.3 METHODS 
In vitro ubiquitylation and degradation assays of RGS proteins.  For in vitro degradation 
assay, RGS proteins were expressed and biotin-labeled, in the absence or presence of 2 mM 
dipeptides, using the rabbit reticulocyte lysate TnT system (Promega), followed by a time-course 
Western blotting with horseradish peroxidase (HRP)-conjugated streptavidin (Pierce). In vitro 
ubiquitylation of RGS proteins was similarly determined except that the reaction was done in the 
presence of MG132, followed by anti-Ub immunoprecipitation and subsequent Western blotting 
with HRP-conjugated streptavidin. Anti-Ub antibody (Biomol International) recognizes both 
mono- and multi-ubiquitinated proteins but not free Ub.  Bestatin (Sigma-Aldrich) with 150 µM 
concentration was added to decrease degradation of dipeptides. The RGS4, C2V-RGS4, and 
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C2G-RGS4 constructs were previously described (Davydov and Varshavsky 2000) as were the 
RGS5, Myc-RGS5, and C2A-RGS5 constructs (Zhou et al. 2001). The C2A-RGS5 construct was 
generated by PCR-mediated mutagenesis. The RGS16 construct was generated by using RT-
PCR, subcloning into pENTR vector (Invitrogen), and subsequent recombination into pcDNA-
cLumio-DEST vector (Invitrogen). Anti-RGS5 antibody was previously described (Zhou et al. 
2001), while anti-RGS4 antibody was purchased (Santa Cruz Biotechnology). For pulse chase 
analysis, mouse embryonic fibroblasts were transiently transfected with RGS4 or RGS5-
expressing plasmid and control plasmid. After 24 hr post-transfection, mouse embryonic 
fibroblasts were labeled with [35S]methionine/cysteine for 12 min, followed by chase for 0, 30 
min, and 60 min in the presence of cycloheximide. Extracts were prepared and 
immunoprecipitated with anti-RGS4 or RGS5 and V5 (for luc) antibodies, and SDS-PAGE, 
autoradiography, and quantification were sequentially performed. ATE1
-/-
, UBR1-/-, and UBR2-/- 
embryonic fibroblasts were previously described(Kwon et al. 2001; Kwon et al. 2002; Kwon et 
al. 2003), while UBR1-/-UBR2 -/- mouse embryonic fibroblasts will be described elsewhere (An et 
al. 2006). The ATE1-1 and ATE1-2 constructs were generated by subcloning their open reading 
frames (ORFs) from the yeast expression constructs into pcDNA3 vector (Invitrogen). 
 
In vitro oxygen depletion.  To generate oxygen-depleted reaction condition, a nitrogen-
containing balloon was connected to microtube with rubber-O-ring cap (Axygen Scientific) 
through a 10-mL syringe and a 23-gauge needle. Before the reaction, nitrogen was introduced 
into the tube by pulling out another plunger gently several times to vent out inside air. For 
control, luciferase-expressing plasmid was cotranslated with RGS-expressing plasmid to 
determine more precise comparison of stability of RGS proteins between in the presence and 
absence of oxygen. For in vivo hypoxic treatment, wild type and ATE1
-/- mouse embryonic 
fibroblasts were co-transfected with RGS5 and control LacZ plasmids. After 6 hr post-
transfection, cells were exposed to either normoxia or hypoxia for 24 h. Hypoxia was achieved 
by exposing cells to 0.1% O2 and 5% CO2 balanced with N2 in an anaerobic incubator (Thermo 
Electron). Reticulocytes in hypoxic condition could be distinguished from those in normoxic 
condition by its dark color, probably from less oxidized heme in red blood cells. 
 
Western Blot Analysis, Kinase Assay, and Expression Analysis.  To examine the activities of 
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MAPKs, total embryonic or embryonic heart extracts from wild type and ATE1-/- embryos and 
mouse embryonic fibroblasts were subjected to immunoblotting using antibodies against 
ERK1/2, phospho-ERK1/2, JNK1, JNK2, phospho-JNK1/2 (Santa Cruz Biotechnology), p38, 
and phospho-p38 (Cell Signaling Technology), MEK1/2, phospho-MEK1/2, Gαq (Santa Cruz 
Biotechnology), and actin (Sigma-Aldrich). The whole embryos and embryonic hearts were 
isolated in ice-cold PBS and homogenized in lysis buffer (20 mM Hepes, pH 7.5, 150 mM KCl, 
10 % glycerol, 0.1 mM EDTA) containing protease inhibitor cocktail, sodium orthovanadate, and 
sodium fluoride (Sigma). A soluble fraction was separated by a two-step centrifugation (9,000 g 
and 100,000 g). The signals were visualized by Supersignal West Pico Chemiluninescent 
Substrate (Pierce) and the membranes were reprobed with anti-actin antibody (Sigma). In vitro 
ERK kinase assay was performed using an assay kit from Upstate Biotechnology. Mouse 
embryonic fibroblasts were grown were grown as monolayers in Dulbecco’s modified Eagle 
medium (GIBCO) supplemented with 10% fetal bovine serum. Genotyping of each embryo and 
mouse embryonic fibroblasts were performed using standard polymerase chain reaction (PCR) 
with primers F1 (CCAGCTCATTCCTCCCACTCATGATC), R1 
(GGTATTTGCTGCCGTCCTTTGGTGGTC), and R2 (CTGGAGACAAAGCCCCAGCCA-
GAC), amplifying 570-bp and 430-bp fragments for wild type allele and knockout allele, 
respectively. For Northern blot analysis, total RNA was subjected to hybridization with cDNA 
fragment probes. Microarray analysis was done using the GPCR signaling pathway GE array 
(SuperArray Bioscience) with a size of 96 genes. 
 
2.4 RESULTS 
2.4.1 RGS4, RGS5, and RGS16 as Substrates of the N-end Rule Pathway 
ATE1
-/-
 mouse embryos die in utero due to various cardiovascular defects (Kwon et al. 2002), 
suggesting that ATE1-dependent proteolysis of cardiovascular regulators may be an essential 
regulatory mechanism for appropriate cardiovascular function. Therefore, I asked whether there  
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Table 3.  RGS constructs and their expected N-terminal residues. MetAPs remove Met from the N-terminus of a 
polypeptide if the residue at position 2 is Val, Gly, Pro, Ala, Ser, Thr, or Cys. Among them, only Cys can function 
as a tertiary destabilizing residue in the N-end rule pathway.  Ala, Val, and Gly are stabilizing residues in the N-end 
rule pathway. N-terminal Myc tag blocks the recognition and cleavage by MetAPs, resulting in a stable form of RGS 
proteins. 
 
are cardiac regulators amongst candidate N-end rule substrates which were identified through a 
recent functional proteomic approach (Meso Scale Discovery, Gaithersburg, MD). In this 
screening, ~18,000 cDNAs encoding ~14,000 distinct proteins were expressed in rabbit 
reticulocyte lysates, labeled with biotin, and allowed to be ubiquitylated. Polyubiquitylated 
proteins were immobilized and detected by using electrochemiluminescence (ECL) technique. 
Approximately 500 proteins were identified to be highly ubiquitylated. Subsequent dipeptide 
treatment to the ubiquitylation reaction further identified 42 candidate substrates for the N-end 
rule pathway (Data not shown). 
In eukaryotes, Met aminopeptidases (MetAPs) can cleave off N-terminal Met when the 
second residue is Cys (pro-N-degron), Ala, Ser, and Thr (type 3 N-degron), Pro (UFD substrate), 
Gly, or Val (stabilizing) (Kendall and Bradshaw 1992). Previous reports indicated that in 
mammals N-terminal Cys can serve as a pro-N-degron through ATE1-dependent N-terminal 
arginylation (Kwon et al. 2002). MetAPs can therefore potentially destabilize, via the ATE1 gene 
activity, a protein only when the second residue is Cys. Analysis of known or predicted open 
reading frames (ORFs) of candidate N-end rule substrates suggested that only RGS4, RGS5, and 
RGS16 bore the Cys2 residue, indicating that their half-lives may be controlled by ATE1-
dependent N-terminal arginylation. Consistent with this finding, RGS4 was previously reported 
to have a short half-life, and its in vitro degradation is inhibited by type 1 dipeptide inhibitors 
(Davydov and Varshavsky 2000). However, it remains unknown whether RGS4 is an in vivo N-
end rule substrate. These results suggested that the remaining 32 proteins (except for RGS4, 
RGS5, and RGS16) are likely to be destabilized via cleavage events by endopeptidases (e.g.,  
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Figure 2.  In vitro degradation RGS4, RGS5, and RGS16. RGS5 and its mutations (left panel), RGS4 and its 
mutation (right panel, upper), and RGS16 (right panel, lower) were expressed in reticulocyte lysates in the presence 
of different dipeptides N-end rule inhibitors, and their degradation was analyzed using anti-biotin Western blotting. 
Reactions were allowed for 60 min in RGS4 and RGS5. Inhibition of RGS5 proteolysis by Arg-Ala diminished after 
120 min perhaps due to instability of dipeptides.  These RGS proteins act as type 1 substrate. Therefore, non-cognate 
dipeptides, such as Trp-Ala and Ala-Arg exert no effect on the stability of the proteins. The stabilization degree of 
RGS16 protein is lower than those of RGS4 and RGS5. 
 
caspases) that produces C-terminal fragments bearing N-degrons, which should be the major 
mechanism that destabilizes proteins for the N-end rule pathway. 
RGS4, RGS5, and RGS16 belong to structurally related R4 RGS subfamily and are 
considered prototypical because they have a 120 residue RGS domain with no other identifiable 
features except for a conserved N-terminal 33 residue amphipathic helix enriched in basic 
residues. Accumulating evidence suggests that RGS4, RGS5, and RGS16 are emerging counter 
regulators of Gq- and Gi-activated cardiovascular signaling pathways (See Background). 
Therefore, it was hypothesized that ATE1-dependent proteolysis of these RGS proteins may be a 
novel regulatory mechanism for the cardiovascular GPCR signaling pathways. RGS4, RGS5, and 
RGS16 were all short-lived in reticulocyte lysates and their degradation was perturbed by 
MG132 or Arg-Ala, but not by Trp-Ala or the control dipeptide Ala-Arg (Fig. 2), suggesting that 
their proteolysis requires type 1 N-degron(s). Inhibition of RGS5 proteolysis by Arg-Ala 
diminished after 120 min (Fig. 2, lane 6) perhaps due to instability of dipeptides (Fig. 16). 
Without an endopeptidase inhibitor, bestatin, dipeptides showed no inhibitory activity on the 
degradation of model substrates. Bestatin itself did not change their stability. The results with 
RGS4 are largely consistent with the previous observation (Davydov and Varshavsky 2000). 
Notably, RGS16 was less destabilizing thanRGS4 and RGS5. The Cys2 residue of RGS16 can be 
palmitolylated, which appears to be important for plasma membrane localization but not for GAP  
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Figure 3.  In vitro ubiquitylation of RGS4, RGS5, and RGS16. RGS proteins were expressed in reticulocyte lysates 
in the presence of MG132. After 15 min, their ubiquitylation was analyzed using anti-Ub immunoprecipitation and 
subsequent anti-biotin Western blotting (top panels), while their expression levels were determined using anti-biotin 
Western blotting (bottom panels). Consistent with the degradation assay result (Fig. 2), ubiquitylation of RGS4 and 
RGS5 were active without Arg-Ala dipeptides. Mutated RGS5, which cannot expose N-terminal Cys, showed no 
ubiquitylation. 
 
activity. Thus, Cys2 palmitoylation may be a regulatory mechanism that prevents Cys2 
recognition by ATE1-encoded Arg-transferases.  
The Cys2 residue of RGS4, RGS5, and RGS16 has been expected to be a common 
degradation determinant. To examine this, wild type RGS proteins and their mutant with 
different N-terminal amino acids were constructed (Table 3). N-terminally Myc-tagged RGS5 
(Myc-RGS5) where the original Cys2 residue cannot be exposed at the N-terminus became long-
lived (Fig. 2) and was insensitive to Arg-Ala. Further, C2A-RGS5, Myc-C2A-RGS5, C2V-
RGS4, and C2G-RGS4, whose predicted N-terminal residues were Ala, Met, Val, and Gly (Table 
3), were all significantly stabilizing (Fig. 2). C2A-RGS5 was more destabilizing than Myc-RGS5 
both in the absence and presence of dipeptides perhaps because of an elusive E3 called E3β that 
targets N-terminal Ala, Ser, or Thr (Heller and Hershko 1990) or a yet unknown E3. Consistent 
with the degradation assay, RGS5 and RGS4 were rapidly ubiquitinated (Fig. 3), and their 
ubiquitylation was inhibited by Arg-Ala but not by Trp-Ala or Ala-Arg, while ubiquitylation of 
C2A-RGS5 and Myc-RGS5 was barely detected (Fig. 3). Altogether these data indicated that 
RGS4, RGS5, and RGS16 are commonly degraded by the type 1 N-end rule pathway, and their 
degradation requires the expose of Cys2 at the N-terminus. 
2.4.2 ATE1-mediated In Vivo RGS protein Degradation 
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Figure 4.  In vivo degradation assay of RGS4 and RGS5 in wild type and ATE1
-/-
 cells.  Anti-RGS4 and RGS5 
immunoblotting of overexpressed RGS4 and RGS5 (A) and endogenous RGS4 (B) in wild type and ATE1
-/-
 cells in 
the absence and presence of MG132. In ATE1
-/-
 mouse embryonic fibroblasts, otherwise unstable RGS4 and RGS5 
were long-lived. MG132 stabilized the proteins in wild type mouse embryonic fibroblasts. Slightly increased RGS 
protein level in ATE1
-/-
 mouse embryonic fibroblasts with MG132 suggests that there may be another controlling 
mechanism of the proteins’ half-lives. Since antibodies sufficient for endogenous RGS5 and RGS16 were 
unavailable, only endogenous RGS4 levels were compared in wild type and ATE1
-/-
 mouse embryonic fibroblasts. 
 
N-terminal Cys2 residue of RGS4 purified from mouse L cells was reported to be arginylated 
(Kwon et al. 2002). However, it remains unknown whether N-terminal Cys2 arginylation is 
required for Ub-dependent proteolysis. I asked whether RGS4 and RGS5 are short-lived in 
mouse embryonic fibroblasts and, if so, whether their degradation is perturbed in ATE1-/- cells. 
RGS4 and RGS5 were expressed in wild type and ATE1-/- cells, and their levels were monitored 
in the absence or presence of MG132. RGS4 and RGS5 were short-lived in wild type cells (Fig. 
4, lane 1), and their degradation was perturbed by either MG132 treatment (lanes 2 and 4) or 
ATE1 knockout (lane 3). Partial degradation of RGS5 in ATE1
-/-
 cells (Fig. 4, lane 3) is perhaps 
due to non-ATE1-dependent E3 activity present in mouse embryonic fibroblasts. Next, the in 
vivo half-lives of RGS4 and RGS5 in wild type and ATE1-/- cells were determined using pulse 
chase analysis. While less than 1% of RGS5 (compared with the level of Myc-RGS5 at the 
beginning of chase) remained intact after the 60 min-chase in wild type cells, 71% remained in 
ATE1-/- cells under the same condition (Fig.5). Further, 51% and 45% of C2A-RGS5 and Myc- 
RGS5, respectively, remained intact after the 60 min- chase even in wild type cells (Fig. 5). 
Similarly, RGS4 also was rapidly degraded in wild type cells, and its degradation was perturbed 
in ATE1-/- cells (Fig. 5). Then, I examined whether the levels of endogenous RGS4, RGS5, and 
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Figure 5.  Pulse chase analysis of RGS5, C2A-RGS5, Myc-RGS5, and RGS4 in wild type and ATE1
-/-
 cells. The 
transfected cells were labeled for 12 min with 35S-Met/Cys, followed by anti-RGS4 or RGS5 immunoprecipitation 
and SDS-PAGE analysis.  Quantitation of autoradiography using PhosphorImager was shown in right. Consistent 
with the in vivo degradation assay (Fig. 4), which measured steady-state level of the proteins, the newly synthesized 
RGS4 and RGS5 exhibited short half-lives in wild type mouse embryonic fibroblasts, while the secondary Cys 
mutations were stable. In ATE1-deficient cells, wild type proteins showed almost same half-lives as the mutant 
proteins. 
 
RGS16 are increased in ATE1-/- cells using anti-RGS4, RGS5, and RGS16 immunoblotting. The 
level of endogenous RGS4 was higher in ATE1-/- cells than in wild type cells (Fig. 4), though 
anti-RGS5 and RGS16 antibodies did not detect endogenous proteins in wild type and ATE1-/- 
cells. (However, more recently, endogenous levels of RGS5 and RGS16 were detected in 
embryonic hearts and brains. See details in Chapter III). Therefore, RGS4 and RGS5 (and 
perhaps RGS16 as well) are suggested to be the physiological substrates, the first to be 
identified, of the ATE1-dependent N-end rule pathway.  
ATE1 produces, through alternative splicing, the 60 kDa ATE1-1 and ATE1-2 that 
contain one of two homologous exons and differ in cellular localization and tissue distribution  
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Figure 6.  Rescuing ATE1 function on RGS proteolysis in ATE1
-/-
 cells.  (Left panels) Structure of ATE1 (top), 
schematics of ATE1-1, ATE1-2, and ATE1-3 (middle), and comparison of sequences encoded by alternative exons 
1A and 1B (bottom). (Right panels) An ATE1 isoform and an RGS protein were coexpressed in ATE1
-/- cells, 
followed by anti-RGS immunoblotting. Total 4 µg of the plasmid mixture (RGS4 or RGS5, 2 µg; ATE1-1 or ATE1-
2, 0, 0.25, 0.5, or 2 µg, respectively; pcDNA3, 2, 1.75, 1.5, 0 µg, respectively) was transfected into cells in a 6-well 
plate. As in Figure 4, RGS4 and RGS5 levels in ATE1
-/-
 cells were significant in a normal condition. However, with 
overexpression of an ATE1 isoform, these protein levels were reduced in concentration-dependent manner. There 
are slightly different rescuing degrees depending on isoforms. 
 
(Kwon et al. 1999). Sequences encoded by alternative exons 1A and 1B shared two highly 
conserved Cys residues (Fig. 6), and a truncated ATE1-1 mutant lacking exon 1B did not exhibit 
Arg-transferase activity for N-terminal Asp and Glu. To answer whether and to what degree 
individual ATE1 isoforms promote the proteolysis of RGS4 and RGS5 whose common 
degradation determinant is N-terminal Cys, a combination of RGS proteins and increasing 
amounts of ATE1 isoforms was expressed in ATE1
-/-
 cells where RGS4 and RGS5 are stabilized 
(Fig. 6). ATE1-1 was the major Arg-transferase that efficiently promotes proteolysis of both 
RGS4 and RGS5 in mouse embryonic fibroblasts, as answered by anti-RGS4 and RGS5 
immunoblotting (Fig. 6). In contrast, ATE1-2 facilitated degradation of RGS4 but not efficiently 
of RGS5, whereas ATE1-3-dependent degradation was inefficient for both RGS4 and RGS5. 
These results suggest that RGS4, RGS5, and RGS16 are physiological substrates of ATE1-
encoded Arg-transferases and that two pairs of alternative exons (1A/1B and 7A/7B) are 
important for the enzymatic specificity in a substrate-specific manner. The detailed biochemical 
mechanism and the role in cardiovascular development of individual ATE1 isoforms are to be 
further investigated. 
2.4.3 Perturbation of RGS protein Degradation by Oxygen Depletion 
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Figure 7.  Proteolysis of RGS4 and RGS5 influenced by oxygen concentration.  (Left panels) RGS5 and C2A-RGS5 
were expressed in reticulocyte lysates under normoxic or hypoxic condition, followed by anti-RGS5 or co-expressed 
luciferase immunoblotting. (Right panels) RGS5 and C2A-RGS5 were expressed in reticulocyte lysates under 
normoxic or hypoxic condition, followed by anti-Ub immunoprecipitation and a subsequent anti-biotin Western 
blotting. Comparison of expression levels using anti-biotin Western blotting is shown on the bottom. Hypoxia 
inhibited ubiquitylation and degradation of RGS5, suggesting that oxygen may play an important role in RGS 
protein degradation. 
 
Based on the observation that the molecular weight of N-terminal Cys2 of a portion of RGS4 
purified from mouse L cells has been increased by 48 Da, it was proposed that the N-terminal 
Cys2 had been oxidized into Cys sulfinate (CysO2) or cysteic acid (CysO3) (Kwon et al. 2002). 
However, it remains unknown whether the 48 Da-increase is due to oxidation. Therefore, I 
examined whether O2 depletion would perturb the proteolysis of RGS5 and, if so, whether the 
Cys2 residue is required for O2-dependent proteolysis. To this end, a novel method for measuring 
the effect of O2 depletion on the proteolysis of newly synthesized proteins in reticulocyte lysates 
was developed (see Methods). The level of normally short-lived RGS5 was increased upon O2 
depletion (Fig. 7), indicating that O2 may be an essential cofactor for the proteolysis of RGS5. In 
contrast, the level of the long-lived C2A-RGS5 mutant was not affected by O2 depletion (Fig.7), 
indicating that Cys2 is required for O2-dependent proteolysis of RGS4, RGS5, and RGS16. To 
determine the effect of O2 depletion on RGS5 ubiquitylation, RGS5 was expressed in the blot 
with HRP-streptavidin: the ubiquitylation of RGS5 was reduced upon O2 depletion (Fig. 7). 
Previously, Cys12 was detected as alkylated Cys, whereas Cys2 could not be identified, 
suggesting that Cys2 of RGS4 is oxidized prior to alkylation (Kwon et al. 2002). Although the 
role of O2 in Cys2-dependent proteolysis of short-lived proteins (including RGS proteins) is to be 
further investigated under physiological conditions, these results together suggest that Cys2 
oxidation of RGS proteins may be an essential and limiting regulatory mechanism for ATE1- 
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Figure 8.  Proteolysis of RGS4 requires UBR1 and UBR2.  Pulse chase analysis of RGS4 and RGS5 in wild type, 
UBR1
-/-
, UBR2
-/-
, and UBR1
-/-
UBR2
-/-
 cells. The transfected cells were labeled for 12 min with 35S-Met/Cys, 
followed by anti-RGS4 or RGS5 immunoprecipitation and SDS-PAGE analysis. Quantitation of data in the left 
panels using PhosphorImager is shown in the bottom panels. RGS4 and RGS5 showed significantly longer half-lives 
in UBR1
-/-
, UBR2
-/-
, and UBR1
-/-
UBR2
-/-
 mouse embryonic fibroblasts, suggesting UBR1 and UBR2 are indeed E3 
Ub ligases for RGS4 and RGS5 degradation. The difference between the single mutant cells and the double mutant 
cell in terms of stabilizing effects was negligible. Non-specific bands are denoted as ns. 
 
dependent proteolysis.   
2.4.4 Overlapping Role of UBR1 and UBR2 for RGS Proteolysis as E3s 
The identity of E3s that are required for proteolysis of RGS4 and RGS5 were not clear. Since the 
Cys2 residue of RGS4 and RGS5 is a determinant for ATE1-dependent arginylation (Figs. 8), N-
terminal Arg is likely to be an N-degron for their ubiquitylation. It was previously observed that 
Ub ligases UBR1 and UBR2 directly bind to N-terminal Arg as well as other type 1 and type 2 
N-degrons (of a model substrate) and it was proposed that UBR1 and UBR2 are functionally 
overlapping E3s for type 1 and type 2 N-degrons (Kwon et al. 2003). However, the physiological 
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Figure 9.  Summarization of RGS Proteolysis.  1. Proteolysis of these RGS proteins initiates from the removal of N-
terminal Met by MetAPs, exposing Cys-2 at the N-terminus. 2. The exposed N-terminal Cys-2 appears to be 
oxidized into Cys-sulfinic acid (CysO2 (H)) or Cys-sulfonic acid (CysO3(H)), which requires  NO as well as oxygen 
(O2) or its derivatives. 3. Oxidized Cys-2 residue is conjugated with Arg by ATE1 R-transferase. 4. N-terminally 
arginylated RGS proteins are ubiquitylated by UBR1 and UBR2 for degradation, perhaps with the help by E2 
enzymes HR6A and/or HR6B. The proteolysis of RGS proteins and cardiovascular homeostasis.  
 
substrates of UBR1 and/or UBR2 remain unknown. To test whether UBR1 and UBR2 are indeed 
required for the proteolysis of RGS4 and RGS5, the in vivo half-lives of RGS4 and RGS5 in wild 
type, UBR1-/-, UBR2-/-, and UBR1-/-UBR2-/- cells were examined. While less than 4% of RGS5 
(compared with the level in UBR1-/-UBR2-/- cells at the end of pulse) remained after the 60 min-
chase in wild type cells (Fig. 8, lanes 1-3; 13D), 30%, 49%, and 61%, respectively, remained in  
UBR1-/-, UBR2-/-, and UBR1-/-UBR2-/- cells under the same condition (Fig. 8, lanes 4-12). 
Similarly, the in vivo degradation of RGS4 was significantly perturbed in these UBR mutant cells 
(Fig. 8). The strong stabilization of RGS4 and RGS5 in UBR1
-/-
 and UBR2
-/-
 single knockout 
cells (Fig. 8, lanes 4-9) may be because RGS4 and RGS5 are ubiquitinated by a UBR1/UBR2 
heterodimer.  
Together, these findings establish RGS4 and RGS5 (and perhaps RGS16 as well) as the 
physiological substrates, the first to be identified, of UBR1 and UBR2, functionally overlapping 
E3s of the mammalian N-end rule pathway. These data indicate that efficient N-end rule-
dependent proteolysis of RGS4, RGS5, and RGS16 requires N-terminal methionine excision by 
MetAPs, oxidation of N-terminal Cys, arginylation by ATE1 isoform-encoded Arg-transferses, 
coordinated recognition of both an N-terminal amino acid (pro-N-degron and N-degron) by UBR 
proteins (Fig. 9). 
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Figure 10.  MAPK activities in ATE1
-/-
 Embryos.  The 12.5 dpc and 13.5 dpc- wild type and ATE1
-/-
 embryonic 
extracts were subjected to anti-ERK1/2, p38, and JNK (phosphorylated and non-phosphorylated forms). As a 
control, the levels of Gαq and β-actin were examined. Two different litters were used for 12.5 dpc embryos. In both 
12.5 dpc and 13.5 dpc, ERK2 activities were significantly reduced in ATE1
-/-
 embryos. In vitro ERK kinase activity 
assay using whole embryonic extract and synthetic ERK substrates also showed reduced ERK activity in ATE1-
deficient embryos. Data represents mean ± s.e.m. of the relative ERK activity from three embryonic extracts. *: p < 
0.05. 
2.4.5 Impaired ERK Activity in ATE1-deficient Embryos and Cells 
Above results suggest that ATE1-dependent N-terminal arginylation is essential for the 
proteolysis of RGS4 and RGS5 (and perhaps RGS16 as well). There is accumulating evidence 
that RGS4, RGS5 and RGS16 act as negative regulators of the Gq- and Gi-activated signaling 
pathways in the cardiovascular system and probably other biological processes as well. 
Consistent with the function of ATE1 in RGS proteolysis, it was reported that ATE1
-/-
 embryos 
die due to various cardiovascular defects (Kwon et al. 2002). Gq and Gi activate a complex 
network of MAPKs: extracellular signal-regulated protein kinases (ERK1 and ERK2), c-Jun N-
terminal kinases (JNKs), and p38 MAPKs. Therefore the activation of MAPKs in ATE1-/- 
embryos was examined by using phospho-specific antibodies. The amounts of Gαq and inactive 
ERK1/ERK2, JNKs, p38 MAPKs were not affected in 12.5 dpc-ATE1
-/-
 embryos (Fig. 10). 
However, the active, phosphorylated form of ERK2, but not of JNKs and p38 MAPKs, was 
decreased in ATE1
-/-
 embryos, although phosphorylated ERK1 was not detected in embryonic 
extracts (Fig. 10). Consistent with this result, total kinase activities of ERK1 and ERK2 in    
*
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Figure 11.  Serum-starved and serum-stimulated ERK1/2 MAPK activities in wild type, ATE1
-/-
, and UBR1
-/-
UBR2
-
/-
 mouse embryonic fibroblasts.  (Upper) Cells were serum-starved for 24 h and subsequently stimulated with 20% 
FBS for the times indicated. Total cell extracts were subjected to immunoblotting with antibodies against Gαq and 
phosphorylated and unphosphorylated ERK1 and ERK2. (Lower) Similar experiment was performed for serum-
starved and serum-stimulated MEK1 activity in wild type and ATE1
-/-
 mouse embryonic fibroblasts. Activation of 
both ERK1/2 and MEK1 on serum stimulation was delayed in ATE1
-/-
 mouse embryonic fibroblasts, compared with 
wild type. Interestingly, UBR1
-/-
UBR2
-/-
 mouse embryonic fibroblasts showed even more delayed activation, 
suggesting these E3 Ub ligases may have an ATE1-independent role in MAPK activities. 
 
ATE1-/- embryonic extracts, as determined by the kinase assay with myelin basic protein as a 
substrate, was ~5 fold lower than in wild type cells (Fig. 10). 
Next, the effect of serum starvation and stimulation on the activation of ERK1 and ERK2 
in wild type, ATE1
-/-
, and UBR1
-/-
UBR2
-/-
 cells were examined. The N-end rule-dependent ERK1 
and ERK2 activation was prominent upon 24 hr-serum starvation when the active forms were 
barely detected in ATE1-/- and UBR1-/-UBR2-/- cells (Fig. 11, lanes 6 and 11). Quantitation 
showed that the total amounts of active ERK1 and ERK2 upon serum stimulation were also 
lower in ATE1-/- and UBR1
-/-
UBR2
-/-
 mouse embryonic fibroblasts (Fig. 11). Notably, the function 
of ERK1 and ERK2 was more severely impaired in UBR1-/-UBR2-/- mouse embryonic fibroblasts 
than in ATE1-/- mouse embryonic fibroblasts, suggesting that UBR1 and UBR2 may have an 
ATE1-independent role in the MAPK pathways. The upstream signal transducers that are 
involved in the ATE1-dependent activation of ERK1 and ERK2 were therefore examined. ERK1 
and ERK2 can be activated by MEK1, a crucial player in cardiovascular signaling pathways. 
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Figure 12.  ERK and MEK activities after serum stimulation.  Quantitation of the active forms of ERK1 and ERK2 
in wild type embryonic extracts, ATE1-mutant, and UBR1UBR2-double mutant cells shown in the previous figure. 
Gαq was used for normalization. Activation of both ERK1/2 and MEK1 on serum stimulation was delayed in ATE1-
/-
 mouse embryonic fibroblasts, compared with wild type. Interestingly, UBR1
-/-
UBR2
-/-
 mouse embryonic 
fibroblasts showed even more delayed activation, suggesting these E3 Ub ligases may have an ATE1-independent 
role in MAPK activities. Unlike ERK1, which showed maximum activity on 15 min after serum-stimulation, ERK2 
showed relatively prolonged activity in wild type mouse embryonic fibroblasts. 
  
ATE1-/- cells did not show detectable activation of MEK1 upon serum stimulation after 24 hr-
serum starvation (Fig. 11), suggesting that the MEK1-ERK1/2 pathway is regulated by the 
ATE1-UBR1/UBR2 pathway.  
The activated GPCR pathways, including the MAPK pathways, promote cell growth via 
transcriptional induction of downstream effectors. To test whether ATE1 has a role in the 
induction of GPCR-regulated gene expression in normally growing mouse embryos, Microarray 
analysis of 96 GPCR-induced genes was employed using total RNAs from 12.5-dpc-wild type 
and ATE1
-/-
 embryos (Fig. 13). The mRNA levels of several MAPK-activated downstream 
effectors, including Jun, Fos, Pdpk1, and cyclin D1, were ~2-fold down-regulated in 12.5-dpc 
ATE1
-/-
 cells (data not shown), which was in part confirmed by Northern blot analysis (Fig. 14). 
Myocardial growth through stimulation of the G protein signaling is accompanied by activation 
of ventricular embryonic genes such as those for βMHC and skeletal α-actin.  To examine the 
role of ATE1 in myocardial growth, Northern blot analysis of these genes was performed using 
12.5-dpc-wild type and ATE1
-/-
 embryos and embryonic hearts.  The mRNA level of βMHC, but 
not of MLC2, RGS4, or α-actin, was ~2-fold decreased in ATE1-/- embryos and embryonic hearts 
(Fig. 14).  Taken together, these results (Fig. 14) suggest that altered expression of a rather broad 
spectrum of cardiovascular downstream effectors that are induced by the G protein pathways 
may collectively underlie the observed cardiovascular phenotypes of ATE1-/- embryos. 
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Figure 13.  GPCR signaling pathway-specific microarray.  Total RNAs from 13.5 dpc- wild type and ATE1
-/-
 
embryonic hearts were used for microarrays that are specific for the GPCR signaling pathway. Induced genes in 
ATE1 mutants were labeled with blue rectangles and suppressed genes with red.  Northern blotting was performed 
to confirm these data (see Fig. 14). 
2.5 DISCUSSION 
There is an increasing need to identify systematically the entire set of ubiquitylation substrates, 
especially for the mammalian proteome to understand the molecular mechanisms of various 
ubiquitin functions. Although S. cerevisiae Ub conjugates have been successfully isolated using 
affinity purification of 6xHis-Ub-conjugates associated with mass spectrometry (Peng et al. 
2003), given the enormous complexity of peptide mixtures to be processed for mass 
spectrometry, it is yet to be applied to the mammalian proteome that has a significantly higher 
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Figure 14.  Analysis of the downstream effectors in ATE1
-/-
 Embryos.  Total RNAs from 12.5 dpc- wild type and 
ATE1
-/-
 embryos (left panels) and embryonic hearts (middle panels) were subjected to Northern blotting to examine 
hypertrophic gene expression. (Right panel) Total RNAs from 11.5- and 12.5 dpc (days post-coitus)-wild type and 
ATE1
-/-
 embryos were subjected to Northern blotting to confirm the initial microarray results. 
 
complexity. Therefore, the genome-wide functional proteomic method described here provides 
for the first time a general tool to detect mammalian ubiquitylation substrates. The advantages of 
this method are that it: 1) allows automatic analysis of the entire proteome in 1-2 days, 2) is 
applicable for different species, 3) allows identification of rare or rapidly degraded substrates, 4) 
is applicable for conditional ubiquitylation by employing defined components (e.g., caspases or 
kinases) or extracts (e.g., UV irradiated HeLa cell extracts), and 5) is applicable for a specific E3 
system by employing purified E3 components or their inhibitors. The disadvantages of this 
method are that: 1) the in vitro expression system may not optimally represent physiological 
conditions and thus may yield false positives, and 2) the selection procedure is sensitive to the 
sorting method. The validity of this method was also confirmed by independent studies using 
other candidates such as aprataxin and MRPL1 (Fig. 15).  
The current study and previous observations (Davydov and Varshavsky 2000; Kwon et 
al. 2002) together suggest a model, in which the MetAPs- O2- ATE1-UBR1/UBR2 proteolytic 
system counter-regulates RGS4, RGS5, and RGS16, and thus functions as a positive regulatory 
mechanism of the G protein signaling pathway in the cardiovascular system as well as other 
biological processes. Given that Cys2 is a degradation determinant of RGS4 and RGS5 and that 
Cys2 of RGS4 has been retrieved as an N-terminally arginylated form, it was indicated that 
MetAPs are essential components for degradation of RGS4, RGS5, and RGS16 as well as 
potentially other short-lived proteins bearing Cys2 as well. However, it is unclear whether N- 
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Figure 15.  Validation of the screening using Aprataxin (upper) and MRPL1 (lower).  Other hits from the functional 
proteomic screening, including aprataxin and MRPL1, were validated by small scale immunobloting in the presence 
of dipeptides that are N-end rule inhibitors. Proteins were expressed in reticulocytes in different reaction times as 
experiment in RGS expression (see Methods). c: PBS, 1: Arg-Ala, 2: Trp-Ala. Both of aprataxin and MRPL1 act as 
type 1 substrate, stabilized by Arg-Ala dipeptides. The cleavage site, which can generate an N-degron, have been not 
characterized yet. 
 
terminal Met cleavage by MetAPs is a licensing step for proteolysis. Notably, MetAP2 is a target 
of angiogenic inhibitors such as fumagillin and its related drugs (Sin et al. 1997). This finding, 
together with the previous reports that ATE1
-/-
 embryos display defective angiogenesis (Kwon et 
al. 2002), suggests that RGS4, RGS5, and RGS16 may be the physiological targets of these anti-
angiogenic drugs. In this model, the treatment of fumagillin may partially inhibit N-terminal Met 
cleavage of RGS4, RGS5, and RGS16, and thus their proteolysis as well, which in turn may 
suppress the cardiovascular GPCR signaling pathway, resulting in angiogenic inhibition in the 
clinical setting. RGS5 is indeed prominently expressed in vascular smooth muscle cells and 
pericytes (Cho et al. 2003) and has been implicated in capillary growth and angiogenesis 
(reviewed in Wieland & Mittmann, 2003 (Wieland and Mittmann 2003)).  Given the findings 
that O2 depletion perturbs the in vitro and in vivo proteolysis of RGS5 (Fig. 7) and that Cys-2 of 
arginylated RGS4 can be converted into CysO3 in mammalian cells, the N-terminal Cys-2 may 
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Figure 16.  Stability of dipeptides in reticulocyte lysates.  Without an endopeptidase inhibitor, bestatin, cognate 
dipeptides, i.e. Arg-Ala for type 1 model substrate, Arg-nsP4, exert no inhibitory effects on the degradation of N-
end rule model substrates. Bestatin itself showed no effect on the stability of the model substrates. 
 
act as a pro-N-degron through an unknown oxidation mechanism.  During oxidation of Cys-2 to 
CysO3, there may be a transiently oxidized form, CysO2, whose structure is similar to Asp 
(Kwon et al. 2002).  Therefore, it is conceivable that the oxidized Cys structurally mimics Asp, 
an ATE1 substrate, for recognition by ATE1 Arg-transferase.  Therefore, the Cys-2 oxidation of 
RGS proteins may be a regulatory mechanism that is essential and limiting for Cys-2 
arginylation.  Taken together, the dissolved O2 gas is proposed to act as a cofactor for the GPCR 
signaling by diffusing across the plasma membrane of the target cell and oxidizing RGS4, RGS5, 
and RGS16, and thereby provides a vital regulatory mechanism for the cardiovascular GPCR 
pathway (Fig. 17).  If this were true, the (unknown) oxidase that mediates Cys-2 oxidation of 
RGS proteins may function as an O2 sensor, like prolyl-4-hydroxylases that oxidize HIF1α in a 
normoxic condition (Ivan et al. 2001).  These data also suggest that a broad range of proteins 
bearing N-terminal Cys may be regulated by the same N-terminal Cys oxidation, opening up a 
new field in studies of the role of protein oxidation in various biological processes.  
The findings that the in vivo degradation of RGS4 and RGS5 requires ATE1-encoded R-
transferases and that the N-terminal Cys2 of RGS4 can be conjugated with Arg suggest that 
arginylation of the N-terminal Cys2 of RGS4, RGS5, and RGS16 is essential and rate-limiting 
for subsequent ubiquitylation by E3s. The mammalian genome encodes ~350 Cys2-bearing 
proteins. However, since the presence of Cys2 is not sufficient for proteolysis, only a small 
subset of proteins bearing Cys2 may be arginylated for proteolysis and possibly for non-
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proteolytic processes as well. Together, this result suggests that the proteolysis of RGS4, RGS5, 
and RGS16 is tightly controlled by Cys2 exposure, oxidation, and arginylation (for pro-
proteolysis), and Cys2 palmitoylation (for anti-proteolysis). Perhaps, these complicated Cy2 
modifications function as a licensing mechanism prior to their irreversible degradation by the Ub 
machinery in response to various physiological states. Since ATE1-dependent arginylation 
requires Arg- tRNAArg which is an essential component for protein synthesis, ATE1 may act as 
a translation sensor for appropriate cell growth (e.g., cardiomyocytes and vascular smooth 
muscle cells). 
The findings that in vivo degradation of RGS4 and RGS5 is perturbed in cells deficient in 
UBR1 and UBR2 and that UBR1 and UBR2 direct bind to N-terminal Arg suggest that Cys2-
arginylated RGS4, RGS5, and RGS16 are ubiquitinated by two functionally overlapping UBR1 
and UBR2. Notably, RGS4 and RGS5 were less stabilized in UBR1-/-UBR2-/- cells than in ATE1-/- 
cells, suggesting the presence of additional E3s for RGS4 and RGS5. Consistent with this result, 
it was reported that RGS4 is more severely stabilized in UBR1-/-UBR2-/-UBR4RNAi cells than in 
UBR1-/-UBR2-/- cells (Tasaki et al. 2005). It is to be further investigated whether UBR4 and 
UBR5 participate in proteolysis of RGS4, RGS5, and RGS16. UBR1-/- mice are alive but show 
mild alteration in fat metabolism and muscle protein degradation, while UBR2-/- mice show male-
specific infertility and female-specific lethality. Notably, UBR1-/-UBR2-/- embryos die at ~12.5-
dpc (days post-coitus) associated with gross morphology indicative of cardiovascular defects at 
~11.5 dpc (An et al. 2006). However, since UBR1-/-UBR2-/- embryos also develop defects in the 
central nervous system at ~10.5-dpc (An et al. 2006), it is to be investigated whether the apparent 
cardiovascular defects are primary or secondary. It is also to be seen whether the known 
physiological functions of UBR1 and UBR2 are related with abnormal proteolysis of RGS4, 
RGS5, and/or RGS16. 
In conclusion, these results raise a model (Fig. 17), in which the controlled proteolysis of 
RGS4, RGS5, and RGS16 by the MetAPs-O2-ATE1-UBR1/UBR2 pathway is important for 
appropriate cell growth in the hearts, blood vessels, and other organs as well. This was supported 
by other reports that: 1) ATE1-/- embryos are impaired in myocardial growth and vascular 
integrity/maturation, 2) RGS4, RGS5, and RGS16 act as negative regulators of Gq and Gi 
pathways, 3) RGS4 is required for normal myocardial function, 4) the pathways composed of
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Figure 17.  Model for the role of the N-end rule pathway in G protein signaling.  The cellular concentrations of 
RGS4, RGS5 and RGS16 are tightly controlled by the N-end rule pathway. RGS4 and RGS5 have been implicated 
as negative regulators of Gq-dependent signaling in the hearts and blood vessels, respectively, while RGS16 has 
been shown to control the chemokine-stimulated signaling and migration of megakaryocytes. This results suggest 
that the regulated proteolysis of these RGS proteins by the ATE1 branch of the N-end rule pathway plays an 
important role in the control of cardiovascular signaling and homeostasis.   
 
Gq, Gi, their agonists, and the downstream signal transducers such as PKC, MAPKs, and Ras are 
critical for cardiac function and in the pathogenesis of myocardial hypertrophy, and 5) the 
expression pattern of ATE1 and these RGS proteins (Wieland and Mittmann 2003) are 
functionally correlate. To further support this model, I also demonstrated that ATE1 knockout in 
embryos reduces the function of ERK1/2 MAPKs, signal transducers downstream of Gq and Gi, 
and the mRNA level of βMHC, a cardiac hypertrophy marker (Fig. 14). Notably, in contrast to 
ERK1/2 activities (Fig. 10), the mRNA level of βMHC was moderately decreased in ATE1-/- 
embryos (Fig. 14). One possible explanation is that the mutant embryos may induce 
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compensatory reserve pathways to overcome the fatal consequences of functional loss. The 
mechanisms underlying the N-end rule-regulated GPCR pathway remain to be further dissected 
using specific organs (e.g., hearts) or cells (e.g., cardiomyocytes and endothelial cells), in the 
absence and presence of activation by various GPCR agonists, associated with conditional, 
tissue-specific knockout approach.  
Cardiac hypertrophy is the major cause of various myocardial diseases. Due to the high 
mortality of cardiac hypertrophy that is frequently associated with hypertension, cardiac valvular 
disease, or ischemia(Dorn and Hahn 2004), the identification of its regulatory determinants is a 
major concern in the pharmaceutical field. In sum, although the clear connection between the N-
end rule pathway, RGS proteins, and the cardiovascular GPCR pathway is to be further 
investigated, these results suggest that the regulated proteolysis of RGS4, RGS5, and RGS16 by 
the MetAPs-O2-ATE1-UBR1/UBR2 proteolytic pathway may be important for the optimal 
function of the cardiovascular GPCR signaling pathway. 
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3.0  CHARACTERIZATION OF PROLIFERATION AND SIGNALING IN ATE1-
DEFICIENT CARDIOMYOCYTES 
3.1 OVERVIEW 
It has been shown that ATE1-deficient mice die during embryogenesis associated with various 
defects in cardiac development. However, the underlying molecular mechanisms of these 
phenotypes remain unclear. In Chapter II, I have identified a set of regulators of G protein 
signaling pathway, RGS4, RGS5, and RGS16, as ATE1 substrates, and demonstrated that 
downstream components of G protein signaling were impaired in ATE1-/- embryos and cells. In 
this study, to understand the role of ATE1-mediated RGS proteolysis in cardiac development, I 
characterized ATE1-/- mice and embryonic cardiomyocytes with an emphasis on GPCR signaling 
pathway. I found that the cell-autonomous function of ATE1 regulates the proliferation of 
developing hearts and cardiomyocytes. ATE1 was prominently expressed in cardiomyocytes of 
the isolated embryonic heart cells, compared to non-cardiomyocytes. Consistent with the 
previous results, I found that the levels of endogenous RGS4 and RGS16 in ATE1
-/-
 embryoninc 
hearts were significantly increased, suggesting that the concentration of these RGS proteins are 
controlled by ATE1 during normal cardiac development. The downstream activities of Gq- and 
Gi signaling pathways, which are known to be regulated by RGS proteins, were also reduced in 
ATE1
-/-
 hearts. These results together indicate that the ATE1-RGS circuit acts as an important 
regulator of cardiomyocyte proliferation during cardiac development.  
 
 
 
CHAPTER III 
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3.2 BACKGROUND 
ATE1 is an evolutionarily conserved protein observed in all eukaryotes from fungi to animal (Hu 
et al. 2006). In prokaryotes, Leu/Phe-transferase, a functionally analogous enzyme to ATE1, 
transfers Leu or Phe to N-terminal Arg, or Lys, distinct from Asp, Glu, or oxidized Cys in 
eukaryotes, which are recognized by the ClpAP protease (Graciet et al. 2006). S. cerevisiae 
mutants lacking the ATE1-encoded Arg-transferase are viable and phenotypically normal (Balzi 
et al. 1990). However, ATE1-deficient mice died at the later stage of cardiac development (about 
at E14.5 to E15.5) associated with cardiovascular defects resembling human congenital heart 
disease (CHD) including ventricular hypoplasia, ventricular septal defect, and impaired 
angiogenesis (Kwon et al. 2002). This result suggests that ATE1-dependent proteolysis of 
unknown substrate(s) is a crucial regulatory mechanism for myocardial growth and blood vessel 
integrity/maturation. However, the underlying molecular mechanism to explain how knocking 
out ATE1 gene in mice induces characteristic features of CHD has remained elusive although the 
details of heart formation in mouse embryos has been known for decades and many genes that 
control its developmental program has been identified, including GATA4, Nkx2.5, TBX5, and 
MEF2 (Fishman and Chien 1997; Srivastava and Olson 2000).  
As described in chapter II, I found that RGS4, RGS5, and RGS16 are degraded through 
the ATE1-dependent N-end rule pathway and that knocking out ATE1 gene in mice reduces the 
activities of downstream effectors of GPCR pathway and the expression of cardiac hypertrophy 
marker genes (see Chapter II) (Lee et al. 2005). Heterodimeric G proteins are signal transducers 
that connect the ligand-activated G protein-coupled receptors (GPCRs) to effectors for the 
intracellular signaling pathways (Neves et al. 2002), and RGS4, RGS5, and RGS16, are negative 
regulators of Gi- and Gq-mediated signaling pathway by accelerating (up to 103-fold) the rate of 
Gα-GTP hydrolysis, resulting in reassociation of the Gαβγ heterotrimer (Ross and Wilkie 2000; 
Hollinger and Hepler 2002). The RGS proteins and G protein signaling pathway have been 
known to have important roles in cardiac development and in the cardiac function under normal 
and pathological condition (Sierra et al. 2000; Riddle et al. 2005). Mammalian R4 RGS proteins 
are highly expressed in the cardiovascular system, including ventricle, atrium, and 
cardiomyocytes (Doupnik et al. 2001; Wieland and Mittmann 2003; Larminie et al. 2004). 
Moreover, transgenic mice overexpressing RGS4 in postnatal ventricular tissue developed left 
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ventricular dilatation, depressed systolic function, and higher postoperative mortality in response 
to pressure overload (Rogers et al. 1999; Rogers et al. 2001). RGS4 levels are elevated in cardiac 
hypertrophy and in failing human heart (Zhang et al. 1998; Owen et al. 2001), while RGS4 can 
impair G protein-mediated signaling in cardiomyocytes (Tamirisa et al. 1999).  
Overexpression of Gq in cardiac myocytes increased heart weight and cardiomyocyte 
size associated with the expression of cardiac hypertrophic markers genes, such as β-myosin 
heavy chain (MHC) (D'Angelo et al. 1997; Adams et al. 1998; Mende et al. 1998). Conversely, 
mice lacking both Gαq and Gα11 die at E11.5 because of hypoplasia in the ventricular wall 
(Offermanns et al. 1998). Gq and Gi pathways are critical for proliferation and differentiation of 
myocardial cells under physiological and pathological conditions (Molkentin and Dorn 2001). 
Angiotensin II, phenylephrine, endothelin, and prostaglandin F2α that activate Gq- or Gi-
coupled receptors all stimulated the hypertrophic response in cardiomyocytes (Adams et al. 
1996). Gαq overexpression in cardiac tissue increased heart weight and cardiomyocyte size 
associated with impaired contractility and the expression of cardiac hypertrophic markers. 
Similarly, various studies using cardiomyocytes or transgenic/ knockout animals indicated that 
Gq- or Gi-activated effectors such as PKC, Ras, and MAPKs are critical for the regulation of 
myocardial cell growth (Molkentin and Dorn 2001). The present study indicates that defective G 
protein signaling underlies reduced proliferation of ATE1-deficient cardiomyocytes, which 
results in the cardiac phenotype of ATE1
-/-
 embryos. Moreover, the function of ATE1, which is 
expressed in the cardiomyocyte, is found to be cell-autonomous and angiotensin II (AngII) is one 
of major proliferative stimuli, whose function is abrogated in ATE1
-/-
 cardiomyocytes. These 
results, therefore, suggest a general physiological control mechanism of the ATE1-RGS-AngII 
circuit for heart development. 
3.3 METHODS 
Mice.  All animal studies were in accordance with protocols approved by the Institutional 
Animal Care and Use Committee at University of Pittsburgh. The exon 1 to exon 3 of ATE1 gene 
was disrupted in CJ7 embryonic stem cells (ES) as previously described (Kwon et al. 2002). 
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Embryos staged E10.5 to E17.5 were obtained from intercrosses of heterozygous mice in the 
129SvEv/C57BL/6 (mixed) genetic background. The presence of a vaginal plug after overnight 
mating was regarded as E0.5. Genotyping of the yolk sac or tail DNA of each embryo was 
performed using standard polymerase chain reaction (PCR) with primers F1 
(CCAGCTCATTCCTCCCACTCATGATC), R1 (GGTATTTGCTGCCGTCCTTTGGTGGTC), 
and R2 (CTGGAGACAAAGCCCCAGCCA-GAC), amplifying 570-bp and 430-bp fragments 
for the wild type allele and knockout allele, respectively. For in vivo proliferation assay, 5-
bromo-2-deoxyuridine (BrdU, Sigma) was intraperitoneally injected into pregnant mice with 
E11.5, E12.5, or E13.5 embryos from ATE1 heterozygous mutant intercrosses at the dose of 150 
mg/g body weight in 250 µL saline. After 2 hrs post-injection, embryos were isolated, fixed, and 
embedded into paraffin for sectioning. 
 
Histology and LacZ staining.  For histological analysis, whole embryos were dissected in ice-
cold PBS and fixed overnight at 4 °C in 4 % paraformaldehyde (PFA, Fisher Scientific) in PBS. 
Samples were treated with 70 % ethanol, dehydrated, embedded in paraffin wax, and sectioned 
transversely or sagittaly at 7 µM, followed by staining with hematoxylin/eosin (H&E). For LacZ 
staining, embryos or tissues were fixed in 4% paraformaldehyde/PBS for 10 min, rinsed in PBS 
three times, and stained overnight at 37 °C in X-Gal solution (1.3 mg/mL potassium 
ferrocyanide, 1 mg/mL potassium ferricyanide, 0.3 % Triton X-100, 1 mM MgCl2, 150 mM 
NaCl, and 1 mg/mL 4-choloro-5-bromo-3-indolyl-β-galactoside (X-Gal, Roche Applied Science) 
in PBS (pH 7.4)) followed by post-fixation. For LacZ staining of cultured primary heart cells, 
cells were fixed in 0.25 % gluta-aldehyde (Fisher Scientific) in PBS for 5 min, and stained in X-
Gal solution for 1 hr, followed by immunostaining with mouse anti-sarcomeric α-actinin (Clone 
EA-53, Sigma) for identifying cardiomyocytes. 
 
Primary cardiomyocytes and explanted heart.  The primary cells from mouse embryonic heart 
were isolated as described with slight modification for obtaining more viable cells (Jung et al. 
2005). Briefly, the dissected hearts at the stage of E13.5 were digested in Hank’s Balanced Salt 
Solution (HBSS) containing 0.2 % collagenase II, 0.005 % trypsin, 0.1 % chicken serum for 15 
min at 37 °C. Enzymes were deactivated by addition of horse serum (HS), and the cells were 
precipitated by mild centrifugation and plated in DMEM supplemented with 10 % fetal bovine 
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serum (FBS). Twenty-four hrs after plating, the medium was replaced by serum-free DMEM 
supplemented with 10 µg/mL insulin, 5.5 µg/mL transferrin, 5 µg/mL selenium, and 110 µg/mL 
pyruvate (Sigma) or with 10% HS and 5% FBS. Approximately 50 % of the cells were identified 
as cardiomyocytes by immunostaining with anti-sarcomeric α-actinin or anti-troponin I (Santa 
Cruz Biotechnology). For cell proliferation assay, cells were incubated with 10 µM of BrdU for 
16 hrs. For heart organ culture, E13.5 embryonic hearts including outflow regions were removed 
and cultured in DMEM containing 5 % FBS, penicillin and streptomycin and media was changed 
serum-free DMEM with supplements. The explanted hearts continued beating during the 
incubation of 40 µM BrdU for 24 hrs in the presence or absence of GPCR agonists. Proliferation 
of the hearts was examined by immunohistochemistry against BrdU after paraffin sections were 
prepared. 
 
Immunotechniques.  For immunoblotting analysis, whole embryos, embryonic hearts, or 
embryonic brain at the stage of E13.5 or E14.5 were isolated in ice-cold PBS and homogenized 
in lysis buffer (20 mM Hepes, pH 7.5, 150 mM KCl, 10 % glycerol, 0.1 mM EDTA) containing 
protease inhibitor cocktail, sodium orthovanadate, and sodium fluoride (Sigma). A soluble 
fraction was separated by a two-step centrifugation (9,000 g and 100,000 g). Total protein extract 
from a heart (~20 µg), one tenth of extracts from a brain (~30 µg), or 50 µg of total protein from 
whole embryos were subjected to electrophoresis, blotted to polyvinylidene fluoride (PVDF) 
membrane, and probed with anti-RGS4, anti-RGS5, or anti-RGS16 antibody (generous gifts 
from Dr. Susanne M. Mumby (Krumins et al. 2004), Dr. Kayoko Moroi (Zhou et al. 2001), and 
Dr. Ching-Kang Chen (Derrien et al. 2003; Hiol et al. 2003), respectively) followed by reprobing 
with anti-actin antibody (Sigma). The signals were visualized by Supersignal West Pico 
Chemiluninescent Substrate (Pierce). 
To detect in vivo BrdU incorporation, sections were antigen-retrieved by heating in 
10mM sodium citrate (pH 6.0) in a microwave oven for 10 min, permeabilized with 0.2 % Triton 
X-100 for 10 min, and incubated with rat anti-BrdU antibody (Serotec, Oxford, UK) diluted 1:50 
in PBST with 2 % goat serum, followed by anti-rat IgG-Alexa555 antibody (Invitrogen). Cells 
were counterstained with 4’6’-diamidino-2-phenylindole (DAPI, Vector Laboratories) to 
visualize the nuclei. Control staining was performed using embryos into which BrdU was not 
injected. For phosphorhistone staining, the sections were incubated with anti-phosphohistone H3 
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antibody (Upstate) (1:100 dilution), followed by anti-rabbit IgG-FITC (Jackson 
Immunoresearch). Each antibody was applied for 1 hr at room temperature in 1 % goat 
serum/PBST and secondary antibody was diluted 1 to 200. 
For detection of BrdU incorporation in the primary cardiomyocytes, cells were fixed in 4 
% PFA for 25 min at 4 °C and for 5 min at room temperature, permeabilized in 0.2 % Triton X-
100 for 10 min, denatured with 2N HCl, and neutralized with 0.1 M sodium borate. Then, cells 
were co-immunostained with rat anti-BrdU antibody and rabbit anti-troponin I antibody, 
followed by secondary antibody incubation (anti rat-IgG-Alexa 555 and anti-rabbit IgG-FITC, 
respectively) and counterstaining with DAPI. For phosphorhiston H3, atrial natriuretic protein 
(ANP) and Flag detection in cardiomyocytes, staining was performed as BrdU staining without 
acid treatment and neutralization. 
For RGS4 immunostaining of paraffin sections, samples were blocked in 10% heat 
inactivated goat serum in PBST, incubated with rabbit anti-RGS4 antibody (1:50 dilution), 
following quenching the endogenous peroxide activity with 3 % H2O2 in MeOH for 30 min. 
Biotinylated goat anti-rabbit IgG and diaminobenzidine were used for the signal development. 
Control sections and embryos were incubated with pre-immune anti-sera instead of anti-RGS4 
antibody. Whole-mount immunohistochemical staining of embryos for RGS4 was performed as 
described (Kwon et al. 2003). The antibody could not be used for location of endogenous RGS4 
in subcellular level. 
 
Hypertrophy.  Cardiomyocyte size was determined by measuring the surface area of sarcomeric 
α-actinin-positive cells in cultured primary cardiomyocyte. Planimetry was performed using 
ImageJ software version 1.34s (NIH) (Rasband 1997-2006) and outcome arbitrary unit was used. 
Although cell surface area does not constitute an accurate measurement of cell size, this 
parameter was generally used to estimate cardiomyocyte hypertrophy (Fredj et al. 2005). 
Immunohistochemical analysis was performed to detect hypertrophic marker genes, such as ANP 
with coimmunostaining for cardiomyocyte marker protein, e.g. sarcomeric α-actinin. For [3H] 
leucine incorporation assay, cultured cardiomyocytes in serum-containing medium were 
incubated with 5.0 µCi/mL of [3H] leucine (Amersham Bioscience) for 24 hrs. The radioactivity 
incorporated into the trichloroacetic acid-precipitatable material was determined.  To analyze 
mRNA expression of heart genes, semiquantitative reverse transcription-PCR was performed on 
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1 µg of total RNA from embryonic hearts for 25 cycles.  
 
GPCR Effectors and GPCR Agonists.  Activities of ERK, CaMKII, PKA, and PKC in the 
embryonic hearts were determined using kinase assay kits from Upstate Biotechnology with 
myelin basic protein, a substrate peptide (KKALRRQETVDAL), kemptide, and a substrate 
peptide (QKRPSQRSKYL) as substrates respectively. Inositol phosphate formation by PLC was 
assayed using [3H] phosphatidylinositol bisphosphate (PIP2) as substrate as described earlier 
(Pandey et al. 2002). To activate (phosphorylate) kinases, DMEM complemented with 20% FBS 
was added to primary cardiomyocytes or immortalized mouse embryonic fibroblasts cultured in 
serum-free medium and cells were subject to immunoblotting as described above. 
After genotyping, cultured primary cells and explanted hearts were stimulated every 24 
hrs with 200 µM phenylephrine (PE), 2 µM Angiotensin II (AngII), 100 nM prostaglandin F2α 
(PGF2α), 50 ng/mL basic fibroblast growth factor (FGFb), or 4 µM isopreterenol (ISO) in 
serum-free culture media for two days. Cells were also incubated with 10 µM of BrdU 16 hrs 
before fixing and proliferation of cardiomyocytes was examined by immunohistochemistry 
against BrdU as described above. 
 
Adenovirus Construction and Infection.  All recombinant adenoviruses were constructed by 
employing the Cre-lox recombination system as described (Hardy et al. 1997; Song and Lee 
2005). Briefly, N-terminally Flag tagged mouse ATE1-1, ATE1-2, or ATE1 -3 genes were 
isolated by PCR using pcDNA3-ATE1-1 to -3 as templates and inserted into BamHI/XhoI-cut 
pAdlox shuttle vector to generate pAdlox-ATE1-1 to -3 shuttle vectors, respectively. The 
selective cell line CRE8 has β-actin-based expression cassette driving a Cre recombinase gene 
with an NH2-terminal nuclear localization signal stably integrated into 293 cells. For the 
production of adenovirus, 2 µg of sfiI-degested shuttle vector was co-transfected into CRE8 cells 
with 2 µg of sfiI-degested Ψ5 viral genomic using LipofectAMINE (Invitrogen). The 
recombinant adenoviruses were generated by intermolecular homologous recombination between 
the shuttle vector and Ψ5 viral DNA. Plaques were harvested, analyzed, and purified. The 
insertion of each component to adenovirus was confirmed by Western blot analysis after the 
infection of corresponding recombinant adenovirus into HeLa S3 cells or DU-145 cells. 
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Table 4.  Genotype Table from ATE1 Heterozygous Intercross.  ATE1-/- embryos died during E12.5 and E14.5 and 
no live embryos from E15.5 was obtained. 
 
Primary cardiomyocytes cultures were infected with adenoviral constructs at a 
multiplicity of infection (MOI) of 10 diluted in serum-free DMEM with supplementation for 3 
hrs. Efficiency of transgene expression of an isoform of ATE1 assessed by coimmunostaining 
with anti-Flag antibody and anti-troponin I antibody is constantly > 95 % up to 48 hr post-
infection. Adenoviral expression in cardiomyocytes cultures did not influence cell viability. 
 
Statistical Analysis.  For experiment using embryonic hearts, at least three different litters (10 
sections each) were analyzed. For cardiomyocyte analyses in vitro, more than 5,000 cells for 
each experimental group were counted. Samples were counted twice, and there was less than 3% 
variability per sample. For enzymatic activity assay, three hearts for each genotype were used 
and it was duplicated. The images were analyzed using ImageJ software, version 1.34s (Rasband 
1997-2006) (NIH) to count BrdU positive cells and to measure the area of cardiomyocytes. Data 
are presented as mean ± sd and statistical analysis was performed by unpaired student’s t-test or 
ANOVA. A value of P < 0.1 was accepted as statistically significant. 
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Figure 18.  Analysis of gross morphology of ATE1-deficient embryos and yolk sacs.  (A) Comparison of wild type 
and ATE1
-/-
 embryos in different stages. (B) Comparison of yolk sacs.  Before E11.5, there is no difference in gross 
morphology between the genotypes. However, the growth retardation and other cardiovascular defects became 
apparent as midgestation stages are higher. Although clear developmental defects were observed after E13.5, 
histological analysis revealed that the defects started from E12.5. 
3.4 RESULTS 
3.4.1 Characterization of ATE1-deficient Mice 
Genotyping of litters retrieved from heterozygous intercross revealed no homozygous mutants 
after E15.5 and of 627 newborn pups (Table 4). This result showed that the deletion of ATE1 
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Figure 19.  Notable phenotypes of 12.5-dpc ATE1
-/-
 embryos.  (A) Closer look of 12.5 dpc-ATE1
-/-
 embryonic heart. 
Hemorrhages in the atrial chambers were frequently observed. (B) Hemorrhages in brain ventricles. This phenotype 
is believed to be related with the circulation defects in ATE1
-/-
 embryos. (C) E16.5 embryo litters with two dead 
embryos, which were identified to be ATE1 homozygous mutants after genotyping. Homozygous mutants showed 
no distinguishable phenotypes from wild types.  
 
gene caused midgestation lethality. To ascertain the timing and nature of the embryonic lethality 
of ATE1
-/-
mice, the morphology of more than 1,000 embryos produced from timed intercrosses 
between ATE1+/- in B6/129S mixed background at various stages from E10.5 to E17.5 was 
dissected (Fig. 18A). ATE1-/- embryos at the stages up to E11.5 were recovered with the expected 
number and outwardly normal although subtle morphological or physiological abnormalities  
could not be ruled out (Fig. 18A-a, and e). In contrast, E12.5 ATE1-/- embryos were 
distinguishable on gross inspection from their wild type or heterozygous mutant littermates (Fig. 
18A-b, f, and g), although E12.5 ATE1-/-embryos were recovered approximately in Mendelian 
ratios. Their growths were clearly retarded (~65 % to 90 % of wild type littermates) although 
somite numbers of homozygous embryos showed no apparent difference from wild type or 
heterozygous littermates. Some of them developed local effusion in the midbrain, hearts (or 
primitive atrium), and/or swollen pericardiac sac (Fig. 19A). About half of them also exhibited 
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Figure 20.  Histological analysis of ATE1-deficient embryonic hearts.  (A-F) H/E staining of wild type (A-C) and 
ATE1
-/-
 (D-F) embryonic hearts in different stages; E11.5 (A, B, G, J), E12.5 (B, E, H, K, R-U), and E13.5 (C, F, I, 
L-Q). (G-L) Magnified image of ventricular wall area from A-F. (M-U) Sagittal section of embryonic hearts. Left 
panels: wild type, right panels: mutant. After E12.5, ATE1
-/-
 embryonic hearts persistently revealed the abnormal 
heart morphology, thin and scarce trabecular cells, and thinner ventricular wall in mutant embryos. The thickness of 
the compact zone was significantly reduced in mutant (2 to 3 myocardial cells compared to ~5 myocardial cells in 
controls) and this difference was more evident at E13.5, where the development of compact zone was arrested at 
E12.5 while wild type embryonic hearts were ~ 10-cell-thick, suggesting that proliferation and/or maturation of 
cardiac myocytes might be defective in ATE1
-/- ventricular wall. 
 
an edematic accumulation of fluid under the dermal layer of the brain and the skin, an indicator 
of suppressed cardiac function. About 18 % of E13.5 ATE1-/- mutants were found dead and 
development of surviving mutants appeared to be arrested in sizes at ~E12.5 and exhibited blood 
leakage into the pericardial cavity and the brain which indicates interauterine heart failure (Fig. 
18A-c, and h). Some of mutant mice were anemic in the extremities, suggesting hemodynamic 
insufficiency Another defect frequently noticed in E13.5 ATE1
-/-
 embryos was hemorrhage in the 
lateral ventricles, which is common in preterm and low birth weight infants and probably arose 
secondarily from the cardiac defects (Fig. 19B) (Cherian et al. 2004). More than 26 % of E14.5 
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Figure 21.  Reduced DNA synthesis of ATE1
-/-
 embryonic hearts.  Immunostaining of BrdU-positive embryonic 
hearts at 12.5-dpc and 13.5-dpc. Compact zone and trabeculae zone were visually separated with dotted lines. 
Ventricular wall areas were magnified. BrdU index in a specific area were quantified. BrdU index in the lung were 
used as control to show cardiac specific defects in proliferation. Data represents mean ± s.e.m. from three non-litter 
embryos (See details in Methods). *: p < 0.05. 
 
ATE1-/- mutants were found dead and surviving embryos showed significant widespread 
hemorrhages (Fig. 18A-d, j, and k). No live ATE1-/- embryos were recovered after E15.5 and 
often they were found resorbed (Fig. 19C). ATE1+/- heterozygotes did not show any discernable 
phenotypic abnormalities and no gross abnormality of other major organ was observed. 
Along with developmental defects in ATE1-/- embryos, their yolk sacs with intact ectoplacental 
cones revealed poorly developed blood vessels and inefficient circulation (Fig. 18B). Analysis of 
E11.5 and earlier embryos revealed no distinguishable difference between ATE1
-/-
 and control 
embryos, both displaying hierarchically organized vessel architecture with vielline vessels, 
suggesting effective initial erythropoiesis. However, at E12.5, ~75 % of mutant embryos 
exhibited less-branched and thinner vitelline vessels, and irregular plexus of enlarged capillaries 
(Fig. 18B-b and f). Transparent and pale yolk sacs were also observed in more than half of 
mutants at this stage. In ATE1-/- embryos, the vitelline vessels started to rapidly degenerate 
during E12.5 to E13.5, probably because of cardiac insufficiency from defects in ATE1
-/-
 
embryonic hearts and subsequent deterioration of blood vessels. At the E14.5 stage, 45 % of 
mutant yolk sac showed no vascular structures and some of them became yellowish (Fig. 18B-d 
and h). These results indicate that the lethality from disruption of ATE1 gene starts from E13.5 
although there might be cardiovascular abnormality as early as E11.5. 
* 
* 
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Figure 22.  Reduced mitosis of ATE1
-/-
 embryonic hearts.  Immunostaining of phosphor-Histone H3 (mitosis 
marker) embryonic hearts at 12.5-dpc. Compact zone and trabeculea zone were visually separated with dotted lines. 
Magnified ventricular wall areas (Left panels) and interventricular septum (right panel) were shown. Percentage of 
H3P-positive nuclei in a specific area were quantified. Data represent mean ± s.e.m. from three non-litter embryos. 
*: p < 0.05. 
3.4.2 Cardiac Abnormality of ATE1-/- Mice 
Because of obvious cardiovascular demise, histology of embryonic hearts from E10.5 to E14.5 
by hematoxylin and eosin (H&E) was examined (Fig. 20). Serial histological sections from up to 
E11.5 embryos exhibited that looping and septation of the heart tubes were normally developed, 
making wild type and ATE1 mutant indistinguishable and suggesting normal epithelial-to-
mesenchymal transition (Fig. 20A, D). One day later, however, at E12.5, they persistently 
revealed the abnormal heart morphology, thin and scarce trabecular cells, and thinner ventricular 
wall in mutant embryos (Fig. 20B, E). The thickness of the compact zone was significantly 
reduced in mutant (2 to 3 myocardial cells compared to ~5 myocardial cells in controls) and this  
difference was more evident at E13.5, where the development of compact zone was arrested at 
E12.5 while wild type embryonic hearts were ~ 10-cells-thick, suggesting that proliferation 
and/or maturation of cardiac myocytes might be defective in ATE1
-/- ventricular wall (Fig. 20C, 
F). Moreover, mocytes from mutant embryos appeared more separated from each other and less 
arrayed than wild type controls, but no significant reduction of the cytoplamic volume was 
observed in the ATE1 mutant cardiomyocytes at the cellular level. These phenotypes are 
biventricular. Intriguingly, the thickened compact layer becomes the major contractile force in 
* * 
* 
* 
* 
* 
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Figure 23.  Expression of ATE1 in embryos.  Whole mount X-gal staining of wild type (indicated) and ATE1
-/-
 
embryos at 12.5-dpc (days post-coitus). Prominent expression was detected in the brain, the neural tube and the 
heart.  
 
embryos during E12.5 and this may explain this observation that embryonic lethality occurs after 
E12.5 rather than earlier stages. 
The ventricular wall is composed of replicating cardiomyocytes, which starts to expand at 
around E11.5 with the ventricular chamber wall thickening with advanced stages, whereas the 
forming trabeculae consists of less proliferating cardiomyocytes. Although the control hearts at 
E13.5 had abundant and thick trabeculae, the mutant ATE1 had thinner and less-abundant 
trabeculations. Additionally, abnormally dilated atrial chambers were frequently observed in 
ATE1-mutants. There was an abnormally deep interventricular sulcus in ATE1-mutant embryos, 
which may be implicated with the abnormal morphogenesis of interventricular septum. 
Interventricular septa began to form normally both in wild type and ATE1
-/- mutants and 
undistinguiable until E11.5. In contrast, at E12.5, mutants exhibited disorganized interventricular 
septum with holes and slower development that that of wild type from E12.5. The membrane 
portion of the ventricular septum (pars membranacea) of ATE1
-/-
 embryos failed to fuse, resulting 
in ventricular septal defects (VSD) which was observed with full penetration. Some of ATE1-/- 
embryonic hearts revealed underdeveloped of dysplastic mitral valve and persistent truncus 
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Figure 24.  Expression of ATE1 in the embryonic hearts.  Xgal staining (left and middle panels) and 
immunohistochemistry for β-galactosidase was performed with paraffin sectioned 13.5-dpc embryonic hearts. LacZ 
signals were observed mainly in trabeculea, ventricular walls, and interventricular septum. 
 
arteriosus. The severity of cardiac and valvular defects of ATE1 mutants varied between 
embryos, possibly reflecting the mixed genetic background. The sizes of lumens of ventricles 
appeared to be normal or slightly reduced in mutant embryos. In summary, these finding indicate 
that the severe heart abnormality such as the hypoplastic ventricular chamber and the poorly 
formed interventricular septum in ATE1
-/-
 embryos accounts for a failure of the circulatory 
system and ultimately in fetal death. 
3.4.3 Reduced Proliferation of ATE1-/- Embryonic Hearts 
To determine whether the aforementioned hypoplastic phenotypes were a result of decreased 
proliferation, increased cell death, or both, the rates of cell proliferation in ATE1-/- hearts were 
first examined by measuring BrdU incorporation into newly synthesized DNA in different 
developmental stages (Fig. 21). At E12.5, the proliferation rates were 26.3 ± 5.1 % and 33.1 ± 
6.1 % in wild type ventricular wall and intraventricular septum, respectively, while ATE1
-/- 
mutants had significantly reduced BrdU index, 12.1 ± 1.7 % and 10.4 ± 2.2 %, respectively. At 
E13.5, the proliferation rates of wild types were 21.6 ± 2.2 % in ventricular wall and 17.6 ± 3.0 
% in septum and, at the same stage, mutants showed 16.4 ± 1.5 % and 14.3 ± 1.7 %, 
respectively. These data indicate that abrogation of ATE1 causes decreased DNA synthesis in the 
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Figure 25.  Expression of ATE1 in cardiomyocytes.  X-gal staining of primarily cultures heart cells from 13.5-dpc 
embryos followed by α-actinin immunostaining, a marker for cardiomyocytes. DIC images (left panel) and 
immunofluorescence image (right panel) shown. Nucleus-specific LacZ signals were observed in the 
cardiomyocyte-specific manner. 
 
heart. While the proliferation of the ventricular wall and the septum which forms by 
cardiomyocytes were markedly reduced, the trabecular layer appeared to be less affected. There 
were no significant differences of BrdU index between wild type and mutants in trabeculae (4.3 
± 1.0 % and 3.9 ± 1.5 %, respectively, at E12.5, and 4.1 ± 0.8 % and 3.1 ± 1.1 %, respectively, at 
E13.5) at both stages. The reduced proliferation appeared to be specific to the hearts, rather than  
global cell growth retardation, since proliferation of other organs, such as brain and lung in 
ATE1-mutant embryos (57.6 ± 5.2 % and 60.2 ± 7.4 %, respectively, at E12.5, and 38.6 ± 6.2 % 
and 40.2 ± 8.3 %, respectively, at E13.5) is indistinguishable from that in wild type controls. The 
discrepancy between trabeculae phenotype in ATE1 mutant and no BrdU difference may be from 
that trabecular layer proliferation occurs at earlier stages (E10.5-E11.5) than the compact zone 
and, at E12.5, the forming trabeculae consists of less proliferating cardiomyocytes (Sucov et al. 
1994; Sedmera and Thomas 1996). 
In addition to the BrdU assay, the mitotic index was measured by immunostaining against 
phosphor-histone H3 (H3P), a mitosis marker, from E11.5 to E13.5.  As shown in Figure 22, 
more H3P-positive cells are observed at the earlier stages and there were markedly reduced 
numbers of relative H3P-positive cells in the heart of null mice when compared to wild type 
littermates, especially in the compact layer and ventricular septum. Mitotic index was peak at 
E11.5. In ventricular wall, wild type showed 1.79 ± 0.18 %, 1.23 ± 0.07 %, and 0.24 ± 0.11 % of 
mitotic index at E11.5, E12.5 and E13.5, respectively. ATE1
-/- mutants had significantly reduced 
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Figure 26.  DNA synthesis defects in ATE1-deficient cardiomyocytes.  (Upper panels) BrdU incorporation assay 
using primarily isolated wild type and ATE1
-/-
 mouse embryonic cardiomyocytes. (Lower panels) Quantificaiton of 
BrdU index from immunostaining. Cell proliferation indices were not altered in ATE1-deficient cardiac fibroblasts 
compared to wild type and heterozygous and homozygous mutants. Data represents mean ± s.e.m. from three 
independent experiments. 
 
mitotic index compared to wild type, which are 0.52 ± 0.21 %, 0.64 ± 0.08 %, and 0.17 ± 0.01 
%, respectively, in ventricular wall, although, at this stage, no lethality or change in gross  
morphology is seen. In the septum, the mitotic index was significantly reduced at E11.5 (1.44 ± 
0.18 % in wild type and 0.73 ± 0.21 % in mutants) and E12.5 (1.41 ± 0.35 % in wild type and 
0.33 ± 0.08 % in mutants), although there was no significant difference at E13.5 (0.19 ± 0.02 % 
in wild type and 0.18 ± 0.03 % in mutants). In trabeculea, E11.5 embryos showed significant 
difference (1.48 ± 0.26 % in wild type and 0.77 ± 0.26 % in mutants).  
The results stated above were consistent with the previous report that the peak of mitotic 
index in compact layer and in trabecular layer is earlier than E11.5 (Toyoda et al. 2003). Cardiac 
myocytes lose their proliferative capacity right after birth in mice or about at E17.5 in rat (Wang 
et al. 1996). Cell death was examined by TUNEL assay to understand whether increased 
apoptosis plays a role in the decreased proliferation in the mutant hearts from E11.5 to E14.5. 
Only a few cardiac cells were stained during the stages prior to global necrosis of mutant 
embryos, indicating no significant cell death by apoptosis, and no indication was observed that 
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Figure 27.  Mitosis defects in ATE1-deficient cardiomyocytes.  Immunostaining against phosphor-Histone H3 
(mitosis marker) using primarily isolated wild type and ATE1
-/-
 mouse embryonic cardiomyocytes and its 
quantification. Similar to BrdU index, cell proliferation indices were not altered in ATE1-deficient cardiac 
fibroblasts compared to wild type and homozygous mutants. Data represents mean ± s.e.m. from three independent 
experiments. 
 
elevated cell death contributes to this phenotype (data not shown). Together, these data 
suggested that impaired proliferation of ATE1-deficient heart, with onset at E11.5, accounts for 
the defective cardiac morphogenesis and, ultimately, for fetal death. 
3.4.4 Expression of LacZ from the ATE1 Allele in Cardiomyocytes 
The expression of LacZ reporter integrated into the targeted ATE1 allele was prominently 
detected in the brain, neural tube, and the heart as monitored by β-galactosidase activity (Fig. 
23), which is consistent with ATE1 mRNA expression detected in wild type embryos by in situ 
hybridization (Kwon et al. 2002). The expression of ATE1 in histological sections was also 
examined (Fig. 24). The β-gal signals were located in the nucleus due to the nuclear localization 
signal placed at the 5’ terminus of the LacZ sequence. Strong signals in the nucleus were 
observed in trabeculae, in atrio-ventricular bulbar cushion, and both in right and left ventricular 
walls. However, the signal was decreased after E12.5. Expression in the atrium was relatively 
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Figure 28.  Hypertrophy in ATE1-deficient Cardiomyocytes.  (A) Immunostaining against ANP, a hypertrophy 
marker. Its peri-nucleic expression was observed in both wild type (a, b) and ATE1
-/-
 (c, d) primary cardiomyocytes. 
(B) mRNA expression of hypertrophic genes were examnined by RT-PCR with GAPDH control. (C) Size analysis 
and leucine incorporation assay. No detectable difference in terms of hypertrophism between these two genotypes 
was seen, suggesting hypoplasia not hypertrophy in ATE1-deficient cardiomyocytes might be responsible the 
phenotype of ATE1
-/-
 embryos. Data represent mean ± s.e.m. from three independent measurements of 
cardiomyocyte size and cpm. No significant difference was observed between the genotypes. 
 
weak. Although ATE1 expression was observed from all over the compact zones of the 
developing heart, cell type specificity of ATE1 expression has not been determined. The 
expression of LacZ in the developing heart was also confirmed by immunohistochemistry by 
using anti-β-galactosidase antibody. To dissect the expression pattern of ATE1 in the heart, LacZ 
staining was performed on primarily cultured heart cells isolated from ATE1-/- mutant hearts (Fig. 
25). LacZ staining followed by immunostaining with sarcomeric α-actinin antibody readily 
revealed that ATE1 expression was mainly observed in cardiomyocyte population, where 
hypoplasia defect was found in the developing ATE1-/- heart while not (or less) in cardiac 
fibroblasts which can also be identified by their characteristic morphology and bigger nucleus 
size. The results suggest an autonomous stimulatory role of ATE1 on the proliferation of 
cardiomyocytes. Abnormal proliferation of cardiomyocytes in ATE1 mutant was also observed 
as described below. 
3.4.5 ATE1 as Cell Autonomous Proliferation Regulator of Cardiomyocytes 
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The thinner ventricular wall layers and the decreased proliferation of ATE1-/- hearts as well as 
restricted expression of ATE1 in the cardiomyocytes suggested less proliferative cardiomyocytes 
in the developing heart. Moreover, it remained to be demonstrated whether ATE1 functions in 
the cardiomyocytes, not from adjacent components of the hearts, to initiate proliferation. In order 
to determine the level of proliferation in ATE1
-/-
 cardiomyocytes, BrdU incorporation assay was 
performed using primary cardiomyocytes cultured from embryonic hearts (Fig. 26A, B). 
Coimmunostaining with anti-cardiac troponin I antibody and with anti-BrdU antibody 
distinguished proliferating cardiomyocytes from noncardiomyocytes. Moreover, the primary 
culture system minimized the multiple growth signals originating from adjacent cell lineages of 
the developing heart or from the whole body. In serum-containing media, the BrdU labeling 
index in ATE1 mutant cardiomyocytes (9.4% ± 3.6%) was significantly lower than heterozygous  
mutant (22.0% ± 5.4%) or wild type (19.4% ± 4.6%), indicating that cell growth is defective in 
mutants. Cardiomyocytes have been known to undergo cell division until postnatal day 3 
although the rate decreases after E11.5 (Wang et al. 1996). To examine whether cell proliferation 
of cardiac fibroblasts was also affected in ATE1 mutants, the cell proliferation index of primary 
cardiac fibroblasts was assessed. The non-cardiomyocyte population that was not stained by 
cardiac troponin I antibodies was regarded as cardiac fibroblasts although other cell populations 
such as endothelial cells and smooth muscle cells may exist as a minor population. As shown in 
Fig. 26, cell proliferation indices were not altered in ATE1-deficient cardiac fibroblasts (60.9% ± 
2.4%) as compared to wild type (62.3% ± 3.2%) and heterozygous mutants (58.1% ± 3.4%). 
Therefore, cell proliferation of cardiomyocytes, but not cardiac fibroblasts was down-regulated 
in ATE1 mutant hearts when cells were cultured. 
To determine if ATE1 also regulates mitosis in primary cardiomyocytes, the mitotic 
index by immunostaining phospho-histone H3 (H3P), a marker for mitotic cells, was evaluated 
(Fig. 27C, D). Most mitotic cells both in wild type and ATE1 mutants were at prophase or 
prometaphase. Knocking out ATE1 gene significantly decreased the number of H3P-positive 
cells by 78.2% in cardiomyocytes (1.73% ± 0.33% wild type and 0.33% ± 0.32% ATE1 mutant). 
However, noncardiomyocyte cells from ATE1-/- had comparable mitotic indices to those observed 
from the wild type (6.85% ± 1.23% wild type and 5.47% ± 1.2% ATE1 mutant). Collectively, 
these data strongly indicate that the cardiac phenotype of ATE1-deficient mice during 
embryogenesis is mainly due to a proliferative deficiency, i.e. decreased DNA synthesis 
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Figure 29.  Level of RGS4 protein in ATE1
-/-
 embryos.  Immunoblot using whole embryonic extract (upper panel), 
embryonic heart extract (lower panel, left), or embryonic brain extract (lower panel, right) to detect and compare 
endogenous levels of RGS4 in wild type and ATE1
-/-
 embryos. RGS4 was not detected in wild type embryos and 
organs while prominent expression was observed in ATE1-deficient samples. Anti-RGS4 antibody is a kind gift 
from Dr. Mumby. 
 
 
associated with perturbed mitotic activities of cardiomyocytes. Moreover, these in vitro data 
indicate that the function of ATE1 is intrinsic to cardiomyocytes in a cell autonomous manner. 
3.4.6 Hypertrophy in ATE1-deficient Cardiomyocytes 
Embryonic cardiomyocytes have two complementary characteristics; hyperplastic (cell division) 
and hypertrophic (cell enlargement) until they are terminally differentiated. I examined whether 
ablation of ATE1 affects hypertrophic behavior in primary cardiomyocytes by measuring cell 
size, protein content increase ([3H] leucine uptake), and hypertrophy marker gene expression 
through RT-PCR and immunostaining against ANP in the primary cardiomyocytes culture 
system under physiological conditions (with serum). As shown in Figure 28, ANP, a representing 
hallmark of hypertrophic genetic reprogramming in cardiomyocytes and a prognostic indicator of 
clinical severity of hypertrophy, was immunostained, revealing a perinulear staining pattern in 
cardiomyocytes (Liu and Olson 2002). However, significant difference was not detected in 
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Figure 30.  Expression of RGS4 mRNA in ATE1
-/-
 embryos.  Quantitative PCR to compare mRNA levels of RGS 
proteins which revealed no significant difference between the mutants and controls indicating that down-regulation 
of RGS proteins occurs posttranscriptionally. Data represent mean ± s.e.m. from three independent measurements of 
mRNA level. No significant difference was observed between the genotypes. 
 
 
expression level and pattern between both genotypes. During this experiment, more 
differentiated cardiomyocytes, which are multinucleated, coexisted (~55% of all 
cardiomyocytes) with mitotically active mononucleated cardiomyocytes both in wild type and in 
the ATE1 mutant, which indicates thatDNA synthesis continued although cell division ceased. 
Organization of sarcomere was also examined by immunofluorescence microscopy, but 
myofilament organization exhibited no significant difference between both genotypes. The 
mRNA level of β-MHC, cardiac α-actnin, ANP was determined by semi-quantative RT-PCR 
using GAPDH as a control and observed not significantly changed in ATE1
-/-
 embryonic hearts. 
Measurement of cell size with NIH ImageJ software revealed that the cell surface area of ATE1 
mutant cardiomyocytes was comparable to that of wild type. Moreover, the hypertrophism was 
measured by [3H] leucine incorporation using primary culture system. However, no detectable 
difference between these two genotypes was seen.  Although many in vivo studies using rat 
cardiomyocytes indicate that chronic stimulation of Gq-coupled receptors is sufficient to induce 
cardiomyocyte hypertrophy(Dorn and Hahn 2004), their contribution in mouse embryonic 
cardiomyocytes remain elusive. This result suggested that lack of ATE1 does not appear to affect 
the transition to hypertrophy of cardiomyocytes and that embryonic mouse cardiomyocytes 
undergo “autonomous hypertrophy” as shown in neonatal mouse cardiomyocytes (Deng et al. 
2000). Therefore, hypoplasia not hypertrophy in ATE1-deficient cardiomyocytes might be 
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Figure 31.  Immunostaining of RGS4 protein in ATE1
-/-
 embryos.  Whole mount immunostaining (left panel) using 
anti-RGS4 antibody and Immunostaining of embryonic hearts (right panel) using 13.5-dpc wild type and ATE1 
mutants. ATE1 mutant embryonic hearts showed defective morphogenesis including sparse trabeculea, thin 
myocardium, and holes in interventricular septum. Consistent with immunoblot data, RGS4 expression was 
prominent only in ATE1-mutant embryos and embryonic hearts. 
 
responsible the phenotype of ATE1-/- embryos.  
3.4.7 RGS proteins and G protein Signaling in ATE1-/- Cardiomyocytes 
In Chapter II, I identified a set of RGS proteins (RGS4, RGS5, and RGS16) as the first in vivo 
substrates of mouse ATE1 (Lee et al. 2005). However, the information was mainly obtained by 
in vitro translated RGS proteins and overexpressed RGS proteins in ATE1-deficient mouse 
embryonic fibroblast cells because of the lack of a good antibody which could detect endogenous 
protein levels and the low natural abundance of the proteins despite the relative abundance of 
their mRNA. Previously, Dr. Mumby’s group (Krumins et al. 2004) and Dr. Druey’s group 
(Derrien et al. 2003) developed monoclonal antibodies with appropriate specificity and sufficient 
sensitivity to detect endogenous RGS4 and RGS16, respectively, and, in the present study, their 
endogenous levels were examined in the ATE1 mutant. Figures 29 shows a Western blot 
performed on extracts of whole E13.5 embryos and embryonic tissues, e.g. brain and heart using 
the antibodies. Strikingly, a substantial level of RGS4 in ATE1
-/- embryos and embryonic hearts 
and brain was observed, while there is no detectable RGS4 in littermate controls. RGS16 level 
was lower than RGS4, but revealed that RGS16 was also stabilized in ATE1-/- embryos. The 
amount of RGS4 was higher in the brain than the heart. Quantitative RT-PCR analysis with total 
RNA prepared from E13.5 embryonic hearts revealed no significant difference between the 
mutants and controls which indicates that down-regulation of RGS proteins occurs 
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Figure 32.  Expression pattern of RGS4 protein in ATE1
-/-
 embryos.  Immunostaining of different stages of ATE1
-/-
 
embryos using the same antibody. Magnified neural tube areas (upper panels) and other neural crest cell destination 
areas (lower panels). RGS4-positive cells appeared along the pathway of neural crest cell migration, including dorsal 
root ganglia, sympathetic ganglia, muscle linage, and developing alveolus. 
 
posttranscriptionally (Fig. 30). Consistent with immunoblot results, the high level of expression, 
probably because of stabilization of otherwise unstable RGS4 protein, was also observed in 
ATE1-deficient embryos and embryonic hearts when immunostained with anti-RGS4 antibody 
(Fig. 31). Moreover, immunostaining revealed RGS4-positive cells along the pathway of neural 
crest cell migration, including dorsal root ganglia, sympathetic ganglia, muscle linage, and 
developing alveolus (Fig. 32). The migration of RGS4-positive cells started as early as E11.5 
when the neural folds had remained open, and begin cranially and then gradually extend caudally 
(Fig. 32).  
In light of the role of RGS proteins as negative regulators in Gq- and Gi-mediated 
signaling and the referential expression of ATE1 in cardiomyocytes, I asked whether GPCR 
signaling pathway in the ATE1-mutant heart might be defective because of stabilized RGS 
protein. To explore this possibility, the downstream kinases of the GPCR signaling pathway in 
the embryonic hearts were measured by in vitro kinase activity assay. The activated α subunit of 
Gq directly stimulates phospholiphase (PLC) leading to hydrolysis of phosphoatihylinositol 
bisphosphate (PIP2) into IP3, which induces Ca++ release from endoplasmic reticulum, and 
diacylglycerol, which regulates the activities of protein kinase C (PKC) and MAPKs. All these 
proteins involve the Gq-signaling pathway have been known to play key roles in regulating 
cardiomyocyte growth (Adams and Brown 2001). Previously, the activity of ERK1 and ERK2, a 
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Figure 33.  Activities of effectors of G protein signaling in ATE1
-/-
 embryos.  Activities of GPCR downstream 
effectors were measured using embryonic heart extracts from wild type and ATE1
-/-
.  Following substrates were used 
for each kinase, MBP for ERK, Kemptide for PKC, PIP2 for PLC, and other synthetic peptides for CaMKII and 
PKA. Data represent mean ± s.e.m. from independent measurements of the kinase activities using embryonic heart 
extract from three non-litter embryos. *: p < 0.05. 
 
 
downstream effector of Gq- and Gi signaling pathway, was reported to be impaired in whole 
embryo. From embryonic heart extracts, total kinase activity of ERKs, which was determined by 
the kinase assay with myelin basic protein as a substrate, was 77.86% lower in ATE1
-/-
 than in 
wild type embryonic hearts (Fig. 33). There was no significant difference in PKA and CaMKII 
activities between these genotypes. PKC and PLC activities also decreased significantly in ATE1 
mutants (64.52% and 82.99%, respectively), while CaMKII and PKA activities showed 
comparable level as controls (Fig. 33). No change of PKA and CaMKII in the ATE1 mutant may 
reflect the weak relation of ATE1/RGS protein to Gs-cAMP signaling pathway. These data 
suggest that ATE1 specifically affects Gq and Gi signaling pathway probably through the RGS 
protein. 
To determine the effect of ATE1 on signaling in cardiomyocytes, the responsiveness 
kinase activities on serum stimulation was examined in primarily cultured wild type and ATE1
-/-
 
mouse embryonic cardiomyocytes, especially for the activation of ERK1/ERK2, a crucial player 
in cardiovascular signaling pathways (See Background in Chapter II), and its upstream kinase, 
MEK1. Primary cardiomyocytes were harvested at multiple time points after serum stimulation, 
and activities were measured by immunoblotting and quantitative analysis with antibodies 
* 
* 
*
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Figure 34.  Serum-starved and serum-stimulated ERK1/2 and MEK1 activities in wild type, and ATE1
-/-
 embryonic 
cardiomyocytes. Primarily cultured mouse embryonic cardiomyocytes were serum-starved for 24 h and subsequently 
stimulated with 20% FBS for the times indicated. Total cell extracts were subjected to immunoblotting with 
antibodies against Gαq and phosphorylated and unphosphorylated ERK1/ERK2 and MEK1. Quantitation of the 
active forms of MEK1 shown in the right graphs. 
 
specific for activated kinases. The increased activities by serum stimulation followed by serum 
starvation were observed as early as 15 min. However, significantly decreased level of active 
forms MEK1 and ERK1/2 were detected in ATE1
-/-
 cardiomyocytes compared to control (Fig. 
34), suggesting that the MEK1-ERK1/2 pathway is regulated by the ATE1-RGS pathway. Taken 
together, these findings, consistent with the previous reports describing that overexpression of 
RGS proteins inhibits G protein signaling in cultured cardiomyocytes (Tamirisa et al. 1999), 
suggest that Gq signaling may decrease in ATE1-deficient cells by stabilization of negative 
regulators of the pathway, namely the RGS proteins. 
3.4.8 Defective AngII-mediated Proliferation in ATE1-/- Cardiomyocytes 
Based on the results that proliferation of ATE1
-/-
 cardiomyocytes was reduced and RGS-regulated 
Gq- and Gi-signaling pathway was defective, it is reasonable to hypothesize that there are 
mitogenic signals mediated by GPCR in cardiomyocytes. To further examine the role of ATE1, 
Gq agonists on proliferation of cultured primary cardiomyocytes were evaluated (Fig. 35). There 
was no significant difference of cell proliferation between wild type and ATE1 mutant
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Figure 35.  Defects in AngII-mediated proliferation in ATE1
-/-
 cardiomyocytes.  (Left panels) BrdU incorporation assay using primary cardiomyocytes in the 
presence of different agonists. (Right panel) Quantification of the BrdU index. Agonists targeting different downstream effectors (ISO, Gs; PE, Gq; PGF2α, Gq; 
AngII, Gq-coupled AT2; FGFb, control, not GPCR agonist) were used. In ATE1
-/-
 cardiomyocytes, AngII did not induce cell proliferation which was seen in wild 
type cardiomyocytes. Data represent mean ± s.e.m. from three independent measurements of cardiomyocyte proliferation rates. *: p < 0.05. 
 
 
 
*
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Figure 36.  Defects in AngII-mediated proliferation in ATE1
-/-
 embryonic hearts.  BrdU incorporation assay using 
explanted hearts in the presence of AngII (left) and its quantification (right panel). Consistent with the results from 
cultured cardiomyocytes, explanted hearts showed reduced proliferation in the presence of AngII in ATE1
-/-
 
embryonic hearts. Data represent mean ± s.e.m. from three independent experiments (See details in Methods. *: p < 
0.05.). 
 
cardiomyocytes when treated with basic FGF, a ligand whose receptors are not directly coupled 
with G protein, which is consistent with a previous report that FGFb did not alter BrdU 
incorporation of mouse cardiomyocytes in the absence of serum (Lepic et al. 2006). However, 
ATE1 significantly enhanced levels of BrdU incorporation in wild type cardiomyocytes, while 
ATE1 mutant showed no difference. AngII has been known to induce cardiac hypertrophy 
though AT1 receptor (Thomas et al. 2002), which is coupled with Gq- and Gi proteins, activating 
primarily the MAPK signaling pathway via PLC and PKC activation (Izumi et al. 2000). 
Moreover, AngII stimulates protein synthesis both in cultured rat cardiomyocytes and in the 
isolated whole hearts (Schunkert et al. 1995; Sundgren et al. 2003). Phenylephrine (PE) and 
prostaglandin F2α (PGF2α) also signals through Gq and Gi-coupled α-adrenergic receptors and 
prostaglandin receptors, respectively. However, no proliferative effect was observed from the 
agonists. Although they activate the same G proteins, the proliferative phenotype differed, which 
may be the result of receptors coupling to more than one G protein and initiating several 
signaling pathways. Isoprotenerol (ISO) stimulates Gs-coupled β-adrenergic receptors. It is 
known to have little effect on the hypertrophic response to pressure overload (Akhter et al. 1998) 
and also exhibited no effect on the proliferation of ATE1
-/-
 cardiomyocytes.  
The proliferation of whole hearts was also examined to further confirm a cell- 
*
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autonomous effect of AngII (Fig. 36). Embryonic hearts were excised from E13.5 embryos and 
the beating hearts were subsequently cultured in the presence or absence of AngII with BrdU. 
The BrdU-positive cells were observed mainly in the ventricular wall area. Consistent with the 
results using cultured cardiomyocytes, explanted hearts showed reduced proliferation in the 
presence of AngII, in ATE1-/- embryonic hearts (wilt type 69.4% and mutant 15.5%) although the 
proliferation rates were greater in the presence of AngII than in the absence of AngII both in 
wild types and mutants. MAPK signaling, which was defective in ATE1-deficient embryonic 
hearts and cardiomyocytes, has been known as a major mediator of AngII-induced 
cardiomyocyte growth (Thomas et al. 2002). These data strongly suggest that the AngII-
mediated signaling pathway, which is controlled by ATE1-RGS circuit, is implicated in normal 
development of the heart. 
3.5 DISCUSSION 
The heart is the first organ to form in the embryo, whose function is essential to embryonic 
survival, even in early midgestation, and whose abnormality during morphogenesis results in 
congenital heart disease (Olson and Schneider 2003). Although it was reported that deficiency of 
ATE1 results in congenital heart disease-like abnormality in mice (Kwon et al. 2002), the role of 
ATE1 at the molecular level has remained unknown. In this study, I attempted to determine the 
function of ATE1 in cardiac development. The results suggest that there is an active pathway 
regulating cardiomyocytes proliferation that is controlled by ATE1. ATE1-deficient mice die 
during E12.5- to E14.5 asscociated with defects in cardiac development. I observed not only 
various morphological abnormality and significantly reduced proliferation in developing ATE1
-/-
 
hearts and cultured embryonic cardiomyocytes. ATE1 was prominently expressed in 
cardiomyocytes of cultured heart cells. Increased number of cardiomyocytes is responsible for 
the enlargement of hearts during embryogenesis until they lose their proliferative capacity right 
after birth in mice or at about E17.5 in rat (Wang et al. 1996). During E11.5 and E14.5, 
cardiomyocytes rapidly proliferate leading to expansion of the ventricular wall and 
cardiomyocytes take 70 % to 80 % of the mass of the adult heart. The diminishing ability of the 
cardiomyocytes proliferation at the latest stage has been attributed to a block in the cell cycle 
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either in the G0 or G1 phases (Brooks et al. 1998). It was observed previously that post-
transcriptional down-regulation of the amount of D-type cyclins, which is crucial for G1-S phase 
transition, in UBR1-/-UBR2-/- embryos compared to littermate controls (An et al. 2006). Although 
we could not provide conclusive evidence here, it is possible that the G1 arresting may cause 
reduced proliferation of ATE1-deficient cardiomyocytes.  
I also identified that the levels of endogenous RGS4 and RGS16 in ATE1-/- embryoninc 
hearts were significantly increased and the downstream activities of Gq- and Gi signaling 
pathways, which are regulated by RGS proteins, were also reduced in ATE1
-/-
 hearts. Gq 
expresses in cardiomyocytes as well as non-cardiomyocytes in the developing heart (Offermanns 
et al. 1998). Although GPCR can interact with most or all members of their preferred G protein 
family, specific downstream pathways from Gq-coupled receptors may be able to distinguish 
among different members and have different roles to regulate heart development. Angiotensin II 
transgenic mice showed midgestation lethality with grossly enlarged atria (Hein et al. 1995), but 
α-adrenergic receptor transgenic mice showed no changes in ventricular morphology (Milano et 
al. 1994). Ang II-induced AT1 receptor activation via Gq or Gi on the rennin-angiotensin system 
stimulates PLC, and activates IP3/Ca2+ signaling, PKC, and MAPKs. Moreover, Ang II mediates 
the production of reactive oxygen species under physiological condition and pathological states 
(Hunyady and Catt 2006), raising a possibility that the role of oxygen in RGS4, RGS5, and 
RGS16 degradation can be expanded (Hu et al. 2005; Lee et al. 2005). At least 13 different 
members of the RGS family, including RGS4, RGS5, and RGS16, are expressed in mammalian 
cardiomyocytes and cardiac tissues which have GAP activity toward the Gαq and Gαi family G 
proteins (Wieland and Mittmann 2003). Interestingly, a recent paper described that RGS2 
regulates the intracellular signaling of AngII and AT1 receptor desensitization in a negative 
feedback manner on aldosterone synthesis, which is one of critical factors in the development of 
Ang II-induced cardiovascular damage (Struthers and MacDonald 2004; Romero et al. 2006). 
However, their exact roles in the developing hearts and in the adult hearts in the normal and 
diseased states have remained poorly defined. Interestingly, knockout mice lacking both Gαq 
and Gα11 die at E11.5 because of hypoplasia in the ventricular wall (Offermanns et al. 1998). 
Consistent with these reports, RGS4 overexpression in the ventricular myocytes blunted the 
stimulated PLC activity (Mittmann et al. 2002) and MAPK activity (Rogers et al. 2001). 
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However, overexpression of Gαq in mouse hearts or in cultured cells also showed activated PLC 
and increased cell growth (LaMorte et al. 1994; D'Angelo et al. 1997). 
The pattern of sarcomeric protein gene expression is tightly regulated in a tissue- and 
developmental stage-specific manner, To evaluate the roles of genes regulating cardiac 
morphogenesis in ATE1-mutant hearts, the levels of GATA4, Nkx2.5, MEF2C, dHAND, 
eHAND, αMHC, βMHC, cardiac α-actinin, and ANP, were examined by using quantitative RT-
PCR. However, no significant differences in the level of the genes were observed in ATE1-/- and 
wild type controls (data not shown). Given the complexity of the heart development and 
crosstalk among G protein signaling pathways, another approach such as genome-wide screening 
with Ang II treatment may clarify genes regulated by the ATE1-RGS-GPCR circuit. To date, 
most study for cardiomyocytes phenotypes and signaling have used neonatal rat cardiomyocytes, 
while there are only few studies using embryonic mouse cardiomyocytes, and they exhibited 
remarkably different characteristics (Deng et al. 2000). Identification of the factors controlling 
mouse cardiomyocytes proliferation and development is of great importance. Based on the 
results that proliferation of ATE1
-/-
 cardiomyocytes was defective in  RGS-regulated Gq- and Gi-
signaling pathway, we examined various mitogenic Gq agonists and  β-adrenergic receptor 
agonist on wild type and ATE1-deficient embryonic cardiomyocytes. Among Gq agonists, only 
Ang II increased the proliferation of wild type cardiomyocytes. However, in ATE1-/- 
cardiomyocytes, that effect was not observed. Moreover, there is no significant morphological 
difference between the genotypes after the treatment of agonists. BrdU index from primary 
cardiomyocytes cultured in serum-free condition showed no significant difference, suggesting 
that proper cardiomyocyte proliferation requires stimulation by specific Gq agonist including 
Ang II.  
I also examined the possibility that hypertrophism may be involved in the phenotypes of 
ATE1
-/-
 mice. However, cardiomyocyte size and hypertrophic gene expression in the mutant were 
comparable with wild type. This result suggested that lack of ATE1 does not appear to affect the 
transition to hypertrophy of cardiomyocytes. Although many in vivo studies using rat 
cardiomyocytes indicate that chronic stimulation of Gq-coupled receptors is sufficient to induce 
cardiomyocyte hypertrophy, their contribution in mouse embryonic cardiomyocytes remain 
elusive. Recently, it was reported that embryonic mouse cardiomyocytes undergo “autonomous 
hypertrophy” regardless of extracellular stimulation (Deng et al. 2000). Therefore, hypoplasia 
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not hypertrophy in ATE1-deficient cardiomyocytes might be responsible the phenotype of  
ATE1-/- embryos.  
The increased RGS4 level in ATE1-/- embryos allowed us to detect its expression pattern 
in different stages of embryogenesis. Immunostaining revealed that its expression was 
significantly overlapped with the destination of neural crest cell migration, including dorsal root 
ganglia, sympathetic ganglia, muscle lineage, and developing alveolus, and the RGS4-positive 
cells migrated cranially at E11.5 when the neural folds had remained not closed and gradually 
extended caudally at the later stages. Although Gq signaling has also been known to be 
implicated in the migration of neural crest cells, ATE1-/- embryos showed no defects in migration. 
However, the outflow defects and valve defects in ATE1-/- embryos, including persistent truncus 
arteriosus and ventricular septal defects (Kwon et al. 2002), may be related with the function of 
neural crest cells or neural crest-differentiated cells, since neural crest cells migrate into the 
cardiac outflow tract and cardiac valves contributing to formation of the ductus arteriosus and 
septation of the truncus arteriosus into the aortic and pulmonary trunks (Clark et al. 2006). This 
result demonstrates that ATE1-deficient mice can be one model system for the study of short-
lived proteins such as RGS4. 
In summary, this study identified a cell-autonomous function of ATE1 in cardiac 
development. ATE1-/-embryonic hearts and cardiomyocytes showed impaired proliferation. ATE1 
was prominently expressed in cardiomyocytes of developing hearts. Moreover, downstream 
activity of Gq- and Gi signaling pathways, regulated by RGS proteins, was decreased in ATE1
-/-
 
embryonic heart and cardiomyocyte. Endogenous levels of RGS4 and RGS16 were significantly 
increased in ATE1-/- embryos. Since proliferation of cardiomyocytes terminates completely 
shortly after birth (Wang et al. 1996), cardiac muscle loss in adults is a leading cause of the 
morbidity and mortality in the industrialized world. These results, suggesting a general 
physiological control mechanism of ATE1-RGS-GPCR signaling circuit for heart development, 
may raise a possibility that the manipulation of ATE1 expression can reinduce cardiomyocytes 
proliferation in adult mammals.  
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4.0  DEVELOPMENT OF HETEROVALENT INHIBITORS TARGETING N-
RECOGNINS  
4.1 OVERVIEW 
Multivalent binding allows high selectivity and affinity in ligand-protein interaction. The N-end 
rule pathway is a Ub-dependent proteolytic system, where specific E3s called N-recognins 
initiate ubiquitylation through recognition of type 1 and type 2 destabilizing N-terminal residues 
of substrates. To explore a model of heterovalent interaction, RF-C11, whose two heterovalent 
ligands were designed to cooperatively target two cognate sites of N-recognins, has been 
developed. Heterovalent RF-C11 selectively inhibited the ubiquitylation and degradation of both 
type 1 and type 2 N-end rule substrates, with higher efficacy than homovalent compounds with 
two homovalent ligands. It directly interacted with UBR1 fragment containing the UBR box 
motif and pulled-down endogenous UBR proteins from rat testis extracts. The treatment of RF-
C11 impaired both proliferation and hypertrophy in cardiomyocytes, unveiling a previously 
unknown function of the pathway in cardiac proliferation and signaling. These results provide a 
molecular basis of designing multivalent inhibitors for specific intracellular pathways and 
identify the most potent inhibitor of the N-end rule pathway.  
 
4.2 BACKGROUND 
Nature employs multivalent interactions for selectivity and avidity of protein/protein or 
protein/ligand interaction, which are beneficial both thermodynamically (enhanced binding 
affinity) and kinetically (lessened rate of dissociation), and various synthetic multivalent  
CHAPTER IV 
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Figure 37.  Models of interhomovalent, interheterovalent, and intraheterovalent interactions.  Interhomovalent 
ligands bind to multiple identical receptors while interheterovalent inhibitors to multiple non-identical proteins. 
Intraheterovalent inhibitors interact with multiple binding sites in a single protein. Most current multivalent 
inhibitors employ interhomovalency-based interaction, targeting surface of bacteria, viruses, or cells. On the other 
hand, rapamycin from Streptomyces hygroscopicus is interheterovalent in that two heterovalent ligands target 
cognate binding sites of two different intracellular proteins (Sabatini et al. 1994). 
 
molecules have been developed to exploit this type of interactions (Fig. 37) (Gestwicki et al. 
2000; Choi 2004). However, the majority of the multivalent inhibitors target multiple, identical 
pairs of receptors on the cell surface, which form “interhomovalent” interactions to increase their 
recognition ability (Matrosovich 1989; Carrithers and Lerner 1996; Rao et al. 1998; Bertozzi and 
Kiessling 2001). For “heterovalent” inhibitors, which, to my knowledge, has not been explored 
extensively, bifunctional small molecules binding with only two distinct cytoplasmic targets 
were reported, e.g. chemical inducer of dimerization CID (Crabtree and Schreiber 1996) and 
synthetic bivalent peptides targeting two regions of a single protein, e.g. bivalirudin (Warkentin 
and Koster 2005). The present work explored the possibility that a small molecule-based 
“intraheterovalent” inhibitor, which retains two different ligands, can have increased efficacy 
and specificity through cooperative and simultaneous binding to the two independent, mutually 
nonexclusive sites of an enzyme or a heterobivalent receptor (Fig. 38).  
In the light of the major challenges of identifying small, organic compound that inhibit 
protein-protein interactions, which are typically mediated through the flat, large, and flexible  
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Figure 38.  Structure of bivalent inhibitor.  (A) Conceptual model for rationally designed bivalent inhibitors. It has 
mainly five building blocks; a core with multiple functional groups, two different “N-terminal” destabilizing 
residues, two appropriate linker/spacer. For the first generation of the bivalent inhibitor, RF-C11, Arg and Phe are 
“N-terminally” conjugated to a Lys core through C11 hydroxycarbon chains. Controls of RF-C11 differ only in the 
“N-terminal” residues. Biotinylated versions of the bivalent inhibitors were also synthesized and showed no loss of 
inhibitory activity. 
 
protein interface, tethering weak monovalent inhibitors can be a good strategy to circumvent this 
problem.  Moreover, unlike targeting cell surface receptors, cell-permeable multivalent inhibitors 
are not affected by the density of target proteins, do not causing receptor clustering, and are able 
to control signaling pathway within the cell. The N-end rule pathway is especially suited for this 
study because of the structural proximity between two substrate binding pockets in a single E3 
Ub ligase enzyme, the independent binding properties of two binding modes, and a well-
characterized binding mechanism that can be used to facilitate extender design (Varshavsky 
1996; Kwon et al. 2001; Kwon et al. 2002; Kwon et al. 2003; An et al. 2006). Dipeptides bearing 
type 1 or type 2 N-degrons have been widely used in cell-free settings as competitive inhibitors 
of the N-end rule pathway. However, dipeptides are at best weak inhibitors in vitro and 
furthermore do not work in mammalian cells. Here the rational, mechanism-based design and de 
novo synthesis of a new class of N-end rule inhibitors are described (Fig. 38). The first 
generation of bivalent inhibitors, RF-C11, has two destabilizing N-terminal residues (e.g. Arg 
and Phe) connected through a Lys residue with hydrocarbon chain linker. The hypothesis is that 
the affinity between an inhibitor and a target protein can be enhanced by bivalent interaction (by 
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two ligands of a single inhibitor) compared to monovalent interaction (by two ligands in two 
independent inhibitors). RF-C11 showed inhibitory activity on the N-end rule pathway both in 
vitro and in vivo, much more effectively than dipeptide inhibitors, validating the concept of 
multivalent interaction. Moreover, the intraheterovalent inhibitor, RF-C11, cooperatively binds 
the UBR box motif and endogenous UBR proteins. I also demonstrated that RF-C11 can inhibit 
the degradation of RGS4, a physiological substrate of the N-end rule pathway (Hu et al. 2005; 
Lee et al. 2005), in vivo and exert anti-hypertrophic effects on primary cardiomyocytes, which 
mimics the effects of RGS4 overexpression (Zhang et al. 1998; Owen et al. 2001). Thus, these 
results contribute to designing small molecule inhibitors with multiple ligands in a single 
molecule and to understanding biochemical mechanisms and physiological functions of the N-
end rule pathway. 
4.3 METHODS 
 
Synthesis of Inhibitors.  The synthesis and characterization of RF-C11 is described in Appendix 
A and B. Controls of RF-C11 and biotinylated versions of bivalent inhibitors were synthesized 
using the similar scheme with modifications. Notably, the intermediate compounds of RF-C11 
and controls were connected by conventional protocols of amide bond formation using EDC with 
high yield (See details in Appendix A and B). For biotin-labeled inhibitors, ethylenediamine-
coupled biotin (8) was initially conjugated with N(ε)-Z-Lysine(-OMe)C11-NH2 6 prior to further 
reactions. The purity and identity of the intermediates and the final products were verified by 
TLC, analytical HPLC, 1H NMR, and mass spectroscopy. Dipeptides, MG132, and bestatin were 
purchased (Sigma-Aldrich, St. Louis, MO).  
 
In Vitro Degradation and Ubiquitylation Assay.  Time- and concentration-dependent in vitro 
degradation and ubiquitylation assays were done as described in Chapter II (Levy et al. 1996; 
Lee et al. 2005) . Briefly, biotinylated lysine-tRNA complex (Transcend tRNA, Promega) was 
added into a reaction mixture for random labeling of expressed proteins and  biotinylated 
proteins were detected against horseradish peroxidase (HRP)-conjugated streptavidin (Pierce). In 
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vitro ubiquitylation of RGS proteins was similarly determined except that the reaction was done 
in the presence of MG132, followed by anti-Ub immunoprecipitation / streptavidin 
immunoblotting. Anti-Ub antibody (Biomol International) recognizes both mono- and multi-
ubiquitinated proteins but not free Ub. IC50 was regressed from sigmoidal dose-response model 
using GraphPad Prism 4.0 version 4.0 (GraphPad). IC50 was determined by using sigmoidal 
dose-response model based on the amounts of X-nsP4, relative to the amounts of DHFR-Ub at 
the same time points and normalized to the amount of the same substrate treated with RF-C11 for 
60 min.  
 
Direct Interaction Assay.  For direct interaction assay, UBR1 fragment was synthesized by 
using the rapid-translation system (RTS) based on wheat germ lysate (Roche Applied Science) 
according to the manufacturer’s instructions.  The fragment was confirmed to be able to bind 
both type 1 and type 2 N-terminal destabilizing residues. RF-C11b or GV-C11b was incubated in 
Hisx6-UBR box-1 immobilized on Ni++-coated microwells and its interaction was determined by 
streptavidin-infrared (IR) 800CW signal (LI-COR Biosciences). Reciprocal experiments were 
performed by adding Hisx6-UBR fragment-flag with immobilized biotinylated RF-C11 on 
streptavidin-coated microwells, followed by anti-Flag-IR incubation.  
To confirm that endogenous UBR proteins bound to RF-C11, the biotin moiety of RF-
C11b and GV-C11b was initially crosslinked to UltraLink Immobilized NeutrAvidin Protein 
Plus beads (Pierce).  Rat testes were homogenized in buffer A (20 mM HEPES, pH 7.9, 75 mM 
KCl, 10 % Glycerol, 0.1 mM EDTA) containing protease inhibitors (Sigma) and diluted to 2 
mg/ml in buffer B (20 mM HEPES, pH 7.9, 200 mM KCl, 10 % Glycerol, 0.05 % Tween-20), 
followed by incubation with RF-C11b or GV-C11b conjugated to beads. Precipitated proteins 
were resolved with 6% SDS/PAGE. Dipeptides (2 mM final concentration) were added to some 
reactions.  Precipitated proteins were subjected to immunoblotting for UBR1 (Kwon et al. 2001) 
or UBR5 (Tasaki et al. 2005).  
 
In Vivo Application and Primary Cardiomyocytes.  For in vivo degradation assay, two 
plasmids expressing RGS4 and the control β-galactosidase, respectively, were cotransfected into 
mouse embryonic fibroblasts.  About 24 h after transfection, cells were treated for 3 h with RF-
C11 or other compounds, followed by immunoblotting.  For pulse chase analysis, mouse 
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embryonic fibroblasts were transiently transfected with pcDNA3-RGS4 plasmid and pCMV-
luciferase plasmid. After 24 hr post-transfection, mouse embryonic fibroblasts were labeled with 
[35S]methionine/cysteine for 10 min, followed by chase for 0, 30 min, and 60 min in the presence 
of cycloheximide. Extracts were prepared and immunoprecipitated with anti-RGS4 and V5 (for 
luc) antibodies, and SDS-PAGE, autoradiography, and quantification were sequentially 
performed.  
The primary cells from mouse embryonic heart were isolated as described with slight 
modification for obtaining more viable cells (Jung et al. 2005). Twenty-four hrs after plating, the 
medium was replaced by serum-free DMEM supplemented with 10 µg/mL insulin, 5.5 µg/mL 
transferrin, 5 µg/mL selenium, and 110 µg/mL pyruvate (Sigma-Aldrich) in the presence or 
absence of the bivalent inhibitors with 5-bromo-2-deoxyuridine (BrdU, Sigma-Aldrich). After 
fixation in 5% paraformaldehyde, cells were coimmunostained with rat anti-BrdU antibody 
(Serotec, Oxford, UK) and rabbit anti-troponin I antibody (Santa Cruz Biotechnology), followed 
by secondary antibody incubation (anti rat-IgG-Alexa 555 and anti-rabbit IgG-FITC, 
respectively) and counterstaining with DAPI.  
The effect of the bivalent inhibitors on MEC viability was determined by the MTT (3-
(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; Promega) colorimetric dye reduction 
method. Cardiomyocyte size was determined by measuring the surface area of troponin I-
positive cells in cultured primary cardiomyocyte. Planimetry was performed using ImageJ 
software version 1.34s (NIH) (Rasband 1997-2006) and outcome arbitrary unit was used. 
Although cell surface area does not constitute the accurate measurement of cell size, this 
parameter was generally used to estimate cardiomyocyte hypertrophy (Fredj et al. 2005). 
Immunohistochemical analysis was performed to detect hypertrophic marker, such as ANP with 
coimmunostaining for a cardiomyocyte marker protein, sarcomeric α-actinin.  
4.4 RESULTS 
4.4.1 In vitro Model System of the N-end Rule Pathway 
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Figure 39.  In vitro model system for the N-end rule pathway.  (A) Generation of the model substrates in 
reticulocytes using modified ubiquitin/protein/reference (UPR) technique (Bachmair et al. 1986). Abundant 
deubiquitylation enzymes (DUB) in the lysates cleave the amide bond of the last amino acid in ubiquitin almost at 
the co-translational stage, generating stable reference protein (DHFR-Ub) and test protein (X-nsP4). (B) Two types 
of the primary destabilizing N-terminal residues. UBR proteins are responsible for the recognition and ubiquitylation 
of the proteins bearing one of these amino acids, making them short-lived. (C) Type-specific inhibition of model 
substrate degradation by cognate dipeptides. Otherwise unstable Arg-nsP4 and Tyr-nsP4 were stabilized in the 
presence of 2 mM of Arg-Ala and Trp-Ala, respectively, while non-N-degron-bearing proteins, such as Met-nsP4 
and Ala-nsP4 have long half-lives. 
 
Small-molecule inhibitors of the N-end rule pathway were tested by using in vitro model 
substrates, which were generated through cleavage of a tripartitie fusion protein, fDHFRh-UbR48 
-X-nsP4f fusions, in rabbit reticulocytes (Fig. 39A)(Levy et al. 1996). For a reference protein, 
DHFR-Ub fragment was stably detected. Half-lives of X-nsP4s were closely related with the 
identity of X, the N-terminal amino acid. Destabilizing N-terminal amino acids, or an N-degron, 
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which can be categorized into type 1 and type 2 (Fig. 39B), are recognized and ubiquitylated by 
a family of E3 Ub ligases named UBR protein (Tasaki et al. 2005). Therefore, the model 
substrates bearing type 1 and type 2 N-degron, such as Arg-nsP4 and Tyr-nsP4, respectively, 
were short-lived in normal condition, while proteins bearing non-N-degron, such as Met-nsP4 
and Ala-nsP4, were robustly expressed as reference (Fig. 39C). Interaction between N-degrons 
and UBR proteins is stereo-selective, and single amino acids do not directly affect the 
degradation of N-end rule substrates although there is a possibility that they may influence non-
canonical function of the proteins. Stereo-selectivity of UBR protein implies a contradictory, less 
important role of α-amine of N-degron at the recognition event and putative basic amino acid(s) 
near UBR box.  
Cognate dipeptides function as competitive inhibitors of the N-end rule pathway. Type 1 
dipeptides, such as Arg-Ala and Lys-Ala, inhibited type 1 model substrates degradation (Fig. 
39C). Type 2 dipeptides, such as Trp-Ala and Phe-Ala, exerted inhibitory activity toward type 2 
substrates, while control dipeptides did not affect substrate stability. Their significantly high 
specificity, for examples, 2 mM of Arg-Ala did not disturb degradation of type 2 substrates (Tyr-
nsP4) and vice versa, suggested that UBR protein has two distinctive binding pockets consisted 
of UBR box motif and this architecture was taken advantage  to explore the possibility of 
bivalency in the present study. Low efficiency of dipeptide inhibitors and their intrinsic 
limitation to in vivo application also made us develop distinguishable inhibitors despite the 
benefits from dipeptides (See Background). It was suggested that appropriate small molecules 
tethering type 1 and type 2 N-terminal destabilizing residues might increase their avidity for 
UBR box binding sites with higher selectivity. We tested this hypothesis using this model 
system. Of note, along with bivalent inhibitors, novel N-end rule inhibitors, including Tat-
derived polyarginines, were also identified to be effective during an orthogonal study. 
4.4.2 Design and Synthesis of Bivalent Inhibitors 
The conceptual model of the bivalent inhibitor for the N-end rule pathway exploits two different 
“N-terminal” destabilizing residues (type 1 and type 2) which are connected to a core molecule 
with multiple functional groups through appropriate linker/spacer (Fig. 38). Non-functional 
modification(s) can be introduced at the core molecule depending on the purpose. Linkages 
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Figure 40.  Chemical structures of RF-C11 and related compounds.  N-terminal Arg and Phe are indicated by orange and green backgrounds, respectively. Core 
Lys moiety and biotin modification are indicated by blue and red background, respectively. C11 hydrocarbon chain was used as linker/adapter. Initially 
carboxylic group of core Lys was esterified to curb further reaction and later biotin moiety was conjugated (RF-C11b and GV-C11b) for direct binding assay. All 
the building blocks were connected through amide bonds. 
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Figure 41.  Docking Model of the bivalent inhibitor into UBR box-like Protein.  (A) Juxtaposition of ground-state 
RF-C11 and UBR box-like domain, both have a similar size of about 45 angstrom. (B) Putative binding model of 
RF-C11 into UBR box. Hydrophobic domains inside pocket interact with Type 2 N-terminal destabilizing residue, 
Phe. 
 
interconnecting the building blocks can be also variable except two parallel amide bonds 
between N-degrons and linkers. 
The prototype of the bivalent inhibitor, RF-C11, is based on a Lys platform whose 
trifunctional groups can afford broad applications (Fig. 40). The detailed synthesis of bivalent 
inhibitors is described in Organic Synthesis. Two linkers, C11 hydrocarbon chains attached to a 
carboxyl end of two “N-terminal” amino acids, Arg (type 1 N-degron) and Phe (type 2 N- 
degron), were connected through ε-amine and α-amine of the core Lys, respectively. All the 
scaffolds were connected via amine linkages for more stability and readiness of synthesis. Lipid-
like structure using hydrophobic linker having the high degree of flexibility was inspired by the 
cell-permeable characteristics of transfection reagents for in vivo and animal model applications 
(Findeis 2001). Other linkers, such as polyethyleneglycol and polylysine, are being tested for 
more favorable pharmacological features. The chain length was determined by the structure of a 
UBR box homologue, mouse zinc finger protein 665 (Segal et al. 2006), whose size 
corresponded to the distance between the phenyl group and the guanidium group of RF-C11 
(~45Å) at the ground state. Crystal structure of the active site indicates relatively spacious 
binding pocket and conserved hydrophobic residues, including Phe, Leu/Ile, and Tyr, in the inner 
part of the pocket, which can contribute to both hydrophobic and π−π interactions with type 2 N-
degrons (Fig. 41).  
Controls of RF-C11 differ only in the “N-terminal” residues. Substitution of Arg and Phe, 
which are destabilizing amino acids or N-degron, into non-N-degron, Gly and Val, respectively, 
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generated GV-C11, a structural negative control, whose synthesis scheme was comparable of 
that of RF-C11. RR-C11 (two “N-terminal” arginines) and FF-C11 were synthesized as 
monovalent controls of bivalent RF-C11. The reactive, free carboxylic acid end of the Lys 
moiety is esterified to curb any further reaction. Biotinylated versions of bivalent inhibitors 
including RF-C11b and GV-C11b were used for further characterization including interaction 
assay, pull-down assay, and localization assay. RF-C11 is highly water-soluble and assumed to 
have emulsion property in aqueous solution. The compounds were characterized by 1H NMR, 
HPLC, and mass spectral data. Z-potential analysis revealed neutral, heterogeneous particle of 
the final chemicals in aqueous solution. Optimization of the synthesis methods provided good 
total yield at near 2.5 %. 
4.4.3 In vitro Activity of the Bivalent Inhibitors 
First, RF-C11 was rigorously evaluated as in vitro inhibitors of type 1 and type 2 N-end rule 
pathways by the in vitro model substrates; Arg-nsP4 for type 1 and Trp-nsP4 for type 2 both 
which are short-lived in reticulocyte lysates and their degradation was perturbed by MG132, a 
proteasome inhibitor (Fig. 42). With concentration- and time-course experiments, the activities 
of RF-C11 with the structural control, GV-C11, dipeptides, Arg-Ala and/or Trp (Phe)-Ala, and 
monovalent controls, RR-C11 and/or FF-C11, were compared. In type 1 model substrate, RF-
C11 inhibited its degradation at the concentration of 10 µM at 40 min, while type 1 dipeptide 
inhibitor, Arg-Ala showed a similar effect at 250 µM concentration. Inhibitors such as Trp-Ala 
and FF-C11, which have type 2 destabilizing residue(s), had no effect on Arg-nsP4 degradation. 
Notably, RR-C11 showed intermediate effectiveness of RF-C11 and Arg-Ala dipeptides. The 
superior potency of RF-C11 compared with RR-C11 substantiated the concept of bivalent 
effects. Inhibitory activities of a mixture of two dipeptides (Arg-Ala plus Phe-Ala) or 
monovalent controls (RR-C11 plus FF-C11) were comparable to that of single dipeptides (Arg-
Ala) or RR-C11 alone, respectively, suggesting no significant allosteric inhibition and further 
supporting cooperative effect of bivalent inhibitors. In type 2 model substrates, RF-C11 
consistently showed higher efficiency than controls. Other N-end rule substrates, including the 
C-terminal fragment of cleaved CDC6 was tested and found that RF-C11, not GV-C11, inhibited 
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Figure 42.  In vitro inhibition of Arg-nsP4 degradation by the bivalent inhibitors.  Type 1 substrate Arg-nsP4 degradation in the presence of different inhibitors. 
The model substrates were expressed in reticulocytes in the presence of different inhibitors or controls, and their degradations were analyzed in time- and 
concentration-dependent manner using Western blotting. GV-C11 is a structural control of RF-C11, and RR-C11 and FF-C11 are heterovalent controls of the 
bivalent RF-C11.  
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Figure 43.  In vitro inhibition of Tyr-nsP4 degradation by the bivalent inhibitors.  Type 2 substrate Tyr-nsP4 degradation in the presence of different inhibitors 
using similar methods in Fig. 42. 
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Figure 44.  In vitro inhibition of Arg-CDC6 degradation by the bivalent inhibitors.  A possible physiological 
substrate of the N-end rule pathway, CDC6 C-terminal fragments, Arg-CDC6 and Val-CDC6 (stabilized control) 
were expressed in reticulocytes in the presence of different inhibitors. Their degradations were analyzed in time- and 
concentration-dependent manner using Western blotting. GV-C11 is a structural control of RF-C11. While, Val-
CDC6 is long-lived, Arg-nsP4 has short-half life, and RF-C11 stabilized the otherwise unstable Arg-CDC6 more 
than MG132.   
 
its ubiqutylation efficiently. Together, these results suggested that RF-C11 is the first N-end rule 
inhibitor which can block both type 1 and type 2 pathways with higher efficiency compared with 
traditional dipeptide inhibitors. Moreover, the higher efficiency of the RF-C11 over homovalent 
controls highlights the advantages of bivalent interaction.  
Single amino acids, such as Arg and Phe, did not affect the efficiency of RF-C11. GV-
C11, a simple substitution of the N-degron from RF-C11, had no inhibitory effect on both type 1 
and type 2 N-end rule substrates up to 2 mM concentration, supporting negligible non-specific 
effect. However, given the fact that small molecule inhibitors often target multiple intracellular 
enzymes(Huskens 2006), the effect of RF-C11 on stabilization of other ubiquitin substrates 
which are not mediated by the N-end rule pathway, such as full-length CDC6 (APC complex 
substrates) and p53 (Mdm2 substrates) were also examined. I found that there is no effect of RF-
C11 on other substrtes of the ubiquitin pathway or the proteasome (Fig. 46). Interestingly, C-
terminal fragment of CDC6 generated by caspase was stabilized by RF-C11, suggesting that 
novel N-end rule pathway substrates can be identified by screening of RF-C11. Kinetics of type 
2 model substrate expression and degradation are different from that of type 1 under the same 
condition. This observation can be explained by that rates of translation or deubiquitylation, 
which happens cotranslationally (Baker et al. 1992; Papa and Hochstrasser 1993), may be slower  
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Figure 45.  In vitro ubiquitylation of model substrates in RF-C11.  Effect of RF-C11 on model substrate 
ubiquitylation. X-nsP4 proteins were expressed in reticulocyte lysates in the presence of MG132 (5 µM) and other 
compounds (50 µM) as indicated.  RA, Arg-Ala; FA, Phe-Ala; AR, Ala-Arg; AF, Ala-Phe.  After 20 min, their 
ubiquitylation was analyzed using anti-Ub immunoprecipitation and subsequent anti-biotin Western blotting (top 
panel), while their expression levels were determined using immunoblotting for the DHFR-Ub reference (bottom 
panels).  
 
in type 2 model substrates than in type 1. It was partially proved by the degree of ubiquitylation 
in Fig.44. Interestingly, the N-terminal methionine excision (NME), one N-degron generating 
mechanism, is also a cotranslational process (Meinnel et al. 2006). The most simple, intuitive 
possibility is that the intrinsic stabilities of Arg-Ala and Trp-Ala in the reticulocyte lysates might 
be different. It seems not to be the case because dipeptides are highly unstable in reticulocytes 
(Fig. 43). However, it is possible that the UBR box conformational/functional changes may be 
accompanied by different substrate binding. 
4.4.4 In vitro Assays Using the Bivalent Inhibitors 
The degree of the in vitro efficiency of N-end rule inhibition of RF-C11 versus dipeptides was 
semi-quantitatively assessed by measuring the percentage of the amount of the remaining model 
substrates compared to the DHFR-Ub reference (Fig. 45). RF-C11 inhibited the degradation of 
model substrates concentration-dependently with at least ten-fold increased half-maximal 
inhibitory concentration (IC50) value compared to dipeptide inhibitors. On the type 1 model 
substrate, quantification of the in vitro activity of RF-C11 showed 15.5 µM of IC50 value while 
Arg-Ala and Lys-Ala dipeptides inhibitors showed 283 µM and 148 µM. Type 2 inhibitors also  
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Figure 46.  In vitro degradation of CDC6 in RF-C11.  Effect of RF-C11 on non-N-end rule substrate CDC6. CDC6 
is a substrate of APC complex and was stabilized by MG132 but not affected by RF-C11, suggesting RF-C11’s 
specificity on the N-end rule pathway. y A long-lived RGS4(C2V)(Lee et al. 2005) mutant was used as a control. 
 
exhibited dose-dependent effectiveness. RF-C11 (2.74 µM) were 10 to 30-fold more potent than 
type 2 dipeptides inhibitors such as Trp-Ala (21.39 µM) and Phe-Ala (72.37 µM). These 
observations were similar to those calculated from a simplified model for bivalent inhibition 
(Gargano et al. 2001). Based on the model, theoretically calculated binding enhancement of RF-
C11 on a per ligand relative to the monomer should be approximately 100-fold, and these results 
exhibited that it was 10 to 30-fold (β≥10, Fig. 56). Moreover, from this study, although type 1 
and type 2 interactions may be individual, dependent events, there is no significant affinity 
change (α≈1) as expected in individual, independent binding events (K1=K1´, K2=K2´. Fig. 56).   
Consistent with the effect of RF-C11 on substrate degradation, the N-end rule model 
substrates were rapidly ubiquitylated under normal conditions, but their ubiquitylation was 
inhibited by the Arg-Ala / Phe-Ala mixture or RF-C11 (Fig. 47). RF-C11 showed a higher 
degree of inhibition of ubiquitylation at the same concentration of dipeptides, suggesting direct 
and specific targeting of UBR proteins. Inhibition of proteolysis of the N-end rule substrates was 
diminished in time-dependent manner due to instability of the inhibitors, which can slowly be 
cleaved by endogenous endopeptidases, and decreased rates of in vitro translation kinetics (Fig. 
47). However, RF-C11 showed more prolonged activity than dipeptides activity as either type 1 
or type 2 substrates. The more effective and prolonged activity of RF-C11 might be partially 
contributed to its metabolic stability. In contrast to dipeptides which cannot exert their inhibitory 
activities in the absence of bestatin (Botbol and Scornik 1983), an endopeptidase inhibitor, RF-
C11 exhibited similar efficiency regardless of the addition of bestatin, suggesting its 
invulnerability on endopeptidase cleavage (Fig. 47).  
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Figure 47.  Metabolic stability of the inhibitors by endopeptidase. In contrast to RF-C11, dipeptides showed no 
effect without bestatin. 
4.4.5 Direct Interaction between RF-C11 and UBR proteins 
Although RF-C11 inhibited the N-end rule pathway and did not affect the proteolysis of non-N-
end rule pathway substrates and proteasome activity, there is no conclusive evidence that RF-
C11 directly binds to the UBR proteins. This question was addressed by employing biotinylated 
derivatives of bivalent inhibitors for newly developed ELISA-like binding assay and pull-down 
assay. As reasonably expected, biotinylated RF-C11 achieved a similar efficacy as RF-C11, 
while biotinylated GV-C11 exerted no effect (Fig. 49A). For the binding assay, target protein, 
UBR1(1-453), which contains the initial 453 amino acids of UBR1 protein. It is the smallest 
fragment of UBR box motif and was proved to be sufficient to bind to both type 1 and type 2 N-
degron (Takafumi Tasaki, Kwon Lab). His6-UBR1(1-453)-Flag with Hisx6 and/or flag epitopes 
was in vitro generated by Rapid Translation System using wheat germ lysates (Fig. 49B) and  
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Figure 48.  Comparison between inhibitory effects of RF-C11 and controls.  Comparison inhibitory effects of RF-
C11, RR-C11, and dipeptides (Arg-Ala and Lys-Ala) on type 1 (upper panel) and type 2 (lower panel) degradation.  
Degradation of X-nsP4 was monitored in reticulocyte lysates in the presence of increasing concentrations (0.5, 1, 5, 
10, 25, 50, 75, 100, 150, and 250 µM).  IC50 values were obtained from quantification of relative X-nsP4 intensity 
and sigmoidal dose-response model. 
 
initially evaluated for optimal immobilization onto Ni++-coated microwell plates (Fig. 49C). 
Under optimized conditions, direct binding of RF-C11b with immobilized UBR box-1 fragment 
was observed in concentration-dependent manner (Fig. 50A). GV-C11b showed no detectable 
binding to UBR box-1. The bound RF-C11 and UBR box-1 was not dissociated by adding up to 
500 µM dipeptides. A reciprocal experiment using immobilized biotinylated bivalent inhibitors 
on streptavidin-coated microwell was also performed and showed specific interaction only 
between RF-C11 and UBR box (Fig. 50B). A negative control matrix and GV-C11 were used as 
controls. To determine whether RF-C11 could bind to endogenous UBR box proteins, from pull-
down assay using rat testis extracts, streptavidin-immobilized RF-C11b was bound to UBR1 and 
UBR5 identified by Western blotting with individual antibodies, while no UBR protein was 
detected binding to GV-C11b (Fig. 50C). In the presence of dipeptide inhibitors, the binding of 
UBR1 was reduced by Arg-Ala and/or Trp-Ala, but Ala-Arg was not displaced from the RF-  
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Figure 49.  RF-C11b and ELISA-like direct binding assay.  (A) Examining in vitro inhibitory activity of biotinylated inhibitors. (B) Expression and epitope 
detection of UBR box proteins. (C) Diagram of ELSA-like binding assay between UBR box and bivalent inhibitors. Preliminary results suggested protein amount 
for future experiment.  
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Figure 50.  Direct binding assay between bivalent inhibitor and UBR fragment.  (A-C) Binding assay using UBR protein immobilized on Nickel coated 
microwell. Diagram (A), IR detection (B) and its quantification (C). (D-F) Reverse binding assay using immobilized bivalent inhibitors using streptavidin-coated 
microwell.  
 
 
  86
 
Figure 51.  Perturbed RGS4 proteolysis by RF-C11 in mouse embryonic fibroblasts.  The levels of overexpressed 
RGS4 in mouse embryonic fibroblasts in the presence of different inhibitors were determined by immunoblotting. 
RGS4 and lacZ were transiently expressed in embryonic fibroblasts, and RF-C11 and GV-C11 (0.1, 10, 50, 75, and 
100 µM) were treated for 3 h, followed by anti-RGS4 immunoblotting.   
 
C11/UBR protein complex in accordance with the N-degron type-dependent competition and 
higher affinity of RF-C11. In addition, Trp-Ala did not interfere with the ability of UBR5 
binding, indicating that UBR5 is indeed type 1-specific UBR protein (Tasaki et al. 2005). These 
data strongly suggest that RF-C11 targets UBR proteins (more precisely UBR box) and this is 
the first identification that endogenous UBR box proteins can be pull-downed by small 
molecules. It is not clear whether RF-C11 acts as an irreversible inhibitor of UBR protein, but it 
is predicted to form a 1:1 stoichiometric complex with the UBR box under steady-state 
conditions with a slow dissociation rate. The availability of highly specific and efficient N-end 
rule inhibitors will allow us to identify unknown cognate proteins of UBR proteins. Notably, RF-
C11 is not a peptide although its major components are amino acids and amide bonds. These data 
suggest that the identity of the N-degron might not be limited to proteins and that the UBR box is 
equipped to interact with other biological small molecules. It is possible that N-ligand, such as 
neurotransmitters and hormones derived from destabilizing amino acids, may regulate non-
proteolytic function of the N-end rule pathway. 
4.4.6 In vivo Application of the Bivalent Inhibitors 
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Figure 52.  Increased half-life of overexpressed RGS4 by RF-C11 in mouse embryonic fibroblasts.  Pulse chase 
analysis of RGS4 and luciferase for control. The transfected cells were labeled for 12 min with 35S-Met/Cys, 
followed by anti-RGS4 and anti-V5 (for luc) and SDS-PAGE analysis. Quantitation of data using PhosphorImager 
shown in the right panel. As expected from relatively mild stabilization by RF-C11 in vivo (Fig. 51), the half-life of 
newly synthesized RGS4 in the presence of RF-C11 increased modestly. 
 
Having shown that RF-C11 worked in vitro both on type 1 and type 2 and it directly binds to 
UBR proteins, in vivo application of the inhibitor was performed using RGS4 as a substrate in 
cultured mouse embryonic fibroblasts. RGS4 protein is a negative regulators of Gi- and Gq-
mediated signaling pathway by accelerating the rate of Gα-GTP hydrolysis, resulting 
reassociation of the Gαβγ heterotrimer (Ross and Wilkie 2000; Hollinger and Hepler 2002), and 
was the first identified in vivo N-end rule substrates (Hu et al. 2005; Lee et al. 2005). In 
physiological condition, overexpressed RGS4 protein was short-lived but its degradation was 
robustly blocked by MG132 in mouse embryonic fibroblasts (Fig. 51). RF-C11 treatment showed 
modest but significant stabilization of RGS4 compared with MG132 at the concentration of 25 
µM while dipeptides or GV-C11 showed no effect. Pulse-chase analysis was performed to 
compare half-lives of RGS4 in the presence and absence of RF-C11 and indicated that RF-C11 
increased RGS4 stability with modest degree (Fig. 52). Since the internalized RF-C11 was not 
clearly localized and in vivo inhibition effect was observed only in serum-free culture media, it 
was reasonable to suspect that poor cell permeability of the compound might be the major hurdle 
for better in vivo inhibitor development. Although the intraheterobivalency concept in this work 
was initially developed as a proof of concept, practical applications may be achievable.  
The RGS protein and G protein signaling pathway have been known to have important 
roles in the cardiac development and in the cardiac function under normal and pathological 
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Figure 53.  Reduced DNA synthesis of cardiomyocytes with RF-C11 treatment.  Cells isolated from mouse 
embryonic hearts were treated with BrdU for 12 h in the presence of 25 µM RF-C11 or GV-C11, followed by 
immunostaining troponin I (for cardiomyocytes, green) and BrdU (for S-phase cells, red).  BrdU indices were 
determined by counting BrdU-positive cells for cardiomyocytes (troponin I-positive) and non-cardiomyocytes 
(troponin I-negative).  Data represent mean ± s.e.m. from three independent experiments (*: p < 0.05). 
 
 
condition (Sierra et al. 2000; Riddle et al. 2005). Previously, I reported that the mice deficient 
ATE1, a component of the N-end rule pathway which regulates RGS proteolysis die in 
midgestation mainly due to a proliferative deficiency, i.e. decreased DNA synthesis associated 
with perturbed mitotic activities of cardiomyocytes (see Chapter III). Therefore, initially, The 
examination of RF-C11’s effect on proliferation of primary mouse embryonic cardiomyocytes 
(MEC) showed that RF-C11 induced not only decreased proliferation of cardiomyocytes, with no 
effect on non-cardiomyocytes (Fig. 52), but also reduced cardiomyocyte size (Fig. 53). The 
cytotoxicity of inhibitors was predetermined on both mouse embryonic fibroblasts and 
embryonic cardiomyocytes (Fig. 54). To further examine RF-C11 regulation of hypertrophism, 
immunostaining was conducted to detect the production of atrial natriuretic peptide (ANP), a 
*
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Figure 54.  Cytotoxicity of RF-C11.  The cytotoxicity of RF-C11 and GV-C11 on mouse embryonic cardiac cells 
was determined by using MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) colorimetric dye. 25 
µM of RF-C11, the experimental concentration for BrdU assay and hypertrophism, do not affect the viability of 
primarily cultured mouse embryonic cardiomyocytes 
 
representative hallmark of hypertrophic genetic reprogramming in cardiomyocytes and a 
prognostic indicator of clinical severity of hypertrophy (Liu and Olson 2002). Notably, decreased 
peri-nucleic ANP signal was observed in RF-C11 treated cardiomyocytes (Fig. 53). Primary 
embryonic mouse cardiomyocytes have been known to undergo “autonomous hypertrophy” 
(Deng et al. 2000) and many in vivo studies using rat cardiomyocytes indicate that stimulation of 
Gq-coupled receptors is sufficient to induce cardiomyocyte hypertrophy (D'Angelo et al. 1997; 
Adams et al. 1998; Mende et al. 1998; Mittmann et al. 2002). 
Transgenic mice overexpressing RGS4 in postnatal ventricular myocardium displayed, 
upon transverse aortic constriction, left ventricular dilatation, depressed systolic 
function, and higher postoperative mortality, and failed to induce βMHC expression (Rogers et 
al. 1999). Therefore, the RF-C11 effect, as a potent inhibitor of the N-end rule pathway, mimicks 
the effect of Gq inhibition or RGS hyperactivation, which is consistent with the study from 
ATE1
-/-
 mouse (Lee et al. 2005). The biological activities of RF-C11 also underscore the fact that 
cardiomyocyte proliferation and differentiation are complex and coordinated. Together, these 
observations suggested that RF-C11 inhibits the onset of autonomous hypertrophy in mouse 
embryonic cardiomyocytes and its mechanism of action, suspected to be related with RGS 
proteins, may bring new insight of the N-end rule pathway on regulation of G protein signaling 
for physiological cardiogenesis and pathophysiological hypertrophism. In analogous experiments 
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Figure 55.  Inhibited hypertrophism by RF-C11.  Significantly reduced cell size in RF-C11-treated cardiomyocytes 
were observed and quantified in the left graph. The surface areas of troponin I-positive cells were determined using 
ImageJ software version 1.34s (NIH).  Data represent mean ± s.e.m. from three independent experiments. Cardiac 
cells, treated with RF-C11 or GV-C11, were immunostained for sarcomeric α-actinin (for cardiomyocytes, green) 
and ANP (for hypertrophism, red) with DAPI counterstaining. Data represent mean ± s.e.m. from three independent 
experiments (See Methods). *: p < 0.05. 
 
with rat neonatal cardiac cells, RF-C11 treatment significantly reduced the size of rat 
cardiomyocytes and the level of ANP expression (data not shown).  These results suggest that the 
N-end rule pathway controls cardiac proliferation and hypertrophy. 
4.5 DISCUSSION 
Ligand-induced dimerization (or proximity) is one of the key regulatory mechanisms in signal 
transduction and pioneering organic chemists recognized the potential of synthetic small 
molecules which can hetero- or homodimerize intracellular proteins and control their cellular 
*
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responses for experimental and therapeutic purposes (Austin et al. 1994; Crabtree and Schreiber 
1996). Perhaps the most widely used chemical inducer of dimerization (CID) has been 
rapamycin. The interest in the immunosuppressant has exploded since it were identified that 
rapamycin is a heterovalent bivalent ligand, which can bind FKBP12 (FK506 binding 
protein)(Harding et al. 1989; Siekierka et al. 1989) and FRB (FKBP-rapamycin binding domain) 
(Brown et al. 1994; Sabatini et al. 1994) to form FKBP-rapamycine-FRB ternary complex. This 
system has been studied not only for its role in the mTOR pathway and cell growth, but also for 
applications in technology, including conditional protein splicing (for gain-of-function) 
(Schwartz et al. 2007) and conditional protein degradation (for loss-of-function) (Sakamoto et al. 
2001). While CIDs simultaneously bind to two different proteins (interbivalent), intrabivalent 
bivalirudin, a synthetic, 20-mer oligopeptide anticoagulant, binds to active site and fibrinogen-
binding region of a single molecule of thrombin (Warkentin and Koster 2005). A few small 
molecule-based intrabivalent inhibitors have been synthesized or screened but tested only in a 
limited set of biochemical analyses (Shuker et al. 1996; Maly et al. 2000; Tsang et al. 2001).  
The aim of the this study was to develop small molecule, lipid-based, bivalent inhibitors 
for the N-end rule pathway through binding to two distinct protein-N-terminal recognition 
pockets of the UBR system. Existing inhibitors that bind to UBR1 recognition pockets are 
dipeptides containing either basic (type I inhibitors) or hydrophobic (type II inhibitors) amino 
acids in the N-terminus. However, structurally they lack the possibility of containing both basic 
and hydrophobic amino acids simultaneously in the two N-termini because the natural peptides 
contain only one N-terminus. Synthetic organic molecules have the flexibility of comprising both 
the N-terminal mimicking sites so they can bind to both the hydrophilic and hydrophobic pockets 
of UBR1. Therefore, a bivalent inhibitor possessing both type I and II residues will bind UBR1 
more effectively and hence be expected to inhibit UBR more efficiently than monovalent 
inhibitors due to simultaneous and co-operative binding with two binding pockets. The molecule 
is expected to possess several advantages over existing peptide based inhibitors: 1) stability, 
because there exist no peptide bond that might otherwise be degraded in the presence of 
peptidases; 2) bio-admissibility, owing to its flexibility offered by its lipid-based structure. The 
lipidic structure offers excellent bio-distribution in vivo and effective fusion with the cell 
membrane, predominantly constituting of lipid-based molecules. 
In the bivalent inhibitor molecule RF-C11, the ε-amino group and α-amino group of L-
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Lys moiety were respectively linked to C-terminal of L- arginine (R) and L- phenylalanine (F) 
with the help of respective C11 carbon chain linkers. The carboxylic acid group of Lys moiety 
remained protected as methyl ester to stop any furthering of chemical reactions through this 
moiety. The overall yield of RFC11 was about 2.8 %. Although the chain length of C11 was 
chosen arbitrarily, later the chain length was determined by the structure of a UBR box 
homologue, mouse zinc finger protein 665 (Segal et al. 2006), whose size corresponded to the 
distance between phenyl group and guanidium group of RF-C11 (~45Å) at the ground state. 
Crystal structure of the active site indicates relatively spacious binding pocket and conserved 
hydrophobic residues, including Phe, Leu/Ile, and Tyr, in the inner part of the pocket, which can 
contribute to both hydrophobic and π−π interactions with type 2 N-degrons.  
In order to ascertain the selective inhibitory effect of RF-C11 towards UBR proteins, a 
negative control called GV-C11 that contains amino acids non-related to either type I or type II 
N-degrons was synthesized. In this molecule, Arg and Phe were replaced by Gly and Val, 
respectively. GV-C11 synthetic scheme was comparable of that of RF-C11. To determine the 
efficacy of bivalent inhibitors, with respect to homovalent inhibitors, two heterovalent inhibitors 
RR-C11 (containing two arginines) and FF-C11 (containing two phenylalanines), where both the 
amino acid residues would show binding to either of the type I or type II binding pockets, were 
also synthesized.  A new molecule i.e., RF-C11b (or, RF-C11b) was also prepared by selectively 
introducing the biotin moiety in the carboxylic acid of the Lys skeleton in RF-C11 with an 
ethylenediamine linker in between. The molecule was synthesized for the purpose of pulling 
down both known and yet unknown UBR proteins and to identify unknown substrates (if any) 
that may interact with UBR proteins. 
The progress of combinatorial chemistry and bioinformatics, along with software 
engineering and automation, allowed us to attempt high throughput and in silico screening for 
drug discovery. However, despite the power of these approaches, such efforts have not been 
entirely successful because of artifacts, off-target effects, and false positives (McGovern et al. 
2002). Moreover, during the high throughput screening, most small interacting molecules, which 
have low affinity but have a higher chance of binding to the target, will not be detected as “hits”  
at a typical submicro-molar concentration (Jackson and Harrington 2005). An emerging 
paradigm in drug development is to develop more sensitive methodologies for screening these 
molecules and to connect them to generate high-affinity molecules with favorable
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Figure 56.  Equilibrium Binding Model for the Bivalent Ligands.  
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pharmacological features (Leach et al. 2006). Increased affinity and selectivity, both 
thermodynamically and kinetically, by employing cooperative weak interactions (multivalency) 
plays a key role in recognition for a wide range of functions, and pioneering organic chemists 
have been intrigued by this ubiquitous but efficient mechanism (Huskens 2006). Most synthetic 
multivalent molecules developed have targeted surface molecules exposed on virus, bacteria, or 
cell membrane with tethered identical ligands (homovalency), although a few studies without 
extensive biological evaluation have unclosed the possibility of molecules with nonidentical 
ligands (heterovalency) for intracellular proteins (See details in Choi, 2004 (Choi 2004)).  
Since the UBR box motif is known to be required and sufficient to bind both type 1 and 
type 2 and the binding mechanisms are mutually exclusive (Kwon Lab, unpublished data), I 
examined whether a bivalent small molecule, which contains both type 1 and type 2 N-terminal 
destabilizing residues, increased binding efficiency compared with those of corresponding 
homovalent interactions. The prototype bivalent inhibitor, RF-C11, which unites type 1 
destabilizing residue, Arg, to type 2, Phe, bridged by a Lys core, showed higher degree of 
inhibition compared to RR-11 or FF-C11 and was applied to the study of biochemical 
mechanisms and physiological function of the N-end rule pathway. These data suggest that 
multivalent inhibition of intracellular proteins is a good strategy for rational drug designs. One of 
the targets of heterovalent inhibitors can be scaffold proteins in kinase cascades. Although more 
than 6,000 new inhibitors to regulate kinase pathways are reported every year, there is no 
evidence of their specificity among the other ~ 500 similar kinases (Frodin 2007). It may be 
possible to make high specific inhibitors with more affinity by heterovalent inhibitors which 
block multiple docking sites of a scaffold protein. Continued efforts to improve RF-C11 are 
being made by modifying the link, destabilizing residue, and core molecules. More biophysical 
information about the interaction between RF-C11 and its binding protein, UBR protein, will 
facilitate the development of more sophisticated, drug-like inhibitors which may modulate the 
functions of the N-end rule pathway in vivo.   
In summary, the rational design and synthesis of bivalent inhibitors of the N-end rule 
pathway are described here. This compound afforded the first demonstration of cooperative 
inhibition of a heterovalent molecule targeting a single enzyme with two different binding sites. 
The prototype bivalent inhibitor, RF-C11, showed enhanced functional activity in vitro both in 
type 1 and type 2 N-end rule pathways compared with dipeptide inhibitors or homovalent 
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controls. This hypothesis was further supported by the direct interaction between the bivalent 
inhibitors and UBR box motif or endogenous UBR proteins. Moreover, the results from in vivo 
applications suggest hitherto unclear links between its hypertrophism and the N-end rule 
pathway by regulating the RGS proteolysis. A reasonably varied collection of RF-C11 
derivatives includes different linker length, linker backbone, linkage identity, and multiple N-
degrons. Cell permeability is strongly desirable. Dynamic combinatorial chemistry or “extended 
tethering” will be a feasible method to identify the second generation of bivalent inhibitors, 
which is more druglike (Erlanson et al. 2003; Shi et al. 2006). More sophisticated design for 
bivalent inhibitors may be provided from the identification of X-ray structure of the UBR box. It 
is expected that further development of bivalent inhibitors, based on this study, will allow a more 
extensive study of the mechanisms and functions of the N-end rule pathway. Finally, the 
inhibition of cardiac proliferation and hypertrophy by RF-C11 may be in part through inhibition 
of multiple N-recognins controlling Gq signaling.  In humans, myocardial hypertrophy, 
associated with hypertension, cardiac valvular disease or ischemia, is typically followed by 
myocardial diseases, the leading causes of death in western society.  Therefore, the N-recognin 
pathway is a potential target to control cardiac hypertrophy. 
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APPENDIX A 
SYNTHESIS AND CHARACTERIZATION OF HETEROVALENT INHIBITORS 
A.1 RF-C11, GV-C11, RR-C11, AND FF-C11 
Synthesis schemes of RF-C11 and related compounds were developed with a collaboration with 
Banerjee Lab (Indian Institute of Chemical Technology, India) and organic synthesis, 
purification, and characterization were performed in his group. Z-Arg(Z)2-OH was purchased 
from Senn chemicals (Dielsdorf, Switzerland). Remaining protected amino acids were purchased 
from Novabiochem (La Jolla, USA). All other chemicals were purchased from Sigma Chemical 
Co. (St. Louis, MO). Organic solvents required for synthesis were purchased from Ranbaxy Fine 
Chemicals Ltd. (New Delhi, India). They were used without further purification. All the 
intermediates in the synthesis were characterized by 1H NMR and mass spectra. The final 
molecules were characterized by ESI or FAB or MALDI-TOF Mass spectral analysis and the 
purity ascertained by HPLC. All the 1H NMR spectra were recorded on a Bruker FT 300 MHz, 
Varian FT 200 MHz instrument or Varian FT 400MHz instrument. HPLC analysis were 
performed at 210nm on a Shimadzu LC10A instrument using Whatman Reverse Phase C18 
column (4.6×250mm) and either methanol or 5 % water in methanol as mobile phase with a flow 
rate of 1 mL/min. Figure 57 outlines the synthetic strategy employed for preparing bivalent 
inhibitor RF-C11, its structural analogue GV-C11, and its homovalent controls, RR-C11 and FF-
C11. The strategy for preparing biotinylated inhibitor RF-C11b and its structural analogue GV-
C11b is shown in Figure 58. 
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tert-butyl-11-aminoundecanoate, 7.  N,N’-dimethylaminopyridine (1.16 g, 9.51 mmol), EDC 
(4.00 g, 20.8 mmol) and 11-bromoundecanoic acid 6 (5.00 g, 18.9 mmol) were added 
sequentially in ice-cold, dry DCM (20 ml), followed by addition of tert-butanol (11.0 ml, 115 
mmol). After 16 h the organic phase was washed with water, dried and evaporated. The residue 
was subjected to column chromatographic purification in 1 % ethyl acetate in hexane, yielding 
tert-butyl-11-bromoundecanoate (3.8 g, 62.7 % yield, Rf = 0.80 in 10 % ethyl acetate in hexane). 
This compound (3.80 g, 11.8 mmol) was reacted with sodium azide (0.77 g, 11.8 mmol) at 70-80 
ºC in anhydrous DMF for 18 h. Following cooling, the mixture was taken up in chloroform, 
washed with water, dried, and evaporated. The crude residue was reacted with 
triphenylphosphine (4.36 g, 16.6 mmol) with THF/water for 4 h. THF was evaporated, and 
compound 7 was purified from the crude mixture through column chromatographic purification 
using 4 % methanol in chloroform (2.8 g, 92.1 % yield, Rf = 0.20 in 5 % methanol in 
chloroform). 1H NMR (300 MHz, CDCl3): δ 1.28 [s, 12H], 1.43 [s, 9H], 1.49-1.62 [m, 4H], 2.13-
2.21 [t, 2H, J= 7.5 Hz], 2.76-2.84 [t, 2H, J= 7.6 Hz], 2.92-3.10 [bs, 2H]. ESI-MS: m/z 258 
([M+H]+, calculated for C15H32O2N, 258.2). 
 
R-C11(-CO2H), 8a.  HOBt (30 mg, 0.196 mmol), EDC (0.37 g, 1.93 mmol) and Z-Arg-(Z)2-OH 
(1.00 g, 1.74 mmol) were mixed in ice-cold, dry DCM (5 ml), followed by reaction with 
compound 7 (0.49 g, 1.91 mmol) for 16 h. R-C11(-CO2But) was isolated (0.85 g, 60.0 % yield, 
Rf = 0.80 in 5 % methanol in chloroform) through chromatographic purification in 1 % methanol 
in chloroform. A DCM solution of this compound (0.85 g, 1.04 mmol) was mixed with TFA (2 
ml) to remove tert-butyl protecting group, yielding R-C11(-CO2H) 8a (0.70 g, 89 % yield, Rf = 
0.60 in 5 % methanol in chloroform). 1H NMR (200 MHz, DMSO-d6): δ 1.25 [bs, 14H], 1.45-
1.76 [m, 6H], 2.11-2.25 [t, 2H, J= 7.3 Hz], 2.72-3.11 [m (overlapping with DMSO peak), 2H], 
3.82-4.00 [m, 2H],  4.01-4.15 [m, 1H],  4.87-5.21 [m, 6H],  6.56-6.69 [d, 1H, J= 8.5 Hz], 7.20-
7.44 [m, 15H], 9.20-9.49 [2bs, 2H]. ESI-MS: m/z 761 ([M+H]+, calculated for C41H54O9N5, 
760.4). 
 
F-C11(-CO2H), 8b.  Yield: 49.7 % from two steps (Rf = 0.60 in 5 % methanol in chloroform). 
1H NMR (500 MHz, DMSO-d6 ): δ 1.16-1.33 [m, 12H], 1.34-1.41 [m, 2H], 1.53-1.61 [m, 2H], 
2.17-2.23 [t, 2H, J= 7.7 Hz], 2.86-3.17 [m (partially overlapping with DMSO peak), 4H], 4.27- 
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Figure 57.  Synthesis scheme of RF-C11, GV-C11, RR-C11 and FF-C11. 
 
4.37 [m, 1H], 5.01 [s, 2H], 7.07-7.33 [m, 10H]. FABMS: m/z 483 ([M+H]+, calculated for 
C28H39O5N2, 483.3). 
 
G-C11(-CO2H), 8c.  Yield: 50.0 % from two steps (Rf = 0.55 in 5 % methanol in chloroform). 
1H NMR (400 MHz, DMSO-d6): δ 1.28 [bs,12H], 1.39-1.49 [m, 2H], 1.51-1.62 [m, 2H], 2.13-
2.26 [t, 2H, J= 8.0 Hz], 3.09-3.20 [m (merged with DMSO peak), 2H], 3.67-3.73 [d, 2H, J= 6.0 
Hz], 5.07 [s, 2H], 7.23-7.41 [m, 5H]. FABMS: m/z 393 ([M+H]+, calculated for C21H33O5N2, 
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393.2). 
 
N(ε)-Z-Lysine(-OMe)C11-NH2, 4.  HOBt (0.28 g, 1.83 mmol), EDC (3.50 g, 18.2 mmol) and 
11-bromoundecanoic acid (4.81 g, 18.1 mmol) were mixed in ice-cold, dry DCM (20 ml), 
followed by addition of N(ε)-Z-lysine methyl ester hydrochloride 3 (5.00 g, 15.1 mmol), drop-
wise addition of DIPEA, and reaction for 16 h. N(ε)-Z-Lysine(-OMe)C11-Br (4.92 g, 60.2 % 
yield, Rf = 0.60 in 5 % methanol in chloroform) was obtained through column chromatographic 
purification (2 % methanol in chloroform). This product (4.92 g, 9.09 mmol) was reacted with 
sodium azide (0.60 g, 9.23 mmol) at 70-80 ºC in dry DMF for 18 h. Following cooling, the 
mixture was taken up in chloroform, washed with water, dried, and evaporated. The crude 
residue was reacted with triphenylphosphine (3.44 g, 13.1 mmol) with THF/water for 4 h. THF 
was evaporated, and N(ε)-Z-Lysine(-OMe)C11-NH2 4 was purified through column 
chromatography using 4 % methanol in chloroform (4.0 g, 92.1 % yield, Rf = 0.20 in 5 % 
methanol in chloroform). 1H NMR (200 MHz, CDCl3): δ 1.26 [bs, 14 H], 1.35-1.73 [m, 8H], 
2.11-2.23 [t, 2H, J= 7.5 Hz], 2.60-2.71 [t, 2H, J= 6.7 Hz], 3.10-3.23 [m, 2H], 3.72 [s, 3H], 4.46-
4.61 [m, 1H], 4.95-5.04 [t, 1H, J= 6.0 Hz], 5.05 [s, 2H], 6.08-6.18 [d, 1H, J= 7.7 Hz], 7.30 [s, 
5H].    
 
N(ε)-Z-Lysine(-OMe)C11F, 5a.  HOBt (0.13 g, 0.85 mmol), EDC (1.61 g, 8.40 mmol) and 
Boc-Phe-OH (2.00 g, 7.55 mmol) were mixed in ice-cold, dry DCM (10 ml) followed by 
addition of compound 4 (4.00 g, 8.38 mmol) and then reacted at r.t. for 16 h. The product N(ε)-
Z-Lysine(-OMe)C11F 5a was obtained through column chromatography using 2% methanol in 
chloroform (3.30 g, 60.3 % yield, Rf = 0.55 in 5 % methanol in chloroform).  
1H NMR (300 MHz, CDCl3): δ 1.11-1.40 [m, 14 H], 1.43 [s, 9H], 1.48-1.75 [m, 8H], 2.15-2.26 
[t, 2H, J= 7.6 Hz], 2.97-3.25 [m, 6H], 3.75 [s, 3H], 4.16-4.28 [m, 1H], 4.52-4.63 [m, 1H], 4.98-
5.06 [t, 1H, J= 6.1Hz], 5.08 [s, 2H], 5.15-5.25 [bs, 1H], 5.78-5.88 [bs, 1H], 6.22-6.30 [d, 1H, J= 
7.5 Hz], 7.15-7.37 [m, 10H]. ESI-MS: m/z 725.8 ([M+H]+, calculated for C40H61O8N4, 725.4). 
 
N(ε)-Z-Lysine(-OMe)C11V, 5b.  Yield: 59.9 % (Rf = 0.55 in 5 % methanol in chloroform). 
1H NMR (300 MHz, CDCl3): δ 0.86-0.97 [t, 6H, J= 6.0 Hz], 1.24 [bs, 12H], 1.41 [s, 9H], 1.50-
1.88 [m, 10H], 1.94-2.06 [m, 1H], 2.12-2.21 [t, 2H, J= 7.6Hz], 3.08-3.26 [m, 4H], 3.71 [s, 3H], 
  100
3.78-3.86 [t, 1H, J= 8.0 Hz], 4.48-4.59 [m, 1H], 5.05 [s, 2H], 7.21-7.33 [s, 5H]. FABMS: m/z 
677 ([M+H]+, calculated for C36H61O8N4, 677.4). 
 
PRF-C11, precursor of 1a.  Compound 5a (1.00 g, 1.38 mmol) was subjected to Z-deprotection 
by conventional hydrogenation with 10 % Pd on charcoal in methanol, yielding Lysine(-
OMe)C11F (0.61 g, 75.3 % yield, Rf = 0.25 in 5 % methanol in chloroform). This product (0.60 
g, 1.02 mmol) was added to an ice cold, dry DCM mixture containing HOBt (15 mg, 0.098 
mmol), EDC (0.20 g, 1.04 mmol) and compound 8a (0.70 g, 0.92 mmol), followed by reaction at 
r.t. for 48 h. PRF-C11 was obtained through  column chromatographic purification using 2% 
methanol in chloroform (0.65 g, 53.3 % yield, Rf = 0.20 in 70 % ethyl acetate in hexane). 1H 
NMR (300 MHz, CDCl3 + CD3OD): δ 1.26 [bs, 32 H], 1.45-1.75 [m, 10H], 2.11-2.28 [two 
triplets, 4H, J = 7.6 and 7.5 Hz], 2.91-3.23 [m, 8H], 3.73 [s, 3H], 3.91-4.03 [m, 2H], 4.12-4.28 
[m, 2H], 4.45-4.54 [m, 1H], 5.01-5.18 [m, 4H], 5.24 [s, 2H], 7.12-7.41 [m, 20H]. 
ESI-MS: m/z 1,334 ([M+2H]+, calculated for C73H107O14N9, 1,333.8) and 667 ([M+2H]2+, 
calculated 666.9) 
 
PGV-C11, precursor of 1b.  Yield: 42.6 % from two steps (Rf = 0.60 in 10 % methanol in 
chloroform). 1H NMR (400 MHz, CDCl3 + CD3OD): δ 0.88-0.98 [t, 6H, J= 7.5 Hz], 1.28 [bs, 
24H], 1.43 [s, 9H], 1.46-1.85 [m, 15H], 2.10-2.26 [two triplets, 4H, J = 8.5 and 9.0 Hz], 3.06-
3.31 [m, 6H], 3.68-3.80 [d, 6H, J = 8.7 Hz], 4.40 [m (overlapped with CD3OD solvent peak), 
1H], 5.08 [s, 2H], 7.25-7.39 [m, 5H]. FABMS: m/z 917 ([M+H]+, calculated for C49H85O10N6, 
917.6). 
 
PRR-C11, precursor of 1c.  HOBt (0.01 g, 0.065 mmol), EDC (0.12 g, 0.626 mmol) and 
compound 8a (0.42 g, 0.552 mmol) were dissolved in cold, dry DCM (5 ml), followed by 
dropwise addition of DMSO solution containing L-lysine methyl ester dihydrochloride 9 (0.05 g, 
0.215 mmol) and DIPEA. The resulting solution was stirred at r.t. for 48 h. PRR-C11 was 
obtained through column chromatographic purification using 1 % methanol in chloroform (0.22 
g, 62.3 % yield, Rf = 0.70 in 5 % methanol in chloroform). 1H NMR (200 MHz, CDCl3 + 
CD3OD): δ 1.08-1.37 [m, 32H], 1.42-1.83 [m, 14H], 2.07-2.28 [two triplets, 4H, J= 7.8 and 7.1 
Hz], 2.88-3.07 [m, 4H], 3.08-3.19 [t, 2H, J = 6.3 Hz], 3.72 [s, 3H], 3.76-4.02 [m, 6H], 4.36-4.47 
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[m, 1H], 4.97-5.26 [m, 12H], 7.20-7.40 [m, 30H]. ESI-MS: m/z 1645 ([M+H]+, calculated for 
C89H119O18N12, 1644.9), and 823 ([M+2H]2+, calculated 822.5). 
 
PFF-C11, precursor of 1d.  Yield 59.8 % (Rf = 0.60 in 10 % methanol in chloroform). 1H NMR 
(400 MHz, CDCl3 + CD3OD): δ 1.11-1.38 [m, 28H], 1.42-1.83 [m,10H], 2.09-2.25 [two triplets, 
J = 7.4 and 7.8 Hz, 4H], 2.85-3.18 [m, 10H], 3.71 [s, 3H], 4.22-4.32 [m (partially overlapped 
with CD3OD solvent peak), 3H], 4.95-5.08 [m, 4H], 7.11-7.34 [m, 20H]. 
ESIMS: m/z 1,090 ([M+H]+, calculated for C63H89O10N6, 1,089.7). 
 
RF-C11, 1a.  PRF-C11 (0.10 g, 0.075 mmol) and TFA (2.0 ml) were mixed under N2 and stirred 
on ice. Thioanisole (0.4 ml, 3.4 mmol) and TMSOTf (0.6 ml, 3.3 mmol) were added sequentially 
to the cold mixture, followed by stirring at r.t. for 24 h. HPLC grade methanol (1.0 ml) was 
added, and the organic phase was flushed out with N2. The residue was four times re-precipitated 
from methanol-diethyl ether (1:8) system. By using chloride ion exchange chromatography with 
Amberlite IRA400Cl resin and repeated re-precipitations, the pure product RF-C11 1a  was 
isolated as a yellowish white semi-solid (0.044 g, 71.0 % yield, Rf = 0.0-0.10 in 
methanol:chloroform:acetic acid (30:70:0.1)). ESI-HRMS: m/z 830.6219 ([M+H]+, calculated 
for C44H80O6N9, 830.6231), and 415.8151 ([M+2H]2+ calculated, 415.8155). RP-HPLC: Rt = 5.8 
min (100 % methanol), purity > 99 %. 
 
GV-C11, 1b. Yield: 60.5 % (Rf = 0.20 in 10 % methanol in chloroform). ESI-HRMS: m/z 
683.5426 ([M+H]+, calculated for C36H71O6N6, 683.5435), and 342.2738 ([M+2H]2+calculated, 
342.2757). RP-HPLC: Rt = 6.2 min (100 % methanol), purity > 92 % 
 
RR-C11. 1c.  Yield: 39.2 % (Rf = 0.00, compound lies in the base for TLC at 
methanol:chloroform:acetic acid (30:70:0.1)). ESI-HRMS: m/z 420.3330 ([M+2H]2+calculated 
for [C41H84O6N12]/2, 420.3312). RP-HPLC: Rt = 2.2 min (0.05 % TFA in methanol), purity > 98 
%. 
 
FF-C11, 1d. Yield: 33.1 % (Rf = 0.25 in 10 % methanol in chloroform). ESI-HRMS: m/z 
821.5909 ([M+H]+, calculated for C47H77O6N6, 821.5899), and 411.2942 ([M+2H]2+ calculated, 
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411.2989). RP-HPLC: Rt = 2.3 min (0.05 % TFA in methanol), purity > 99 %. 
A.2 SYNTHESIS AND CHARACTERIZATION OF RF-C11B AND GV-C11B 
Biotinylated versions of bivalent inhibitors, RF-C11b and GV-C11b, were synthesized using the 
similar synthesis scheme as RF-C11 and GV-C11, mainly using conventional protocols of amide 
bond formation using EDC and HOBt. However, for biotin-labeled inhibitors, ethylenediamine-
coupled biotinwas initially conjugated with N(ε)-Z-Lysine(-OMe)C11-NH2 prior to further 
reactions. 
 
Boc-protected biotinylated ethylenediamine. 11.  HOBt (0.19 g, 1.24 mmol), EDC (0.23 g, 
1.20 mmol) and biotin (0.20 g, 0.82 mmol) was added in cold, dry DMF (5 ml), followed by 
addition of DMF solution of mono-BOC-ethylenediamine (0.20 g, 1.25 mmol) and DIPEA 
dropwise. The resulting solution was stirred at r.t. for 16 h. Compound 11 was obtained through 
column chromatographic purification using 4 % methanol in chloroform (0.21 g, 66.4 % yield, Rf 
= 0.40 in 10 % methanol in chloroform). 1H NMR (300 MHz, CDCl3 + CD3OD): δ 1.25 [s, 2H], 
1.41 [s, 9H], 1.51-1.78 [m, 4H], 2.16-2.23 [t, 2H], 2.68-2.97 [m, 2H], 3.11-3.37 [m, 5H], 4.23-
4.35 [m, 2H]. 
  
N(ε)-Z-lysine(-O-biotinylated ethylenediamine )-C11F, 12.  Compound 5a was demethylated 
using LiOH in THF:water:methanol (3:1:1) solvent mixture, yielding N(ε)-Z-Lysine(OH)-C11F 
(78.1 % yield, Rf = 0.30 in 5 % methanol in chloroform).  Compound 11 was subjected to BOC 
deprotection using TFA, yielding biotinylated ethylenediamine (97.1 % yield).  HOBt (0.043 g, 
0.28 mmol), EDC (0.065 g, 0.34 mmol) and N(ε)-Z-Lysine(-OH)-C11F (0.20 g, 0.28 mmol) 
were added in cold, dry DMF (2 ml), followed by addition of DMF solution of biotinylated 
ethylenediamine (0.135 g, 0.34 mmol) and dropwise addition of DIPEA.  The resulting solution 
was stirred at r.t. for 48 h. After washing with 0.5 N HCl in brine solution and column 
chromatography using 3 % methanol in chloroform, compound 12 was obtained in pure form 
(0.144 g, 52.2 %, Rf = 0.40 in 10 % methanol in chloroform. 1H NMR (200 MHz, CDCl3 + 
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Figure 58.  Synthesis scheme of biotinylated version of compounds, RF-C11b and GV-C11b. 
 
CD3OD): δ 1.10-1.34 [bs, 18H],  1.38 [s, 9H], 1.50-1.79 [m, 10H], 2.09-2.32 [m, 4H], 2.57-3.57 
[m, 13H], 4.06-4.36 [m, 3H], 4.38-4.54 [m, 1H],  5.05 [s , 2H], 7.12-7.43 [m, 10H] 
 
PRF-C11b, precursor of 2a.  Compound 12 was subjected to Z-deprotection using 
hydrogenolysis with 10 % Pd on charcoal in methanol afforded Lysine(-O-biotinylated 
ethylenediamine)-C11F (78.8 % yield).  HOBt (6 mg, 0.039 mmol), EDC (9 mg, 0.047 mmol) 
and compound 8a (30 mg, 0.039 mmol) was added in cold, dry DMF (1 ml), followed by 
addition of DMF solution of Lysine(-O-biotinylated ethylenediamine)-C11F (0.05 g, 0.059 
mmol) and dropwise addition of DIPEA. The resulting solution was stirred at r.t. for 72 h. 
Washing with 0.5 N HCl in brine solution and column chromatographic purification using 5 % 
methanol in chloroform yielded PRF-C11b  in pure form (0.028 g, 44.8 % yield, Rf = 0.50 in 10 
% methanol in chloroform). 1H NMR (200 MHz, CDCl3 + CD3OD): δ 1.20-1.39 [bs, 34H],  1.42 
[s, 9H], 1.53-1.81 [m, 14H], 2.14-2.39 [m, 6H], 2.62-3.42 [m, 13H], 3.81-4.62 [m, 5H, ring 
junction protons], 5.08-5.19 [m, 4H], 5.28 [s, 2H], 7.17-7.58 [m, 20H]. 
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PGV-C11b, precursor of 2b.  PGV-C11 was demethylated using the same method as described 
above.  Demethylated PGV-C11 and compound 12 were coupled using HOBt and EDC in DMF 
as described above (42.3 % yield from two steps, Rf = 0.35 in 10 % methanol in chloroform).  
1H NMR (200 MHz, CDCl3 + CD3OD): δ 0.82-0.97 [d, 6H, J= 6.8 Hz], 1.28 [bs, 34H],  1.43 [s, 
9H], 1.50-1.78 [m, 11H], 2.01-2.30 [m, 6H], 2.65-3.78 [m, 15H], 4.00-4.39 [m, 4H, ring junction 
protons], 5.08 [s, 2H], 7.31 [s, 5H].  
 
RF-C11b, 2a.  PRF-C11b was deprotected and purified through selective precipitation using 
methanol/diethyl ether solvent mixture, yielding pure RF-C11b 2a (58.4 % yield). 
ESI-MS: m/z 1,085 ([M+H]+, calculated for C55H98O7N13S, 1,084.7), and 543 ([M+2H]2+ 
calculated, 542.9). RP-HPLC: Rt = 4.1 min (5 % water in methanol), purity > 98 %. 
 
GV-C11b, 2b.  Yield: 43.6 %. ESI-MS: m/z 937.6 ([M+H]+, calculated for C47H89O7N10S, 
937.7), and 469.4 ([M+2H]2+ calculated, 469.3). RP-HPLC: Rt = 3.3 min (10 % water in 
methanol), purity > 94 %. 
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